Continuous Renal Replacement Therapy
This page intentionally left blank
Continuous Renal Replacement Therapy Edited...
426 downloads
2506 Views
6MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Continuous Renal Replacement Therapy
This page intentionally left blank
Continuous Renal Replacement Therapy Edited by
John A. Kellum Professor and Vice Chair Department of Critical Care Medicine University of Pittsburgh Pittsburgh, Pennsylvania
Rinaldo Bellomo Professor of Medicine Director of Intensive Care Research Melbourne University Melbourne, Australia
Claudio Ronco Professor of Clinical Nephrology and Medicine Director, Department of Nephrology St. Bortolo Hospital Vicenza, Italy
1
2010
1
Oxford University Press, Inc., publishes works that further Oxford University’s objective of excellence in research, scholarship, and education. Oxford New York Auckland Cape Town Dar es Salaam Hong Kong Karachi Kuala Lumpur Madrid Melbourne Mexico City Nairobi New Delhi Shanghai Taipei Toronto With offices in Argentina Austria Brazil Chile Czech Republic France Greece Guatemala Hungary Italy Japan Poland Portugal Singapore South Korea Switzerland Thailand Turkey Ukraine Vietnam
Copyright © 2010 by Oxford University Press, Inc. Published by Oxford University Press, Inc. 198 Madison Avenue, New York, New York 10016 www.oup.com Oxford is a registered trademark of Oxford University Press All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of Oxford University Press. Library of Congress Cataloging-in-Publication Data Continuous renal replacement therapy/edited by John A. Kellum, Rinaldo Bellomo, Claudio Ronco. p. ; cm. Includes bibliographical references and index. ISBN 978–0-19–539278-4 (pbk. : alk. paper) 1. Acute renal failure—Treatment. 2. Continuous arteriovenous hemofiltration. I. Kellum, John A. II. Bellomo, R. (Rinaldo), 1956- III. Ronco, C. (Claudio), 1951[DNLM: 1. Kidney Failure, Acute—therapy. 2. Hemodialysis Solutions. 3. Kidney— injuries. 4. Renal Dialysis. 5. Renal Replacement Therapy—methods. WJ 342 C7625 2009] RC918.R4C658 2009 616.6’14—dc22 2009011944 Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work.
10 9 8 7 6 5 4 3 2 1 Printed in the United States of America on acid-free paper
We dedicate this volume to the nursing professionals that deliver CRRT—for without their hard work and dedication this therapy would not exist—and to the patients and their families in the hope that we can make some difference in their lives.
This page intentionally left blank
Preface
John A. Kellum Rinaldo Bellomo Claudio Ronco 2009
vii
Significant advances have occurred in the care of patients with acute kidney injury. Continuous renal replacement therapy (CRRT) has become the standard of care for many critically ill patients with severe acute kidney injury, and most major medical centers have developed the capability of providing CRRT. However, many hospitals lack the capacity, and many that have it underutilize it. Our goal with the CRRT handbook is to provide a concise but authoritative guide to the use of CRRT. In a single, slim volume, we have covered the basics to management of acute kidney injury both with and in addition to CRRT. The intent of this book is to provide a quick reference for both novice and experienced CRRT providers, to enrich existing expertise, and to achieve a better understanding of this powerful treatment. Our ultimate goal is to improve outcomes for patients with acute kidney injury through teamwork and education.
This page intentionally left blank
Contents Abbreviations xiii Contributors xvii
Part 1 Theory 1 The critically ill patient with acute kidney injury Aditya Uppalapati and John A. Kellum 2 History and rationale for continuous renal replacement therapy Ilona Bobek and Claudio Ronco 3 Terminology and nomenclature Ian Baldwin and Rinaldo Bellomo 4 Basic principles of solute transport Zhongping Huang, Jeffrey J. Letteri, Claudio Ronco, and William R. Clark 5 Principles of fluid management Rinaldo Bellomo and Sean M. Bagshaw 6 Indications, timing, and patient selection John A. Kellum 7 Extended indications for continuous renal replacement therapy Rinaldo Bellomo and Ian Baldwin 8 Dose adequacy and assessment Zaccaria Ricci and Claudio Ronco 9 Acid-base and electrolyte disorders John A. Kellum
3
11 19
25 33 39
47 53 61
Part 2 Practice 10 Choosing a renal replacement therapy in acute kidney injury Jorge Cerdá and Claudio Ronco 11 Vascular access for continuous renal replacement therapy Alexander Zarbock and Kai Singbartl 12 The circuit and the prescription Rinaldo Bellomo and Ian Baldwin
79 93 99
CONTENTS
x
13 The membrane: size and material Zhongping Huang, Jeffrey J. Letteri, Claudio Ronco, and William R. Clark 14 Fluids for continuous renal replacement therapy Paul M. Palevsky and John A. Kellum 15 Alarms and troubleshooting Zaccaria Ricci, Ian Baldwin, and Claudio Ronco 16 Nonanticoagulation strategies to optimize circuit function in renal replacement therapy Ian Baldwin 17 Anticoagulation Rinaldo Bellomo and Ian Baldwin 18 Regional citrate anticoagulation Nigel Fealy 19 Drug dosing in continuous renal replacement therapy Kimberly A. Maslonek, Kelly A. Killius, and John A. Kellum
107 115 121
129 135 141 147
Part 3 Special Situations 20 Renal replacement therapy in children Michael L. Moritz 21 Therapeutic plasma exchange in critical care medicine Joseph E. Kiss 22 MARS: molecular adsorbent recirculating system Nigel Fealy and Rinaldo Bellomo 23 Sorbents Dehua Gong and Claudio Ronco 24 Hybrid therapies Dinna N. Cruz and Claudio Ronco
159 167 175 181 189
Part 4 Organizational issues 25 The ICU environment Younghoon Kwon 26 Patient care quality and teamwork Kimberly Whiteman and Frederick J. Tasota 27 Organizational aspects: developing policies and procedures for continuous renal replacement therapies Jorge Cerdá
199 205
213
223
CONTENTS
28 Documentation, billing, and reimbursement for continuous renal replacement therapy Kevin W. Finkel 29 Machines for continuous renal replacement therapy Claudio Ronco 30 Quality assurance for continuous renal replacement therapies Ian Baldwin and Rinaldo Bellomo 31 Educational resources Ian Baldwin and Kimberly Whiteman
229
247 253
xi
Index 263
This page intentionally left blank
AC ACD ACE ACT ADQI AKI AKIN AoCLF APACHE aPTT ARDS ARF ASFA AV VH BUN CAVH CAVHD CAVHDF CDI CPFA CRBSI CRRT CVC CV VH CV VHD CV VHDF DP EC ECLS ECU ECV EDD ESRF
Activated Charcoal Acid Citrate Dextrose Angiotensin-Converting Enzyme Activated Clotting Time Acute Dialysis Quality Initiative Acute Kidney Injury Acute Kidney Injury Network Acute on Chronic Liver Failure Acute Physiology and Chronic Health Evaluation Activated Partial Thromboplastin Time Acute Respiratory Distress Syndrome Acute Renal Failure American Society for Apheresis Accelerated Venovenous Hemofiltration Blood Urea Nitrogen Continuous Arterio-Venous Hemofiltration Continuous Arterio-Venous Hemodialysis Continuous Arterio-Venous Hemodiafiltration Central Diabetes Insipidus Coupled Plasma Filtration and Adsorption Catheter-Related Bloodstream Infections Continuous Renal Replacement Therapy Central Venous Catheter Continuous Veno-Venous Hemofiltration Continuous Veno-Venous Hemodialysis Continuous Veno-Venous Hemodiafiltration Drop Pressure Extracorporeal Circuit Extracorporeal Lung Support System Emergency Case Units Extracorporeal Volume Extended Daily Dialysis End-Stage Renal Failure
xiii
Abbreviations
ABBREVIATIONS
xiv
GFR GPCI HF HFR HITTS HP HPHD HVHF ICU IHD IJV INR LMW MODS MOST MPM NSAID PD PIRRT PT PTH RBRVS RCA RHTE RIFLE RRT RVU SAg SAPS SBE SC SCrt SCUF SID SIRS SLED SLEDD
Glomerular Filtration Rate Geographic Practice Cost Indexes Hemofiltration Double Chamber Hemodiafiltration Heparin Induced Thrombocytopenia Thrombosis Syndrome Hemoperfusion Hemoperfusion Coupled with Hemodialysis High-Volume Hemofiltration Intensive Care Unit Intermittent Hemodialysis Internal Jugular Vein International Normalization Ratio Low Molecular Weight Multiple Organ Dysfunction Syndrome Multi-Organ Support Therapy Mortality Prediction Model Nonsteroidal Antiinflammatory Drug Peritoneal Dialysis Prolonged Intermittent Renal Replacement Therapy Prothrombin Time Parathyroid Hormone Resource-Based Relative Value Scale Regional Citrate Anticoagulation Right Heart Thromboembolism Risk, Injury, Failure, Loss, and End-Stage Kidney Disease Renal Replacement Therapy Relative Value Unit Superantigen Simplified Acute Physiologic Score Standard Base Access Sieving Coefficient Serum Creatinine Slow Continuous Ultrafiltration Strong Ion Difference Systemic Inflammatory Response Syndrome Slow Low Efficiency Dialysis Sustained Low Efficiency Daily Dialysis
ABBREVIATIONS
Sustained Low Efficiency (Daily) Diafiltration Sepsis-Related Organ Failure Assessment Temporary Dialysis Catheter Toll-Like Receptor Transmembrane Pressure Tumor Necrosis Factor Therapeutic Plasma Exchange Ultrafiltration
xv
SLEDD-f SOFA TDC TLR TMP TNF TPE UF
This page intentionally left blank
Contributors Sean M. Bagshaw, MD
William R. Clark, MD
Assistant Professor Division of Critical Care Medicine University of Alberta Hospital University of Alberta Edmonton, Canada
Vice President, Medical Strategy and Therapy Development Gambro Renal Products Lakewood, Colorado
Clinical Educator Department of Intensive Care Austin Hospital Department of Nursing and Health Sciences RMIT University Melbourne, Australia
Rinaldo Bellomo, MD Professor of Medicine Director of Intensive Care Research Department of Intensive Care Melbourne University Melbourne, Australia
Ilona Bobek, MD Nephrologist Department of Nephrology, Dialysis and Transplantation San Bartolo Hospital Vicenza, Italy
Jorge Cerdá, MD, FACP, FASN Clinical Associate Professor of Medicine Albany Medical College and Capital District Renal Physicians Albany, New York
Assistant Clinical Professor of Medicine Nephrology Division Indiana University School of Medicine Indianapolis, Indiana
Dinna N. Cruz, MD, MPH Nephrologist Department of Nephrology, Dialysis and Transplantation San Bortolo Hospital International Renal Research Institute Vicenza Vicenza, Italy
Nigel Fealy, RN Clinical Nurse Educator Department of Intensive Care Austin Hospital Heidelberg, Australia
Kevin W. Finkel, MD, FACP, FASN Professor and Director Division of Renal Diseases and Hypertension University of Texas Medical School at Houston Houston, Texas
xvii
Ian Baldwin, RN
CONTRIBUTORS
Dehua Gong, MD Associate Professor Research Institute of Nephrology Jinling Hospital Nanjing University School of Medicine Nanjing, P.R.China
Zhongping Huang, PhD Assistant Professor Department of Mechanical Engineering Widener University Chester, Pennsylvania
xviii
John A. Kellum, MD Professor of Critical Care Medicine, Medicine, Bioengineering, and Clinical and Translational Sciences Vice Chair of Research Department of Critical Care Medicine University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
Kimberly A. Maslonek, PharmD Clinical Pharmacist Cardiothoracic and Surgical ICU University of Pittsburgh Medical Center Presbyterian Pittsburgh, Pennsylvania
Michael L. Moritz, MD Associate Professor of Pediatrics Division of Nephrology Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania
Paul M. Palevsky, MD Professor of Medicine University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
Zaccaria Ricci, MD
Clinical Pharmacy Specialist, Emergency Medicine Boston Medical Center Boston, Massachusetts
Consultant Intensive Care Unit Department of Pediatric Cardiac Surgery Bambino Gesù Children’s Hospital Rome, Italy
Joseph E. Kiss, MD
Claudio Ronco, MD
Associate Professor of Medicine Department of Medicine Division of Hematology/Oncology Pittsburgh, Pennsylvania
Director Department of Nephrology, Dialysis and Transplantation San Bortolo Hospital Vicenza, Italy
Kelly A. Killius, PharmD, BCPS
Younghoon Kwon, MD Staff Intensivist Health East Care System Saint Paul, Minnesota
Jeffrey J. Letteri, BS, CHT Director Development Gambro, Inc. Lakewood, Colorado
Kai Singbartl, MD, EDIC Assistant Professor of Critical Care Medicine and Anesthesiology Department of Critical Care Medicine University of Pittsburgh Pittsburgh, Pennsylvania
Critical Care Advanced Practice Nurse University of Pittsburgh Medical Center Presbyterian Pittsburgh, Pennsylvania
Advanced Practice Nurse Educator University of Pittsburgh Medical Center Presbyterian Pittsburgh, Pennsylvania
Aditya Uppalapati, MD
Alexander Zarbock, MD
Resident Internal Medicine University of Pittsburgh Medical Center McKeesport, Pennsylvania
Resident Department of Anesthesiology and Critical Care Medicine University of Muenster Muenster, Germany
CONTRIBUTORS
Kimberly Whiteman, RN, MSN, CCRN
xix
Frederick J. Tasota, RN, MSN, CCRN
This page intentionally left blank
Part 1
Theory
This page intentionally left blank
Chapter 1
The critically ill patient with acute kidney injury The terms acute kidney injury (AKI) and acute renal failure (ARF) are not synonymous. While the term renal failure is best reserved for patients who have lost renal function to the point that life can no longer be sustained without intervention, AKI is used to describe the milder as well as severe forms of acute renal dysfunction in patients. Although the analogy is imperfect, the AKI–ARF relationship can be thought of as being similar to the relationship between acute coronary syndrome and ischemic heart failure. AKI is intended to describe the entire spectrum of disease from being relatively mild to severe. In contrast, renal failure is defined as renal function inadequate to clear the waste products of metabolism despite the absence of or correction of hemodynamic or mechanical causes. Clinical manifestations of renal failure (either acute or chronic) include the following: • Uremic symptoms (drowsiness, nausea, hiccough, twitching) • Hyperkalemia • Hyponatremia • Metabolic acidosis
Oliguria Persistent oliguria may be a feature of ARF but nonoliguric renal failure is not uncommon. Patients may continue to make urine despite an inadequate glomerular filtration. Although prognosis is often better if urine output is maintained, use of diuretics to promote urine output does not seem to improve outcome (and some studies even suggest harm).
Classification International consensus criteria for AKI have been purposed. The acronym RIFLE is used to describe three levels of renal impairment (Risk, Injury, Failure) and two clinical outcomes (Loss and End-stage kidney disease), as shown in Figure 1.1.
3
Aditya Uppalapati and John A. Kellum
Urine output criteria
Increased creatinine x 1.5*
UO < 0.5mL/kg/h x6h
Increased creatinine x2
UO < 0.5mL/kg/h x 12 h
Injury
Failure
Loss
ESRD
Increased creatinine x3 UO < 0.3mL/kg/h or creatinine ≥4mg/dL x 24 h or (Acute rise of Anuria x12 h ≥0.5 mg/dL)
High sensitivity
Oligu ria
The critically ill patient with AKI CHAPTER 1
4
Risk
Creatinine criteria
High specificity
Persistent ARF = complete loss of renal function > 4 weeks End stage renal disease
Figure 1.1 The RIFLE Criteria for diagnosis and staging of AKI—used to describe three levels of renal impairment (Risk, Injury, Failure) and two clinical outcomes (Loss and End-stage kidney disease). Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure— definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204-R212. Used with permission. *An alternative proposal is to define “Risk” to include any increase in serum creatinine of at least 0.3 mg/dL, over 48 hours or less even if less than 50% increase.
Incidence and etiology of acute kidney injury The classification system includes separate criteria for serum creatinine and urine output. The criteria, which lead to the worst classification, define the stage of AKI. Note that RIFLE-F is present even if the increase in serum creatinine (SCrt) is less than threefold, so long as the new SCrt is <4.0 mg/dL in the setting of an acute increase of at least 0.5 mg/dL. The figure shows that more patients (high sensitivity) will be included in the mild category, including some without actually having renal failure (less specificity). In contrast, at the bottom, the criteria are strict and therefore specific, but some patients will be missed.
Incidence and progression Acute kidney injury occurs in 35%–65% of ICU admissions and 5%–20% of general hospital admissions. Mortality rates increase significantly with AKI, and most studies show a—threefold to fivefold increase in the risk of death among patients with AKI compared to patients without AKI. Furthermore, increases in severity of AKI are associated with a stepwise increase in risk of death such that patients reaching RIFLE-F are far more likely to die before hospital discharge
Etiology of AKI Clinical features may suggest the cause of AKI and dictate further investigation. AKI is common in the critically ill, especially in patients with sepsis and other forms of systemic inflammation (e.g., major surgery, trauma, burns), but other causes must be considered. In sepsis, the kidney often has a normal histological appearance. Volume-responsive AKI It is estimated that as many as 50% of cases of AKI are “fluid responsive,” and the first step in managing any case of AKI is to ensure appropriate fluid resuscitation. However, volume overload is a key factor contributing to the mortality attributable to AKI, so ongoing fluid administration to nonfluid responsive patients should be discouraged. In general, fluid resuscitation should be guided by hemodynamic monitoring. Sepsis-induced AKI Sepsis is a primary cause or contributing factor in more than 50% of cases of AKI, which includes cases severe enough to require renal replacement therapy (RRT). Patients with sepsis, including those outside the ICU, develop AKI at rates as high as 40%. Septic shock appears to be an important factor in the development of sepsis-induced AKI; however, patients without overt shock do not appear to be any less likely to develop AKI.
The critically ill patient with AKI
Risk factors for developing AKI as defined by RIFLE criteria are as follows: • Sepsis • Increasing age, especially age > 62 years • Race—Black patients for developing RIFLE-F • Greater severity of illness as per Acute Physiology and Chronic Health Evaluation (APACHE) III or Sepsis-related Organ Failure Assessment (SOFA) scores • Preexisting chronic kidney disease • Presiding admission to a non-ICU ward in the hospital • Surgical admissions more likely than medical admissions • Cardiovascular disease • Emergent surgeries • Being on mechanical ventilation
CHAPTER 1
Risk factors for AKI
5
compared to patients who do not progress from RIFLE-R or RIFLE-I. Hospital mortality rates for ICU patients with AKI are approximately as follows: R—9%, I—11%, F—26% compared to 6% for ICU patients without AKI. Unfortunately, more than 50% of patients with RIFLE-R progress to class I (in approximately 1–2 days) or F (in approximately 3–4 days), and almost 30% of RIFLE-I progress to F.
The critically ill patient with AKI CHAPTER 1
Hypotension Hypotension is an important risk factor for AKI, and many patients with AKI have sustained at least one episode of hypotension. Treating fluid-responsive AKI with fluid resuscitation is clearly an important step, but many patients will also require vasoactive therapy (e.g., dopamine, norepinephrine) to maintain arterial blood pressure. Despite a common belief among many practitioners, norepinephrine does not increase the risk of AKI compared to dopamine and renal blood flow actually increases with norepinephrine in animals with sepsis. Postoperative AKI Risk factors include hypovolemia, hypotension, major abdominal surgery, and sepsis. Surgical procedures (particularly gynecological) may be complicated by damage to the lower urinary tract with an obstructive nephropathy. Abdominal aortic aneurysm surgery may be associated with renal arterial disruption. Cardiac surgery may be associated with atheroembolism and sustained periods of reduced arterial pressure as well as systemic inflammation.
Other causes
6
• Nephrotoxins—may cause renal failure via direct tubular injury, interstitial
• •
• •
•
•
nephritis, or renal tubular obstruction. In patients with AKI, all potential nephrotoxins should be withdrawn. Rhabdomyolysis—suggested by myoglobinuria and raised creatine kinase in patients who have suffered a crush injury, coma, or seizures. Glomerular disease—red cell casts, hematuria, proteinuria, and systemic features (e.g., hypertension, purpura, arthralgia, vasculitis) are all suggestive of glomerular disease. Renal biopsy or specific blood tests (e.g., Goodpasture’s syndrome, vasculitis) are required to confirm diagnosis and guide appropriate treatment. Hemolytic uremic syndrome—suggested by hemolysis, uremia, thrombocytopenia, and neurological abnormalities. Crystal nephropathy—suggested by the presence of crystals in the urinary sediment. Microscopic examination of the crystals confirms the diagnosis (e.g., urate, oxalate). Release of purines and urate are responsible for acute renal failure in the tumor lysis syndrome. Renovascular disorders—loss of vascular supply may be diagnosed by renography. Complete loss of arterial supply may occur in abdominal trauma or aortic disease (particularly dissection). More commonly, the arterial supply is partially compromised (e.g., renal artery stenosis) and blood flow is further reduced by hemodynamic instability or locally via drug therapy [e.g., nonsteroidal antiinflammatory drugs (NSAIDs), angiotensin-converting enzyme (ACE) inhibitors]. Renal vein obstruction may be due to thrombosis or external compression (e.g., raised intra-abdominal pressure). Abdominal compartment syndrome—suggested by oliguria, a firm abdomen on physical examination, and increased airway pressures (secondary to upward pressure on the diaphragms). Diagnosis is likely when sustained increased
Table 1.1 lists some common nephrotoxins.
Key references Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204-R212. Kellum JA. Acute Kidney Injury. Crit Care Med. 2008;36:S141-S145. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813-818.
The critically ill patient with AKI
Nephrotoxins
CHAPTER 1
intra-abdominal pressures (bladder pressure measured at end-expiration in the supine position) exceed 25 mmHg. However, abdominal compartment syndrome may occur with intra-abdominal pressures as low as 10 mmHg.
Identification and correction of reversible causes of AKI is critical. All cases require careful attention to fluid management and nutritional support.
Urinary tract obstruction Lower tract obstruction requires the insertion of a catheter (suprapubic if there is urethral disruption) to allow decompression. Ureteric obstruction requires urinary tract decompression by nephrostomy or stent. A massive diuresis is common after decompression, so it is important to ensure adequate circulating volume to prevent secondary AKI.
Hemodynamic management Fluid-responsive AKI may be reversible in its early stage. Careful fluid management to ensure adequate circulating volume and any necessary inotrope or vasopressor support to ensure renal perfusion will help improve chances for renal recovery. Admission to intensive care and use of hemodynamic monitoring should be considered for all patients with AKI and is mandatory for patients not responding to conservative therapy. Table 1.1 Common nephrotoxins Allopurinol
Organic solvents
Aminoglycosides Amphotericin Furosemide
Paraquat Pentamidine Radiographic contrast
Herbal medicines Heavy metals NSAIDs
Sulfonamides Thiazides
7
Management of AKI
The critically ill patient with AKI CHAPTER 1
8
Glomerular disease Specific therapy in the form of immunosuppressive drugs may be useful after diagnosis has been confirmed.
Interstitial nephritis Acute interstitial nephritis most often results from drug therapy. However, other causes include autoimmune disease, and infection (e.g., Legionella, leptospirosis, Streptococcus, cytomegalovirus). Numerous drugs have been implicated, but the most common ones are as follows: • Antibiotics (penicillins, cephalosporins, sulfa, rifampin, quinolones) • Diuretics (furosemide, bumetanide, thiazides) • NSAIDs (including selective COX-2 inhibitors) • Allopurinol • Cimetidine (rarely other H-2 blockers) • Proton pump inhibitors (omeprazole, lansoprazole) • Indinavir • 5-Aminosalicylates Urine sediment usually reveals white cells, red cells, and white cell casts. Eosinophiluria is present in about two-thirds of cases and specificity for interstitial nephritis is only about 80%. Other causes of AKI in which eosinophiluria is relatively common are rapidly progressive glomerulonephritis and renal atheroemboli. Discontinuation of the potential causative agent is a mainstay of therapy.
Abdominal compartment syndrome Abdominal compartment syndrome is a clinical diagnosis in the setting of increased intra-abdominal pressure—pressures below 10 mmHg generally rule it out, while pressures above 25 mmHg make it likely. Baseline blood pressure and abdominal wall compliance influence the amount of intra-abdominal pressure that can be tolerated. Surgical decompression is the only definitive therapy and should be undertaken before irreversible end-organ damage occurs.
Renal replacement therapy CRRT forms the mainstay of replacement therapy in critically ill patients who often cannot tolerate standard hemodialysis due to hemodynamic instability. Hybrid techniques (discussed in Chapter 24) may be reasonable alternatives in settings where CRRT cannot be accomplished but outcome data are limited. Peritoneal dialysis is not usually sufficient. Mortality in the setting of acute renal failure in the critically ill is high (50%–60%). Renal recovery in survivors may be as high as 90% but recent studies suggest that sustained renal failure or incomplete renal recovery is more common than previously thought (as many as 50% of survivors do not return to baseline renal function following an episode of acute renal failure).
System Electrolyte disturbances
Mechanisms 1. Hyponatremia 2. Hyperkalemia 1. Downregulation of Beta receptors, increased iNOS 2. Hyperchloremia 3. Impairing the insulin resistance 4. Innate immunity
Acid-base (decreased chloride excretion, accumulation of organic anions like PO4, decreased albumin l decreased buffering) Cardiovascular 1. Volume overload Pulmonary
Gastrointestinal
Immune
Hematological
Nervous system
Pharmacokinetics and dynamics
1. Volume overload, decreased oncotic pressure 2. Infiltration and activation of lung neutrophils by cytokines 3. Uremia 1. Volume overload 2. Gut ischemia and reperfusion injury
1. Decreased clearance of oxidant stress 2. Tissue edema 3. White cell dysfunction 1. Decreased synthesis of RBC increased destruction of RBC, blood loss 2. Decreased production of erythropoietin, von willebrand’s factor 1. Secondary hepatic failure, malnutrition, altered drug metabolism 2. Hyponatremia, acidosis 3. Uremia 1. Increased volume of distribution 2. Decreased availability, albumin binding, elimination
Complications 1. CNS (see below) 2. Malignant arrhythmias 1. Decreased cardiac output, blood pressure 2. Lung, Intestinal injury, decreases gut barrier function 3. Hyperglycemia, increased protein break down 4. See below 1. Congestive heart failure 2. Secondary hypertension 1. Pulmonary edema, pleural effusions 2. Acute lung injury 3. Pulmonary hemorrhage 1. Abdominal compartment syndrome 2. Acute gastric and duodenal ulcerlbleeding; impaired nutrient absorption 1. Increased risk of infection 2. Delayed wound healing
1. Anemia 2. Bleeding
1. Altered mental status 2. Seizures, impaired consciousness, coma 3. Myopathy, neuropathyl prolonged length on mechanical ventilation 1. Drug toxicity or under dosing
The critically ill patient with AKI
Table 1.2 Clinical consequences of AKI
CHAPTER 1
Until recently it was assumed that patients with AKI died not because of AKI itself but because of their underlying disease. Several studies, however, have documented a substantial mortality attributable to AKI after controlling for other variables, including chronic illness and severity of underlying acute illness. Table 1.2 lists some of the more important clinical consequences of AKI.
9
Clinical consequences of AKI
This page intentionally left blank
Chapter 2
History and rationale for continuous renal replacement therapy Ilona Bobek and Claudio Ronco
11
New therapeutic advances have coped with an increasing clinical demand for adequate and effective renal replacement therapies in the critically ill patient. The history of continuous renal replacement therapy (CRRT) is one of the best examples of multidisciplinary progress and collaboration between medical knowledge and industrial technology toward therapy improvement.
Medical demand/necessity for CRRT Change in the clinical picture of acute renal failure in the 1980s Severe sepsis was considered to be the underlying disease leading to ARF, and earlier ARF occurred frequently after abortions; however, ARFs epidemiological pattern and the involvement of other organs became more and more clear after the 1990s: • The cases of isolated (purely nephrological) ARF decreased due to early diagnosis and better prophylaxis. • More patients received increasingly extensive operations and survived serious accidents. • Number of intensive care unit (ICU) patients significantly increased. • There was evidence of longer stay with possibility of better outcomes in ICU.
Change in the pathogenesis of ARF Main factors that are currently considered to be responsible for ARF are as follows: • Shock • Perfusion disturbances • Hypoxia
History and rationale for CRRT CHAPTER 2
12
Chronology/cornerstones of CRRT 1960s The idea of CRRT was born, but resources and technology were not available. Most ARF cases were treated with peritoneal dialysis (PD) because hemodialysis (HD) was difficult to perform and it was not tolerated by intensive care patients.
1970s Henderson played an important role in developing the technical groundwork for hemofiltration (HF). Isolated ultrafiltration (UF) and the use of convection for solute removal was experimentally established.
1977 First description of an arterio-venous hemofiltration technique was given by Kramer et al. in Göttingen, Germany. A vascular catheter that was accidentally placed into the femoral artery gave rise to the idea of using the systemic arterio-venous pressure difference in an extracorporeal circuit to generate the ultrafiltrate, providing an effective method for elimination of both fluid and solutes. Heparin could be added before and fluid could be reinfused after the filtration. Continuous arterio-venous hemofiltration (CAVH) was soon accepted worldwide in ICUs (Figure 2.1). Advantages of CAVH: • Hemodynamic stability over conventional HD at that time • Simplicity • No necessity of blood pump • Continuous physiological fluid removal Limitations of CAVH: Low efficiency compared to HD Reduced clearance capacity in the presence of high catabolic states Necessity of additional, intermittent HD or HF Complications associated with arterial access (indwelling catheters, thrombosis) • Reliance on arterial pressure to pump blood through the circuit • Danger of balancing errors • Necessity of continuous supervision by the staff • • • •
1979 Continuous veno-venous hemofiltration (CVVH) was first employed in ARF after a cardiac surgery in Cologne, Germany. Any desired filtrate volume could be arranged and uraemia could be controlled. A pump and control and balancing system became necessary (see Figure 2.2).
Ultrafilter
A
B
Venous return line
Pr Po
(2)
Substitutions lösung
Pi
(1) Ultrafiltrate clamp Graduated cylinder
(3)
Blood pump
Bubble trap Venous return clamp
Figure 2.1 The concept from Peter Kramer and Lee Henderson of continuous filtration and the first patient treated with continuous arterio-venous hemofiltration in Vicenza, 1978.
Minifilters
Figure 2.2 A typical system for continuous veno-venous hemofiltration (Hospal BM32).
13
CHAPTER 2
Heparin
History and rationale for CRRT
Po
(2) To dialyzer
History and rationale for CRRT CHAPTER 2
14
1980s Numerous technical and methodical improvements in CRRT have contributed to the following: Changes in arterio-venous technique: • Different types of catheters to obtain adequate blood flow • Shorter blood line with no gadgets to reduce resistance • Positioning the collecting bag to apply a negative pressure • Optimization of treatment parameters and the concept of filtration fraction • Changes in filter geometry and in the structure of fiber; an entire family of diafilters was created to fulfil the hemodynamic requirements • Implementation of CAVHD; to increase the efficacy, dialyses fluid was filtered through the external port of the filter • Combination of hemofiltration and hemodialysis, that is, CAVHDF was performed Replacement of the arterio-venous techniques by the pump-driven venovenous techniques: • Introduction of CVVH, employing blood pump to further increase efficiency • Use of double lumen catheters through jugular vein • Development of highly permeable polysulfone, polyacrylonitrile, and polyamid membranes with a cut off between 15,000 and 50,000 dalton • Availability of bicarbonate-buffer solutions • Establishment of new anticoagulation methods, even for patients at high risk of bleeding
1982 The use of CAVH in intensive care patients was approved by the Food and Drug Administration (FDA) in the United States.
1984 For the first time in the world history a neonate was treated with CAVH in Vicenza, Italy (Figure 2.3).
1990–2000 Establishment of new technologies, modalities, and adequate dose of CRRT. • Adoptive technology • Machines specifically created for CRRT (Figure 2.4) • Different modalities chosen for the need of the patient • The progression of dose delivery and prescription • CRRT is achievable in most of the ICUs worldwide
2000 to present Multiorgan support therapy Patients do not die of ARF, but of multiorgan failure. The probability of death is directly correlated to the number of failing organs other than the kidney and
Reinfusion pump
Blood pump
Figure 2.3 The first neonate treated in the world with continuous arterio-venous hemofiltration (CAVH) and a special minifilter (Vicenza, 1984).
Evolution
CRRT evolution
RT
f CR
so gres
Pro
1977
1985
1989
2004
?
Years Figure 2.4 Evolution of continuous renal replacement therapy (CRRT) technology over the years. The case of a single company.
the severity of physiological disorders. The proper goal of extracorporeal blood purification in ICU should be multiorgan support therapy (MOST). Treatment should not be directed at various organs as separate entities (Figure 2.5). It should be integrated and directed at patients. Therefore a wide range of supportive therapy in sepsis and liver failure were established, such as high-volume
History and rationale for CRRT
Heparin
CHAPTER 2
Bubble trap
15
Pressure monitoring
History and rationale for CRRT CHAPTER 2
CRRT
ECLS
M.O.S.T SCUF
LiverSupport - HVHF CPFA - CAST
16
Figure 2.5 The concept of MOST: Multiorgan supportive therapy. Blood can be circulated by a platform through different filtration/adsorption systems, leading to removal of specific compounds and support to different failing organs.
hemofiltration (HVHF), coupled plasma filtration and adsorption (CPFA), bioartificial liver, and endotoxin removal strategies. Acute dialysis quality initiative Acute dialysis quality initiative (ADQI) is an ongoing process that seeks to produce evidence-based recommendations for the prevention and management of acute kidney injury (AKI) and on different issues concerning acute dialysis. The following goals have been achieved: • Definition and classification of ARF [RIFLE criteria, acute kidney injury network (AKIN)] • Practice guidelines adopted in clinical practice (cardiac surgery-associated AKI)
Recent interests focus on timing of treatment initiation on patient survival and the effect of dialysis modality on recovery of renal function in ARF. Future processes involve the online preparation of reinfusion fluids during high-volume hemofiltration, intracorporeal microfluidics and technology for plasma separation, intracorporeal ultrafiltration plasma water extraction, bioartificial tubulus, new sorbent techniques, nanotechnology, and wearable/transportable devices. Renal replacement therapy (RRT) has evolved from the concept that we need to treat the dysfunction of a single organ, the kidney. However, CRRT has opened the door also to the concept of MOST. The future should require a single multifunctional machine with a very user-friendly interface and flexibility in parameters and prescription such that it can be used to respond to
History and rationale for CRRT
Henderson LW, Besarab A, Michaels A, Bluemle LW. Blood purification by ultrafiltration and fluid replacement (Diafiltration). Trans ASAIO. 1967;13:216-222. Henderson LW. Peritoneal ultrafiltration dialysis: enhanced urea transfer using hypertonic peritoneal fluid. JCI 1966;45:950-961. Kellum JA, Mehta R, Angus DC, Palevsky P, Ronco C; ADQI Workgroup. The first international consensus conference on continuous renal replacement therapy. Kidney Int. 2002;62:1855-1863. Kramer P, Wigger W, Rieger J, Matthaei D, Scheler F. Arterio-venous hemofiltration: a new simple method for treatment of overhydrated patients resistant to diuretic. Klin Wschr. 1977;55:1121-1122. Ronco C, Bellomo R, Brendolan A, et al. Effect of different doses in continuous venovenous haemofiltration on outcomes of acute renal failure: a prospective randomized trial. The Lancet. 2000;355:26-30. Ronco C, Bellomo R. Acute renal failure and multiple organ dysfunction in the ICU: from renal replacement therapy (RRT) to multiple organ support therapy (MOST). Int J Artif Organs. 2002;25:733-747. Sieberth HG, History and development of continuous renal replacement (CRRT). Critical Care Nephology. 1161-1167, Dordrecht: Kluwer Academic Publishers, 1998.
CHAPTER 2
Key references
17
different medical needs using different disposable layouts. The new generation of machines should be usable by different operators in different hospitals and settings.
This page intentionally left blank
Chapter 3
Terminology and nomenclature Ian Baldwin and Rinaldo Bellomo
As with any specialized field of therapy, specific terms and languages are used to describe the use of renal replacement therapy (RRT). Key acronyms are also used to describe different extracorporeal circuits (EC) for the various techniques used for RRT. These terms generally differentiate solute and solvent removal methods, treatment schedule or timing, and the intensity or “dose” of treatment. In addition, there are also specific terms used for the circuit itself and “system” components for the clinical device or machine used for RRT and for the prescription of a treatment. For clinical care, clarity of prescription orders, research, audits, reporting, and publications it is necessary and useful to have a common language.
Definitions and relevant key terms Continuous renal replacement therapy (CRRT) Continuous renal replacement therapy is a general term referring to any extracorporeal blood purification therapy intended to substitute for impaired renal function over an extended period of time and applied for or aimed at being applied for 24 hours per day.
Continuous veno-venous hemofiltration (CV VH) Continuous veno-venous hemofiltration is a technique of CRRT whereby blood is driven through a highly permeable membrane by a peristaltic pump and via an EC originating in a central vein and also terminating in a central vein (Figure 3.1). The pressure generated by the pumped blood induces the passage of plasma water (the solvent) across the membrane. This process is called ultrafiltration. The ultrafiltrate produced during the transit of blood through the membrane contains all molecules to which the membrane is permeable. As solvent moves across the membrane it takes with it (solvent drag) many toxins that require removal. This process of blood purification is called convection. The fluid loss is
19
Introduction
Terminology and nomenclature CHAPTER 3
CVVH
Replacement fluid
Membrane Blood pump
Pump
Waste collection
Pump
Heater Patient
20
Figure 3.1 Continuous veno-venous hemofiltration (CVVH) circuit. In this circuit, the replacement fluid is being delivered before the filter in predilution mode.
replaced in part or completely with appropriate replacement solutions to achieve blood purification while maintaining volume and electrolyte homeostasis.
Continuous veno-venous hemodialysis (CV VHD) Continuous veno-venous hemodialysis is a technique of CRRT whereby blood is driven through a highly permeable membrane by a peristaltic pump and via an EC originating in a central vein and also terminating in a central vein but where solute removal is achieved by diffusion (exchange of solutes dependent on a concentration gradient) of molecules across a membrane. Such diffusion is achieved by pumping a toxin-free fluid, which contains appropriate plasma electrolytes, into the nonblood side of the membrane and in a direction countercurrent to that of blood (Figure 3.2). As this fluid (dialysate) passes through the blood, molecules to which the membrane is permeable move from plasma water to dialysate. The dialysate is then discarded.
Continuous veno-venous hemodiafiltration (CV VHDF) Continuous veno-venous hemodiafiltration is a technique of CRRT that combines CV VH and CV VHD. During CV VHDF, solute removal is achieved by a combination of convection and diffusion (Figure 3.3). Blood is pumped into the EC from a central vein and returned into a central vein.
Continuous arterio-venous techniques Continuous arterio-venous techniques include all techniques of CRRT (hemofiltration, hemodialysis, and hemodiafiltration) whereby the patient’s blood pressure (instead of pump) drives blood through a filter, which contains the highly permeable membrane. This process is achieved via an EC originating in an artery and terminating in a vein. The method of blood purification is otherwise
CVVHD Heater
Blood pump
Spent dialysate
CHAPTER 3
Pump
Terminology and nomenclature
Dialysate
Patient
Figure 3.2 Continuous veno-venous hemodialysis (CVVHD) circuit.
CVVHDF
21
Dialysate
Replacement fluid Heater
Blood pump
Pump
Pump Heater
Diafiltrate/waste
Patient
Figure 3.3 Continuous veno-venous hemodiafiltration (CVVHDF) circuit in predilution mode.
identical to veno-venous techniques. They can be abbreviated in the same way as veno-venous techniques except for the use of AV instead of VV. Thus, for example, continuous arterio-venous hemofiltration would be abbreviated as CAVH. These techniques have all been abandoned in developed countries in favor of veno-venous techniques. For all techniques, fluid balance is maintained by the difference between fluid input (dialysate and/or replacement fluid or both) and output (spent dialysate and/or ultrafiltrate or both). Both input and output can be regulated by pumps.
Terminology and nomenclature CHAPTER 3
22
If output is greater than input, there is a negative fluid balance, which can be regulated in intensity as deemed necessary.
Predilution Predilution is the administration of replacement fluid into the patient’s blood before its entry into the hemofilter (prefilter delivery).
Postdilution Postdilution is the administration of replacement fluid into the patient’s blood after its exit from the hemofilter (postfilter delivery).
Intermittent hemodialysis (IHD) Intermittent hemodialysis is a term that describes a diffusive blood purification treatment during which blood and dialysate are circulated on the opposite sides of a semipermeable membrane in a countercurrent direction in order to achieve diffusive solute removal. IHD is performed using a machine, which is purpose-built for this technique and which can generate dialysate flow rates that are much higher than those used during CRRT. IHD machines can generate dialysate from tap water through a process of bacteria and endotoxin removal and reverse osmosis with subsequent electrolyte and buffer additives to provide a dialysate fluid for high flow use (Figure 3.4). Prescription is commonly for 3–4 hours per session with the frequency and intensity of such sessions regulated in response to perceived clinical need. Ultrafiltration can also be achieved to remove fluid by applying a negative pressure on the dialysate side of the membrane. This allows the removal of excess fluid as clinically estimated.
Tap water Electrolytes R.O.
IHD
K+ HCO3Heater
Waste
Blood pump
Patient
Figure 3.4 Intermittent hemodialysis circuit. Tap water is further purified by reverse osmosis and mixed with concentrates containing potassium, sodium, chloride, and bicarbonate to achieve physiological concentrations of each. The dialysate is then run countercurrent to blood and discarded as waste.
Extracorporeal circuit (EC) Extracorporeal circuit is the path for blood flow outside the body. The EC includes the plastic tubing carrying the blood to the filter (or hemofilter or dialyzer) from the vascular access catheter and from the filter back to the body via the access catheter again.
Terminology and nomenclature
Slow low efficiency dialysis is a dialysis treatment equivalent in nature to IHD but where dialysate and blood flow rates are reduced to provide a less efficient clearance rate but with an extended time of treatment (e.g., 8–12 hours instead of 3–4 hours). The acronym SLEDD is used when this technique is applied daily (D = daily). SLEDf is used when the technique includes some convective clearance in addition to diffusion (Figure 3.5). Extended daily dialysis (EDD) and extended daily dialysis with filtration (EDDf) are also used to describe these respective techniques.
CHAPTER 3
Slow low efficiency dialysis (SLED)
Vascular access catheter is a device inserted into a central vein to allow blood to be pumped in and out of a filter. This device is typically in the form of a large central vein catheter (French gauge from 11.5 to 14.0) and has two lumens, one for outflow of blood from the body (typically referred to as “arterial” lumen) and one for the return of blood to the body (typically referred to as the “venous” lumen). Blood flows between 150 and 300 mL/min can be typically achieved through such catheters.
Tap water Electrolytes R.O.
SLED(f)
K+ HCO3Fluid pump
Heater
Waste
Blood pump Patient
Figure 3.5 The circuit used to provide diffusive and convective clearance for SLED(f) usually for a daily treatment of 6–12 hours. The dialysate and blood flow rates are lower than that for intermittent hemodialysis.
23
Vascular access catheter
Terminology and nomenclature CHAPTER 3
Diffusion Diffusion is a term that describes a type of solute transport across a semipermeable membrane. During diffusion a solute has a statistical tendency to reach the same concentration in the available distribution space on both sides of a semipermeable membrane. Thus, molecules move from the compartment with higher concentration to the compartment with lower concentration.
Convection Convection is a term that describes a type of solute transfer across a semipermeable membrane in which solute is transported together with a solvent by means of a process (filtration) that occurs in response to a transmembrane pressure gradient.
Filter or dialyzer Filter or dialyzer is a tubular-shaped device that is made up of the plastic casing and the capillary fibers of the semipermeable membrane within it.
24
Summary There are many techniques of CRRT, and it is useful to understand their nomenclature for ease of communication and understanding. Comparison of such circuits with those of intermittent therapies such as IHD and SLED can further help one understand the mechanisms and principles involved in achieving blood purification during CRRT. Familiarity with the various abbreviations used in the clinical setting can help with rapid communication with other medical and nursing personnel.
Key references Bellomo R, Baldwin I, Ronco C. High-volume hemofiltration. Curr Opin Crit Care. 2000;6:442-445. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; ADQI workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy an dinformation technology needs: the second international consensus conference of the ADQI Group. Crit Care. 2004;8:R204-R212. Bellomo R, Ronco C. Nomenclature for CRRT. In: Bellomo R, Baldwin I, Ronco C, Golper T, eds. Atlas of Hemofiltration. London: WB Saunders; 2001:11-14. Bellomo R. Choosing a therapeutic modality: hemofiltration vs. hemodialysis vs. hemodiafiltration. Semin Dial. 1996;9:88-92. Ronco C, Bellomo R. A nomenclature of continuous renal replacement therapies. Contrib Nephrol. 1995;116:28-33.
Chapter 4
Basic principles of solute transport Zhongping Huang, Jeffrey J. Letteri, Claudio Ronco, and William R. Clark
Renal replacement therapy (RRT) is required in a significant percentage of patients developing acute kidney injury (AKI) in an intensive care unit (ICU) setting. One of the foremost objectives of continuous renal replacement therapy (CRRT) is the removal of blood solutes retained as a consequence of decreased or absent glomerular filtration. Because prescription of CRRT requires goals to be set with regard both to the rate and extent of solute removal, a thorough understanding of the mechanisms by which solute removal occurs during CRRT is necessary. This chapter provides an overview of solute transfer during CRRT.
Characterization of filter performance in CRRT Clearance Quantification of dialytic solute removal is complicated by the confusion relating to the relationship between clearance and mass removal for different therapies. By definition, solute clearance (K) is the ratio of mass removal rate (N) to blood solute concentration (CB): K = N/CB
[1]
From a kinetic perspective, Figure 4.1 depicts the relevant flows for determining CRRT clearances while Figure 4.2 provides the solute clearance expressions, which differ from those used in conventional hemodialysis. In the latter therapy, the mass removal rate (i.e., the rate at which the dialyzer extracts solute from blood into the dialysate) is estimated by measuring the difference in solute concentration between the arterial and venous lines. In other words, a “blood-side” clearance approach is used. On the other hand, in CRRT, the mass removal rate
25
Introduction
Basic principles of solute transport CHAPTER 4
QACA
QECE i
QR d
QD d QCCV
Filter
Clearance =
Mass removal rate Blood concentration QECE
=
CA
Figure 4.1 Relevant flow considerations for the determination of solute clearance in CRRT. The modality represented is CV VHDF.
CVVHD/CVVHDF
(
K = E·QD
Concentration in effluent dialysate/diafiltrate Concentration in blood
)
26
E=
Postdilution CWH Concentration in filtrate ( S = Concentration ) in blood
K = S·QUF
Predilution CWH
( Q Q+ Q ) BW
K = S·QUF ·
BW
R
Figure 4.2 Solute clearance in CRRT.
is estimated by measuring the actual amount of solute appearing in the effluent. The mass removal rate is the product of the effluent flow rate (QE) and the effluent concentration of the solute (CE). In continuous veno-venous hemodialysis (CV VHD) and continuous venovenous hemodiafiltration (CV VHDF), the effluent is dialysate and diafiltrate, respectively. For these therapies, the extent of solute extraction from the blood is estimated by the equilibration ratio (E), also known as the degree of effluent saturation. The benchmark for efficiency in these therapies is the volume of fluid (dialysate and/or replacement fluid) required to achieve a certain solute clearance target (see below). Clearance in postdilution CV VH is the product of the SC (see below) and the ultrafiltration rate (QUF). For small solutes like urea and creatinine, the SC is
When a dialyzer is operated as an ultrafilter (i.e., ultrafiltration with no dialysate flow, e.g., CV VH), solute mass transfer occurs almost exclusively by convection. Convective solute removal is primarily determined by membrane pore size and treatment ultrafiltration rate. Mean pore size is the major determinant of a dialyzer’s ability to prevent or allow the transport of a specific solute. The sieving coefficient (SC) represents the degree to which a particular membrane permits the passage of a specific solute: SC = C UF/CP
[2]
In this equation, CUF and CP are the solute concentrations in the ultrafiltrate and the plasma (water), respectively. Irrespective of membrane type, all filters in the “virgin” state have small solute SC values of 1, and these values are typically not reported by dialyzer manufacturers. SC values for solutes of larger molecular weight are more applicable and manufacturers frequently provide data for one or more middle molecule surrogates, such as vitamin B12, inulin, cytochrome C, and myoglobin. As is the case for solute clearance, the relationship between SC and solute molecular weight is highly dependent on membrane mean pore size. Sieving coefficient (SC) data provided by manufacturers are usually derived from in vitro experimental systems in which (nonprotein containing) aqueous solutions are used as the blood compartment fluid. In actual clinical practice, nonspecific adsorption of plasma proteins to a dialyzer membrane effectively reduces the permeability of the membrane. Consequently, in vivo SC values are typically less than those derived from aqueous experiments, sometimes by a considerable amount.
Transmembrane solute removal mechanisms Diffusion Diffusion is the process of transport in which molecules that are present in a solvent and can freely move across a semipermeable membrane tend to move
Basic principles of solute transport CHAPTER 4
Sieving coefficient
27
essentially 1 (under normal filter operation). Therefore, small solute clearance in postdilution CV VH essentially is equal to the QUF. On the other hand, estimation of clearance in predilution CV VH has to account for the fact that the blood solute concentrations are reduced by dilution of the blood before it enters the filter. Thus, the clearance has a “dilution factor” that is represented by the third term on the right hand side of the second equation above. This term essentially is the ratio of the blood flow rate (QB) to the sum of QB and the replacement fluid rate (QRF). (The actual blood flow parameter, QBW, is blood water flow rate.) In essence, the dilution factor can be viewed as a measure of the extent to which predilution differs from postdilution for a specific combination of QB and QUF.
Basic principles of solute transport CHAPTER 4
28
from the region of higher concentration into the region of lower concentration (Figure 4.3). In reality, molecules present a random movement. However, since they tend to reach the same concentration in the available space occupied by the solvent, the number of particles crossing the membrane toward the region of lower concentration is statistically higher. Therefore, this transport mechanism occurs in the presence of a concentration gradient for solutes that are not restricted in diffusion by the porosity of the membrane. In addition to transmembrane concentration gradient, Fick’s Law states that diffusive solute is influenced by the following: • Membrane characteristics: surface area, thickness, porosity • Solute diffusion coefficient (primarily a function of molecular weight) • Solution temperature Based on the previous discussion, the clearance of a given solute can be predicted with reasonable certainty under a given set of operating conditions. However, several factors may lead to a divergence between theoretical and empirically derived values. As an example, protein binding or electrical charges in the solute may negatively impact the final clearance value. Conversely, convection may result in a measured clearance value that is significantly greater than the value based on a “pure” diffusion assumption. Diffusion is an efficient transport mechanism for the removal of relatively small solutes, but as solute molecular weight increases, diffusion becomes limited and the relative importance of convection increases.
Convection Convection is the mass transfer mechanism associated with ultrafiltration of plasma water. If a solute is small enough to pass through the pore structure of the membrane, it is driven (“dragged”) across the membrane in association Diffusion is solute transport across a semipermeable membrane—molecules move from an area of higher to an area of lower concentration
Best for small molecule clearance
Convection is a process where solutes pass a cross the semipermeable membrane along with the solvent (‘‘solvent drag’’) in response to a positive transmembrane pressure
Effectiveness less dependent on molecular size
Figure 4.3 Mechanisms of diffusion and convection.
In this equation, KF is the membrane-specific hydraulic permeability (units: mL/h/ mmHg/m2) and TMP is a function of both the hydrostatic and oncotic pressure gradients. Convective flux of a given solute is a function mainly of the following parameters: • Ultrafiltration rate • Blood solute concentration • Membrane sieving properties In clinical practice, however, because plasma proteins and other factors modify the “native” properties of the membrane, the final observed SC is smaller than that expected from a simple theoretical calculation. As noted above, nonspecific adsorption of plasma proteins (i.e., secondary membrane formation) occurs instantaneously to an extracorporeal membrane after exposure to blood. This changes the effective permeability of the membrane and can be explained by the action of proteins to essentially “plug” or block a certain percentage of membrane pores. Postdilution fluid replacement tends to accentuate secondary membrane effects because protein concentrations are increased within the membrane fibers (due to hemoconcentration). On the other hand, higher blood flow rates work to attenuate this process because the shear effect created by the blood disrupts the binding of proteins to the membrane surface.
Kinetic considerations for different CRRT techniques In CV VH, high-flux membranes are utilized and the prevalent mechanism of solute transport is convection. Ultrafiltration rates in excess of the amount required for volume control are prescribed, requiring partial or total replacement of ultrafiltrate losses with reinfusion (replacement) fluid. As described in greater detail elsewhere, replacement fluid can either be infused before the filter (predilution) or after the filter (postdilution). Postdilution hemofiltration is inherently limited by the attainable blood flow rate and the associated filtration fraction constraint. On the other hand, from a mass transfer perspective, the use of predilution has several potential advantages over postdilution. First, both hematocrit and total blood protein concentration are reduced significantly before the blood enters into the hemofilter. This effective reduction in the red cell and protein content of the blood attenuates the secondary membrane and concentration
Basic principles of solute transport
[3]
CHAPTER 4
JF = KFTMP
29
with the ultrafiltrated plasma water. This movement of plasma water is a consequence of a transmembrane pressure (TMP) gradient. Quantitatively, the ultrafiltration flux (JF), defined as the ultrafiltration rate normalized to membrane surface area, can be described by
Basic principles of solute transport CHAPTER 4
30
polarization phenomena described above, resulting in improved mass transfer. Predilution also favorably impacts mass transfer due to the augmented flow in the blood compartment because prefilter mixing of blood and replacement fluid occurs. This achieves a relatively high membrane shear rate, which also reduces solute-membrane interactions. Finally, predilution may also enhance mass transfer for some compounds by creating concentration gradients that induce solute movement out of red blood cells. However, the major drawback of predilution hemofiltration is its relatively low efficiency, resulting in relatively high replacement fluid requirements to achieve a given solute clearance. In a group of patients treated with a “traditional” blood flow rate for CRRT, the efficiency loss associated with predilution has recently been quantified. Troyanov et al. demonstrated the significant negative effect on efficiency when a relatively low QB (less than 150 mL/min) is used with a relatively high QUF and QRF in predilution CV VH. This specific combination of QB = 125–150 mL/min and QUF = 4.5 L/h (75 mL/min) is associated with a loss of efficiency of 30%–40% relative to postdilution for several different solutes. In other words, to achieve the same solute clearance, 30%–40% more replacement fluid is required in predilution under these conditions, relative to postdilution under the same conditions. However, it should be noted that the likelihood of achieving such an ultrafiltration rate in postdilution is very remote at such a low blood flow rate, as this would require a filtration fraction in excess of 50%. This condition is likely to lead to very short-term filter patency. In CV VHDF, a high-flux hemodiafilter is used, and the operating principles of hemodialysis and hemofiltration are combined. As such, this therapy may allow for an optimal combination of diffusion and convection to provide clearances over a very broad range of solutes. Dialysate is circulated in countercurrent mode to blood and, at the same time, ultrafiltration is obtained in excess of the desired fluid loss from the patient. The ultrafiltrate is partially or totally replaced with reinfusion fluid, either in predilution or postdilution mode. Latergeneration CRRT machines allow a combination of predilution and postdilution with the aim of combining the advantages of both reinfusion techniques. Information from the chronic hemodiafiltration literature suggests that a combination of predilution and postdilution may be optimal in terms of clearance and operational parameters. This may also be the case for CV VHDF in AKI, although this possibility has not been assessed carefully. The optimal balance is most likely dictated by the specific set of CV VHDF operating conditions, namely blood flow rate, dialysate flow rate, ultrafiltration rate, and filter type. Due to the markedly lower flow rates used and clearances obtained in CV VHDF, the effect of simultaneous diffusion and convection on overall solute removal is quite different from the situation in chronic hemodiafiltration (HDF). In the latter application, diffusion and convection interact in such a manner that total solute removal is significantly less than what is expected if the individual components are simply added together. On the other hand, in CV VHDF
M-100 70
Urea, CVVH Urea, CVVHDF B2-Microglobulin, CVVH B2-Microglobulin, CVVHDF
Clearance (mL/min)
60 50 40 30 20 10 0 0
0.5
1.0
1.5
2.0 2.5 3.0 Effluent (mL/h)
3.5
4.0
4.5
Figure 4.4 Comparison of solute clearance in predilution CVVH and CVVHDF. From Troyanov S, Cardinal J, Geadah D, et al. Solute clearances during continuous venvenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters. Nephrol Dial Transplant. 2003;18:961-966. Reprinted by permission of Oxford University Press.
Basic principles of solute transport CHAPTER 4
31
the small solute concentration gradient along the axial length of the filter (i.e., extraction) is minimal compared to the one that is seen in chronic HDF, in which extraction ratios of 50% or more are the norm. Thus, the minimal diffusionrelated change in small solute concentrations along the filter length allows any additional clearance related to convection to be simply additive to the diffusive component Troyanov et al. have performed a direct clinical comparison of CV VHDF and predilution CV VH with respect to urea and E2-microglobulin (B2M) clearance at a “traditional” blood flow rate of 125 mL/min. The study compared clearances at the same effluent rate over an effluent range of up to 4.5 L/h. As Figure 4.4 indicates, urea clearance was higher in CV VHDF than in predilution CV VH and, in fact, the difference between the two therapies increased as effluent rate increased. These results are consistent with the “penalizing” effect of predilution, which is especially pronounced at low blood flow rates. For B2M, the results are contrary to the “conventional wisdom,” which would suggest that a purely convective therapy like CV VH should inherently be superior to a partly convective therapy like CV VHDF for clearance of a molecule of this size. However, once again, the penalty of predilution in CV VH is apparent, as the B2M clearances for the two modalities are equivalent except at very high effluent rates (greater than 3.5 L/h). Until the impact of higher blood flow rates on solute clearances in CRRT can be assessed, these and other data suggest that CV VHDF is a logical modality choice to achieve the broadest spectrum of solute molecular weight range in the most efficient way.
Basic principles of solute transport CHAPTER 4
32
Summary Rational prescription of CRRT to critically ill patients with AKI is predicated upon an understanding of the basic principles of solute and water removal. In this chapter, the major ways in which filter function is characterized have been reviewed clinically. In addition, the fundamental mechanisms for solute and fluid transport have been discussed. Finally, these principles have been applied in a therapeutic context to the various CRRT modalities used by clinicians managing AKI patients.
Suggested readings Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999;34:486-492. Clark WR, Turk JE, Kraus MA, Gao D. Dose determinants in continuous renal replacement therapy. Artif Organs. 2003;27:815-820. Henderson LW. Biophysics of ultrafiltration and hemofiltration. In: Jacobs C, ed. Replacement of Renal Function by Dialysis. 4th ed. Dordrecht: Kluwer Academic Publishers; 1996:114-118. Huang Z, Letteri JJ, Clark WR, Ronco C. Operational characteristics of continuous renal replacement therapy modalities used for critically ill patients with acute kidney injury. Int J Artif Organs. 2008;31:525-534. Huang Z, Letteri JJ, Clark WR, Zhang W, Gao D, Ronco C. Ultrafiltration rate as dose surrogate in pre-dilution hemofiltration. Int J Artif Organs. 2007;30:124-132. Troyanov S, Cardinal J, Geadah D, et al. Solute clearances during continuous venvenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters. Nephrol Dial Transplant. 2003;18:961-966.
Chapter 5
Principles of fluid management Rinaldo Bellomo and Sean M. Bagshaw
The control and optimization of fluid balance is a clinically important component of continuous renal replacement therapy (CRRT). Inadequate fluid removal is associated with peripheral edema and vital organ edema (i.e., pulmonary edema). Such edema can retard weaning from mechanical ventilation or comprise wound healing. Fluid overload has been identified as an independent predictor of increased mortality in critically ill patients and is clearly undesirable. Similarly, excessive fluid removal may contribute to hypovolemia with increased doses of vasopressor drug therapy, exposing the patients to the risks of unnecessary beta and alpha receptor stimulation. Hypovolemia may induce hypotension and, thereby, possibly aggravate organ injury and, specifically, retard or block renal recovery. Accordingly, careful clinical assessment of the patient’s fluid status and careful prescription of CRRT to optimize fluid balance, together with frequent review of such assessment and prescription, represent a key aspect of best practice in the field of CRRT. Patient fluid balance: This term refers to the total balance over a 24-hour period of fluids administered (intermittent drugs, continuous infusion of drugs, blood, blood products, nutrient solutions, additional fluids) and measurable fluids removed (drainage from chest or abdomen, urine —if present, blood loss, and excess fluid removed by the CRRT machine). Machine (CRRT) fluid balance: This term refers to the total balance over a 24-hour period of fluids administered by the CRRT machine (dialysate or replacement fluid or both depending on the technique and any additional anticoagulant infusion) and fluids removed by the CRRT machine (spent dialysate or ultrafiltrate or both depending on the technique). Effluent: It is the total amount of fluid discarded by the machine. In continuous veno-venous hemofiltration (CV VH), this is the same as ultrafiltrate. In continuous veno-venous hemodialysis (CV VHD), this is equal to the spent dialysate + any additional ultrafiltrate generated by the machine. In continuous veno-venous
33
Introduction
Principles of fluid management CHAPTER 5
34
hemodiafiltration (CV VHDF), this is the same as the sum of spent dialysate and ultrafiltrate discarded by the machine (also called spent ultradiafiltrate). Dry weight: This is the patient’s normal/optimal weight before the onset of illness. This weight is often available in detail in elective operative patients where it is typically measured before the operation. In other cases, it might need to be estimated. Edema: This term refers to the accumulation of excess fluid in the extracellular compartment. In the subcutaneous tissue, it can be detected by the phenomenon of pitting of the skin under pressure. In the lungs, if significant, it can be detected by radiography. Assessment of fluid status: This term refers to the clinical process of estimating the patient’s intravascular and extravascular fluid status. Such assessment is complex and imperfect. It requires consideration of vital signs, invasive and noninvasive hemodynamic measurements, information of fluid balance and body weight, and radiological information. Such assessment is necessary to guide fluid balance prescription during CRRT.
Approach to fluid balance during CRRT The prescription of CRRT-related fluid management and its integration into overall patient fluid management can be assisted by a specific order chart (Table 5.1) for the machine fluid balance. The above order chart will tell the nurse how to set the machine and how to achieve the planned hourly fluid balance. However, in the intensive care unit (ICU), the fluid needs of the patients are not static and require frequent review. For example, should the same patient require the administration of 600 mL of fresh frozen plasma over 2 hours prior to an invasive procedure, necessary adjustments to the order should be made with specification for the duration of change and the reasons (Table 5.2). The fluid balance prescription related to the machine can be usefully related to the patient and a fluid balance prescription describing the overall patient fluid balance goal for a 12-hour time period is useful for informing the nurse what the broad goals of fluid therapy are in a given patient. This may be expressed in an additional prescription attached to the previous machine fluid balance chart (Table 5.3).
Table 5.1 Example Order Chart Technique
Dialysate flow rate
CV VHDF
1000 mL/h
Replacement fluid flow rate 1000 mL/h
Effluent flow rate 2300 mL/h
Anticoagulant infusion flow rate 100 mL/h
Machine fluid balance –200 mL/h
Dialysate flow rate
CV VHDF
1000 mL/h
Replacement Effluent Anticoagulant Machine fluid balance fluid flow rate flow rate infusion flow rate 1000 mL/h 2600 mL/h 100 mL/h –500 mL/h (for 2 hours only during FFP treatment)
Note: FFP = Fresh frozen plasma
Table 5.3 Example Order Chart 3 Patient
Medical record number
Name
00123
Overall fluid balance from midnight to 12:00 (noon) –1000 mL
Overall fluid balance from 12:00 (noon) to midnight –1000 mL/h
Right atrial pressure notification range
Principles of fluid management
Technique
CHAPTER 5
Table 5.2 Example Order Chart 2
<6 or >15 mmHg
The above goals can be achieved by means of physician and nursing education and by ensuring that no CRRT session can be started unless such orders are clearly and legibly written, signed, and accompanied by the physician’s printed name and contact number. They also require the regular recording of fluid balance on an hourly basis and its correct final addition of fluid losses and gains. This can be done in a computerized system or added by the nurse at the bedside using a pocket calculator and then charted. This process allows the creation of a running hourly balance, which is useful in ensuring that progress is being made at the appropriate speed, in the appropriate direction, and to the prescribed amount.
Expected outcomes, potential problems, cautions, and benefits The expected outcome of a systematic process for the prescription, delivery, and monitoring of fluids during CRRT is the ability to ensure that the patient will receive prescribed therapy in a safe and effective manner. This approach will minimize errors and their consequences (persistent fluid overload or dangerous intravascular volume depletion). Despite this careful approach, problems can still arise. A relatively common problem is related to off-time (time during which CRRT is not operative due to filter clotting or an out-of-ICU procedure or investigation). Under such circumstances, the fluid removal cannot proceed as planned. If the patient has 5 hours of off-time, then the consequence may be that close to 1 L of planned
35
Practical considerations
Principles of fluid management CHAPTER 5
36
fluid removal fails to occur (assuming fluid balance of 200mL/h). Moreover, during this off-time, patients may be administered additional fluid that will counter earlier fluid balance goals. If this happens, the physician and the nurse need to be alert to the consequences and respond appropriately. This my require an adjustment in fluid removal during the ensuing 12 or 24 hours, which safely compensates for the off-time by increasing the hourly fluid removal by, for example, an extra 100 mL/h. Due consideration needs to be paid to specific patients where such fluid removal may be problematic. However, typically, machine fluid removal rates of 300–400 mL/h are well tolerated in fluid-overloaded patients. Nonetheless, caution should be exerted and the patient’s condition should be reviewed frequently. Another relatively common problem is the frequent interruptions of therapy due to machine alarms. In some patients who are agitated or who have frequent leg flexion in the presence of a femoral access catheter or who sit up and move in the bed in the presence of a subclavian access device, the machine pressure alarms may be frequently triggered. In addition, other alarms related to substitution fluids bag or waste bag changes interrupt treatment. This may lead to periods of 5–10 minutes over an hour and over a day create “lost treatment time” and failure to achieve fluid balance goals. It is often prudent to prescribe a greater fluid loss than desired to compensate for these factors. Most machines allow the operator to check what the actual fluid removal achieved was over a given time period. Such checks should be done to ensure that the correct fluid removal is entered into the fluid balance calculations; many nursing protocols mandate fluid balance check each hour particularly for inexperienced nurses. The benefits of such continuous monitoring of fluid delivery and removal are many. They include frequent patient assessment, vigilance with regard to other simultaneous therapies, attention to detail, avoidance of dangerous swings in fluid status, and competent and detailed machine operation.
Conclusion Attention to fluid balance during CRRT is of great clinical importance. Inadequate fluid removal leads to clinical complications, especially in relation to weaning from mechanical ventilation. Excessive fluid removal can cause hypovolemia and hypotension, and retard renal recovery. Best practice in this field can only be achieved by a systematic combination of frequent and thoughtful assessment, attention to detail, rigorous and vigilant monitoring of fluid input and output, and clear and explicit description and prescription of the goals of therapy with regard to both machine settings and patient management.
Principles of fluid management CHAPTER 5
Bagshaw SM, Baldwin I, Fealy N, Bellomo R. Fluid balance error in continuous renal replacement therapy: a technical note. Int J Artif Organs. 2007;30:435-440. Bagshaw SM, Bellomo R. Fluid resuscitation and the septic kidney. Curr Opin Crit Care. 2006;12:527-530. Bagshaw SM, Bellomo R. The influence of volume management on outcome. Curr Opin Crit Care. 2007;13:541-548. Bagshaw SM, Brophy PD, Cruz D, Ronco C. Fluid balance as a biomarker: impact of fluid overload on outcome in critically ill patients with acute kidney injury. Crit Care. 2008;12:169.
37
Key references
This page intentionally left blank
Chapter 6
Indications, timing, and patient selection John A. Kellum
Indications for renal replacement therapy
39
Indications for renal replacement therapy (RRT) fall into two broad categories, so-called “renal” (i.e., to specifically address the consequences of renal failure) and “nonrenal” (without necessitating renal failure). Although the distinction is not always precise, it is a reasonably easy way to categorize indications for RRT.
Renal indications The manifestations of acute kidney disease (as discussed in Chapter 1 and summarized in Table 6.1) include oliguria, (leading to volume overload), azotemia (leading to a host of clinical complications), hyperkalemia, and metabolic acidosis. While there is no consensus regarding the precise level of dysfunction in any of these areas that should prompt initiation of RRT, general agreement exists on the following general indications for RRT: • Volume overload (e.g., pulmonary edema) • Azotemia with uremic symptoms • Hyperkalemia (>6.0 mmol/L) • Metabolic acidosis (pH < 7.2) due to renal failure Volume overload Volume overload usually occurs in the setting of oliguria, but it may occur simply because urine output is insufficient to maintain fluid balance in the face of large
Table 6.1 Diuretic dosing Metolazone Chlorothiazide Furosemide Torsemide Bumetanide
Oral 10–20 mg qd 20–40 mg 6–24-hourly 5–20 mg 6–24-hourly 0.5–1 mg 6–24-hourly
IV
Infusion
250–500 mg IV 5–80 mg 6–24-hourly 5–20 mg 6–24-hourly 0.5–2 mg 6–24-hourly
1–10 mg/h 1–5 mg/h 1–5 mg/h
Indications, timing, and patient selection CHAPTER 6
40
volume input—even if true oliguria is not present. Furthermore, most authorities recommend therapy before volume overload becomes clinically manifest, and thus RRT may be used to “create space” for additional fluids (e.g., nutritional support, antibiotics) that are scheduled to be administered. There is a controversy regarding the role of diuretics in the setting of volume overload secondary to acute renal failure (ARF). While most clinicians will attempt diuretics prior to initiation of RRT, there is a wide variation as to how long or intense such a trial will be or how the success will be defined. Although it is obviously desirable to avoid RRT, there is little evidence to suggest that diuretics can be successful in achieving this goal and even the available evidence suggests potential harm. Importantly, attempts to increase urine output with diuretics should only be directed toward treatment of volume overload or hyperkalemia, not oliguria per se. Large observational studies have failed to show benefit from diuretics in critically ill patients with oliguria, and some studies have shown harm. Diuretic therapy A loop diuretic such as furosemide is given in a dose of 20–40 mg intravenously. If this dose is ineffective, a higher dose can be tried within 30–60 minutes. Higher doses may be needed if the patient has previously received diuretic therapy (see Table 6.2). If boluses doses of 80 mg every 6 hours are infective, an infusion may be started (1–5 mg/h IV). A thiazide diuretic such as chlorothiazide (250–500 mg IV) or metolazone (10–20 mg PO) can be used in conjunction with a loop diuretic to improve diuresis. In general, there is no point in continuing diuretic therapy if it is not effective; loop diuretics in particular may be nephrotoxic. Discontinue all diuretics prior to initiating RRT. Azotemia Azotemia, the retention of urea and other nitrogenous waste products, results from a reduction in glomerular filtration rate (GFR) and is a cardinal feature of kidney failure. However, like oliguria, azotemia represents not only disease but also a normal response of the kidney to extracellular volume depletion or a decreased renal blood flow. Conversely, a “normal” GFR in the face of volume depletion could only be viewed as renal dysfunction. Thus, changes in urine output and GFR are neither necessary nor sufficient for the diagnosis of renal pathology. Yet, no simple alternative for the diagnosis currently exists. Azotemia is also a biochemical marker of the uremic syndrome, a condition caused by a diverse group of toxins that are normally excreted but build up in the circulation and in the tissues during renal failure. The clinical manifestations of the uremic syndrome are shown in the Table 6.2. Although uremic symptoms correlate with the level of urea in the blood, the relationship between blood urea nitrogen (BUN) and uremic symptoms is not consistent across individuals or even within a given individual at different times. Thus, there is no threshold level of BUN that defines uremia or provides a specific indication for RRT. Instead, the provision of RRT and, indeed, decisions
Complication(s)
Mechanism(s)
Cardiovascular
Volume overload
Electrolyte and acid-base
Hyponatremia, hyperkalemia, acidosis, azotemia
Gastrointestinal
Impaired nutrient absorption, GI bleeding, abdominal compartment syndrome Anemia, platelet dysfunction
Salt/water retention Edema, heart failure, hypertension Impaired free water Hypotension, impaired excretion, chloride glucose metabolism, decreased muscle accumulation protein synthesis, cardiac dysrhythmias Nausea, vomiting, Bowel edema, platelet dysfunction, decreased mucosal/ intestinal absorption, volume overload increased intra-abdominal pressures
Immune Nervous Respiratory
Infections, immune suppression Encephalopathy Pleural effusions, pulmonary edema
Decreased erythropoietin, decreased von Wilibrand’s factor Impaired neutrophil function Uremic toxins, hyponatremia Volume overload, decreased oncotic pressure, ? direct uremic toxicity
Anemia, bleeding
Infection, sepsis Asterixis, delirium, coma Pleural effusion, pulmonary edema, respiratory failure
regarding timing and intensity should be individualized to patients on the basis of clinical factors and not solely on the basis of biochemical markers. Hyperkalemia Hyperkalemia may be severe and can be life threatening. The risks of hyperkalemia are greatest when it develops rapidly, where serum concentrations in excess of 6 mmol/L may produce cardiac dysrhythmias. The earliest electocardiographic sign of hyperkalemia is peaking of the T waves. This finding is associated with cardiac irritability and should prompt emergent treatment. Temporary management of severe hyperkalemia (while preparing for RRT) includes intravenous calcium chloride (10 mL of 10% solution) to reduce cardiac irritability and a combination of insulin (10 units IV) and dextrose (50 mL D50) given together over 20 minutes to shift potassium intracellularly (blood glucose should be monitored). Metabolic acidosis Renal failure causes metabolic acidosis by retention of various acid anions (e.g., phosphate, sulfate) as well as from renal tubular dysfunction resulting in hyperchloremic acidosis. Clinical manifestations range from acute alterations
41
Hematological
Clinical features
Indications, timing, and patient selection
System
CHAPTER 6
Table 6.2 Manifestations of renal failure
Indications, timing, and patient selection CHAPTER 6
42
in inflammatory cell function to chronic changes in bone mineralization. Mild alterations can be managed using oral sodium bicarbonate or calcium carbonate. RRT is effective in removing acids as well as correcting plasma sodium and chloride balance and is generally targeted at maintaining an arterial pH > 7.30.
“Nonrenal” indications So-called nonrenal indications for RRT are to remove various dialyzable substances from the blood. These substances include drugs, poisons, contrast agents, and cytokines.
Drug and toxin removal Blood purification techniques have long been used for removal of various dialyzable drugs and toxins. A list of common drugs and toxins that can be readily removed using RRT is shown in Table 6.3. The majority of poisoning cases do not require treatment with RRT. Indeed, the drugs or toxins that are most commonly responsible for poisoning-related fatalities are not amenable to RRT (e.g., acetaminophen, tricyclic antidepressants, short-acting barbiturates,
Table 6.3 Common poisonings treated with RRT Substance Methanol
Extracorporeal method Hemodialysis
Isopropanol
Hemodialysis
Ethylene glycol
Hemodialysis
Lithium
IHD/CRRT
Salicylate
IHD/CRRT
Theophylline
IHD/CRRT/ hemoperfusion
Valproic acid
IHD/CRRT/ hemoperfusion
Comments RRT should be continued until the serum methanol concentration is < 25 mg/dL and the anion-gap metabolic acidosis and osmolal gap are normal. Rebound may occur up to 36 hours. RRT effectively removes isopropanol and acetone, although it is usually unnecessary except in severe cases (prolonged coma, myocardial depression, renal failure). RRT should be continued until the ethylene glycol level is <20 mg/dL and metabolic acidosis or other signs of systemic toxicity have been resolved. Rebound may occur up to 24 hours. IHD removes lithium faster but rebound is a significant problem and can be addressed effectively with CRRT. Both IHD/CRRT have been reported in the management of salicylate poisoning. RRT should be continued until clinical improvement and a plasma level < 20 mg/L is obtained. Rebound may occur. At supratherapeutic drug level plasma proteins become saturated, and the fraction of unbound drug increases substantially and becomes dialyzable.
Note: Other treatments are also required for many of these substances.
Indications, timing, and patient selection CHAPTER 6
stimulants, and “street drugs”). In general, the size of the molecule and the degree of protein binding determines the degree to which the substance can be removed (smaller, nonprotein bound substances are easiest to remove). Continuous renal replacement therapy (CRRT) may be effective in removing substances with higher degrees of protein binding and is sometimes used to remove substances with very long plasma half-lives. Techniques such as sorbent hemoperfusion may also be used for this indication and are discussed further in Chapter 23. The role of CRRT in the management of acute poisonings is not well established. There is relatively lower drug clearance per unit of time compared to intermittent hemodialysis (IHD) but CRRT has a distinct advantage in hemodynamically unstable patients who are unable to tolerate the rapid solute and fluid losses associated with IHD or even other techniques such as hemoperfusion. CRRT may also be effective for the slow, continuous removal of substances with large volumes of distribution, a high degree of tissue binding, or for substances that are prone to “rebound phenomenon” (e.g., lithium, procainamide, and methotrexate). In such cases, CRRT may even be used as adjuvant therapy with IHD or hemoperfusion. RRT has been used to remove radio-contrast agents for many years, but the purpose of this treatment has changed over time. In the past, ionic, high-osmolar contrast was used for imaging studies, and RRT was often used to remove these substances and to remove fluid in patients with renal failure who were at risk of congestive heart failure from the large osmotic load. These patients could not excrete the contrast and would develop pulmonary edema after contrast administration. In more recent years, nonionic, low-osmolality, or even iso-osmolar agents have been developed, and the risk of pulmonary edema has decreased significantly. However, all radio-contrast agents are nephrotoxic and CRRT is being advocated by some experts to help prevent so-called contrast nephropathy. Standard IHD has been shown to remove radio-contrast agents but does not appear to prevent contrast nephropathy. Despite less efficiency in removing contrast, CRRT has been shown to result in less contrast nephropathy, particularly when it has begun prior to or in conjunction with contrast administration (see Table 6.4). However, the effect is controversial and most centers do not currently offer RRT for prevention of contrast nephropathy.
Cytokines Many endogenous mediators of sepsis can be removed using continuous venovenous hemofiltration (CV VH) or continuous veno-venous hemodiafiltration (CV VHDF) (dialysis is not able to remove these mediators). This observation has prompted many investigators to attempt to use CV VH as an adjunctive therapy in sepsis. While it remains controversial as to whether CV VH offers additional benefit in patients with renal failure and sepsis, available evidence does not support a role of CV VH for the removal of cytokines in patients without
43
Contrast agents
Indications, timing, and patient selection CHAPTER 6
44
Table 6.4 Methods to reduce contrast nephropathy Saline
IV 0.9% (154 mEq/L)
Dosinga 1 mL/kg/h begun 12 hours or 3 mL/kg/h begun 1 hour prior to procedure and 1 mL/kg/h continuing 6 hours after procedure
NaHCO3 in water
150 mEq/L
1 mL/kg/h begun 12 hours or 3 mL/kg/h begun 1 hour prior to procedure and 1 mL/kg/h continuing 6 hours after procedure beginning 24 hours before and continuing 24 hours after procedure
Oral
N-acetylcysteine
1200 mg every 1200 mg every 12 hours 12 hours
: a Dosing ranges are provided as a general guide only—none of the above agents are approved for this indication.
renal failure. If CV VH is capable of removing cytokines, the effect of standard “renal dose” CV VH appears to be small. However, some individuals appear to respond with improved hemodynamics, especially to higher doses of CV VH (also see Chapter 7).
Key studies Lee PT, Chou KJ, Liu CP, et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol. 2007;50:1015-1020. Mehta RL, Pascual MT, Soroko S, et al; PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547-2553. Uchino S, Doig GS, Bellomo R, et al; B.E.S.T. Kidney Investigators. Diuretics and mortality in acute renal failure. Crit Care Med. 2004;32:1669-1677.
Timing of RRT When to initiate RRT The simplest answer to the question “when should RRT be started?” would be when the indications discussed above are met. Numerous attempts have been made to reach a consensus on timing of RRT. The Acute Dialysis Quality Initiative (ADQI) first addressed this issue in 2000 but was unable to reach consensus beyond stating that a patient is considered to require RRT when he or she has “an acute fall of GFR and has developed, or is at risk of, clinically significant solute imbalance/toxicity or volume overload.” In essence this amounts to saying that RRT should begin when a patient has “symptomatic” ARF. What constitutes symptomatic ARF is a matter of clinical judgment and how “at risk”
An even more difficult question to answer than when to start is when to stop RRT. Again the simplest answer would be “when renal function has recovered,” but two problems exist with this simple answer. First, it is not always easy to determine when renal function has recovered and it is also unclear what amount of recovery should be sought prior to cessation of therapy. In essence the question is not dissimilar to so-called weaning from mechanical ventilation and very little is actually known about how and when “weaning” from RRT should occur. One approach that was used in the largest trial of dialysis intensity published to date used the rule described in Table 6.5.
Key studies Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury is associated with hospital mortality in critical ill patients: A cohort analysis. Crit Care. 2006;10:R73. Kellum JA, Mehta RL, Levin A, et al; AKIN. Development of a clinical research agenda for acute kidney injury using an international, interdisciplinary, three-step modified Delphi process. Clin J Am Soc Nephrol. 2008;3:887-894.
Table 6.5 Assessment for recovery of renal function if urine volume > 30 mL/h Creatinine clearance <12 mL/min 12–20 mL/min >20 mL/min
Management of RRT Continuation of RRT Clinician’s judgment Discontinuation of RRT
Note: 6 hours’ timed urine collections obtained for assessment of creatinine clearance.
Indications, timing, and patient selection CHAPTER 6
When to stop RRT
45
is interpreted. Most, but not all, experts advise that RRT should begin before clinical complications occur, but it is often difficult to know exactly when such a point occurs. For example, subtle abnormalities in platelet function can begin early in acute kidney injury (AKI) prior to when most clinicians would begin RRT. Observational studies of AKI using RIFLE criteria have provided two important pieces of information: ARF (stage F by RIFLE) is common among critically ill patients (10%–20% of ICU patients) and is associated with a 3- to10-fold increase in the risk of death prior to discharge. Given the profound increase in the risk of death, many investigators have asked why more patients do not receive RRT, yet many patients with ARF recover renal function without ever receiving RRT. Should these patients receive RRT? Current evidence is insufficient to answer this question, but given the low rates of complications associated with CRRT, and high risk of death associated with AKI, consideration should be given to starting therapy early (e.g., when F criteria is present rather than waiting for complications to occur).
Indications, timing, and patient selection CHAPTER 6
46
Palevsky PM, Zhang JH, O’Connor TZ, et al. Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury. N Engl J Med. 2008; EPub May 20. Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: a worldwide practice survey. Intensive Care Med. 2007;33(9):1563-1570. Uchino S, Bellomo R, Morimatsu H, et al. Discontinuation of Continuous Renal Replacement Therapy: A Prospective Multi-center Observational study. Crit Care Med, In press.
Patient selection for CRRT Which patients should receive CRRT? Once the decision is made to initiate RRT the question of which modality (intermittent vs. continuous) arises. The following considerations influence the choice of modality, although, strictly speaking, there are few absolute indications for one modality over the other. • Hemodynamic stability: CRRT is preferred for patients with or at risk for hypotension. In practice, this usually means patients who require vasopressor support either at baseline or as a result of treatment. The ARF trial network (ATN) study demonstrated that hypotension is extremely common with IHD. • Intracranial hypertension: This is an absolute indication for CRRT. IHD induces much greater fluid shifts and is therefore contraindicated in patients with increased intracranial pressure. • Severe volume overload and high obligatory fluid intake: Even hemodynamically stable patients with severe volume overload or patients with mild fluid overload but high daily fluid requirements (usually for medications and nutritional support) may be more effectively managed with CRRT. For example, it is unusual to remove more than 3–4 L of volume in a 4-hour dialysis session. Yet it is quite common to remove 200–300 mL/h (5–7 L per day) or even more with CRRT. • Mechanical ventilation: For patients who are unable to tolerate weaning trials on nondialysis days, CRRT (or daily dialysis) may be better. • High protein turnover/catabolic patients: For some critically ill patients it may be difficult to control solute with alternate day dialysis. Patient with very high predialysis BUN may be better treated with CRRT. • Hyperkalemia: When rapid solute clearance is necessary, such as in severe hyperkalemia, intermittent therapy is generally preferred. CRRT is usually quite effective for hyperkalemia, but intermittent therapy will be somewhat faster.
Chapter 7
Extended indications for continuous renal replacement therapy Rinaldo Bellomo and Ian Baldwin
Continuous renal replacement therapy (CRRT) was developed to deal with the issue of offering a form of renal replacement therapy (RRT) that was better suited to the needs of critically ill patients than intermittent hemodialysis (IHD), and this remains the primary reason for its use in the intensive care unit (ICU). However, with increasing use, it has become clear that CRRT can be applied to the treatment of other conditions relevant to critical illness. Such situations are described as “extended indications” because they extend the reach of CRRT beyond the simple treatment of acute kidney injury (AKI). Although such extended indications are not supported by evidence from large multicenter, randomized, controlled trials, many studies have provided sufficient evidence to justify the use of CRRT outside the simple replacement of lost renal function.
Key terms Blood purification: This term refers to the use of extracorporeal therapies such as CRRT for the treatment of a variety of conditions (drug overdose, liver failure, volume overload, diuretic resistant cardiac failure, severe sepsis) for which a biological rationale exists for their application. Soluble mediators: This term refers to molecules (mostly small- to medium-sized peptides) that participate in the pathogenesis of the inflammatory and counterinflammatory response seen after major body injury or infection. These molecules are water soluble and therefore potentially removable by CRRT. Many of these molecules are referred to with the term “cytokines.” Humoral theory of sepsis: This term refers to a particular framework of biological thinking used to explain the clinical manifestations of severe sepsis. According to this theory, the clinical syndrome of severe sepsis or septic shock is due to the excessive release into the blood stream of cytokines. This ideological framework provides the rationale for using CRRT in sepsis.
47
Introduction
Extended indications for CRRT CHAPTER 7
High-volume hemofiltration (HVHF): This term refers to a technique of CRRT where the amount of fluid removed and replaced is much higher than the typical 2–3 L/h and reaches values of 6–10 L/h. The goal of such therapy is to increase the intensity of blood purification to address not just any renal dysfunction, but also any humoral components of sepsis (cytokines) whose removal from the circulation may be desirable (see Figures 7.1 and 7.2). High-cutoff hemofiltration: This term refers to the use of special filters with larger pore size to increase CRRT’s ability to remove soluble mediators in patients with sepsis. Middle-molecular weight molecules: This term refers to all molecules that are >500 daltons in molecular weight but less than albumin in size. These molecules,
P < 0.017
600 500
*
48
ng/mL
400 *
300 200 100 0 0
2
6 Time (h)
8
20
Figure 7.1 Impact of high-volume hemofiltration (HVHF) on C3a levels (triangles) compared with standard Continuous veno-venous hemofiltration (CVVH) (diamonds).
P < 0.017
30
ng/mL
25
*
20 15
* HFHV CVVH
*
10 5 0 0
2
6 Time (h)
8
20
Figure 7.2 Impact of high-volume hemofiltration (HVHF) on C3a levels compared with standard Continuous veno-venous hemofiltration (CVVH).
Free drug concentration: This term refers to the percentage or amount of a given drug that is not protein bound. This concept is important because, in case of drug overdose with a water soluble drug (e.g., lithium or sodium valproate), it is only the free drug that is available for removal by CRRT. Diuretic resistance: This term refers to conditions where marked edema (anasarca) develops despite intensive, high-dose, multiple diuretic-based attempts to remove excess fluid.
Extended indications for CRRT
Adsorption: This term refers to the removal of molecules from the circulation not by means of diffusion or convection but rather by means of binding of the molecules to the spongy layer of the filtering membrane. Such removal is one of the mechanisms by which CRRT can remove cytokines from blood.
CHAPTER 7
if water soluble, can, theoretically, be removed by CRRT. Because of their size, they are more efficiently removed by convection than by diffusion. Many of these molecules are soluble mediators/cytokines.
CRRT can be used to achieve its logical clinical goals in extended indications using different methods. For example, if the issue at stake is that of fluid removal with a degree of inevitably accompanying uremia, standard CRRT can be used to lower the urea concentration while aiming for a significant negative fluid balance of –200 to –400 mL/h. With this approach, large amounts of fluid can be removed from patients with diuretic resistant fluid overload. If the patient has severe sepsis or septic shock and the goal of therapy is to remove soluble mediators, then either HVHF or high-cutoff hemofiltration can be applied. HVHF requires high blood flows (>300 mL/min) in order to avoid either excessive predilution (if the replacement fluid is administered before the filter) or excessive hemoconcentration within the filter (if the replacement fluid is administered after the filter). If HVHF is used, attention must be paid to fluid balance and to phosphate levels. This is because relatively minor errors in fluid balance can cause problems when 10 L of fluids are exchanged every hour and because the rapid removal of phosphate will inevitably lead to hypophosphatemia. If high-cutoff hemofiltration is used, special filter membranes are necessary. HVHF may also be used to remove a water-soluble free toxic drug like lithium or sodium valproate at higher efficiency than standard CRRT. If this is done, such therapy is best followed by a spell of standard CRRT to avoid the so-called rebound in plasma concentration that follows the cessation of a high-efficiency treatment of blood. In some case, CRRT can be used to control body temperature in situations like malignant hyperthermia or severe fever due to infection or cerebral injury. In such cases, replacement fluid is not warmed prior to administration or can even be cooled prior to administration.
49
Methods, techniques, and approach
Extended indications for CRRT CHAPTER 7
50
Practical considerations The choice to apply CRRT in the techniques described earlier is entirely based on clinical judgment and a view that the possible benefits of therapy are greater than its risks. This requires that those applying CRRT for extended use should have a very high level of clinical competence in this field so that the treatment can be applied with minimal risk. This requirement particularly applies to HVHF, which requires adequate machines, accurate fluid balance monitoring, frequent monitoring of electrolytes and phosphate, and attention to body temperature. The risks are much less with severe diuretic refractory fluid overload, especially when secondary to advanced cardiac failure. In such patients, the typical desired fluid removal (10–15 L ) can be achieved over 24–48 hours by means of a steady negative fluid balance of –300 mL/h. This is easily executed, as it is commonplace during CRRT for acute renal failure (ARF) in any case. For water-soluble drugs with limited or little protein binding and with limited volumes of distribution (< 0.5 L/kg), in case of serious life-threatening intoxication, CRRT (perhaps initially at high volume and then once the levels are within a safe range, at standard volumes) also appears justified, biologically sound, and relatively safe. CRRT has now been used as an adjunctive treatment for the following: • Sepsis • Controlling body temperature not responding to conventional approaches • Decreasing the inflammatory response associated with cardiac arrest • Achieving or maintaining acid-base homeostasis in patients with severe academia • Removing radiocontrast and attenuating renal injury in patients at risk of radiocontrast nephropathy • Correcting anasarca of different etiology • Preventing massive fluid overload in patients receiving large amounts of clotting factors • Attenuating the inflammatory response associated with prolonged cardiopulmonary bypass • Correcting sodium disturbances in patients with limited renal function Once all the potential biological, physiological, and clinical effects of CRRT are appreciated, logical use of this therapy outside the field of CRRT is inevitable.
Summary CRRT has the ability to affect multiple biological and clinical targets. Once such ability is appreciated and the technique is mastered, CRRT becomes a tool that can be easily applied to situations outside the simple need for RRT. CRRT can lower body temperature, remove fluid, deliver large amounts of buffer, remove water-soluble drugs, affect the inflammatory and counterinflammatory systems,
Extended indications for CRRT
Bellomo R, Baldwin I, Cole L, Ronco C. Preliminary experience with high-volume hemofiltration in human septic shock. Kidney Int. 1998;53(suppl 66):S182-S185. Bellomo R, Baldwin I, Ronco C. Extracorporeal blood purification for sepsis and systemic inflammation: its biologic rational. Contrib Nephrol. 2001;132:367-374. Bellomo R, Baldwin I, Ronco C. High-volume hemofiltration. Curr Opin Crit Care. 2000; 6:442-445. Bellomo R, Baldwin I, Ronco C. Rationale for extracorporeal blood purification therapies in sepsis. Curr Opin Crit Care. 2000;6:446-450. Cruz DN, Perazella MA, Bellomo R, et al. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 2006;48:361-371. Haase M, Bellomo R, Baldwin I, et al. Hemodialysis membrane with a high-molecular weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase I randomized trial. Am J Kidney Dis. 2007;50:296-304. Kellum JA, Bellomo R, Mehta R, Ronco C. Blood purification in non-renal critical illness. Blood Purif. 2003;21:6-13.
CHAPTER 7
Key references
51
modulate electrolyte concentration, and allow the rapid administration of large amounts of blood products without the associated development of fluid overload. Once these properties are appreciated, extended indications for CRRT simply become logical physiological interventions similar to those achieved with mechanical ventilation.
This page intentionally left blank
Chapter 8
Dose adequacy and assessment Zaccaria Ricci and Claudio Ronco
Approximately 5%–6% of critically ill patients admitted to intensive care unit (ICU) develop severe acute kidney injury (AKI), and more than 70% of them receive renal replacement therapy (RRT). The mortality rate for severe AKI has exceeded 50% over the past three decades, and it represents an independent risk factor for mortality of critically ill patients. Strategies to improve patient outcome in AKI may include optimization of delivered RRT dose.
Theoretical aspects of renal replacement therapy dose The conventional view of RRT dose is that it is a measure of the quantity of blood purified by “waste products and toxins” achieved by means of renal replacement. The operative measure of RRT dose is the elimination amount of a representative marker solute: • The marker solute, however, does not represent all the solutes that accumulate during AKI because kinetics and volume of distribution are different for each solute. • The removal of marker solute during RRT is not necessarily representative of the removal of other solutes. A significant body of data suggests that single solute marker assessment of the dose of dialysis appears to have a clinically meaningful relationship with patient outcome and, therefore, clinical utility. The amount (dose) of delivered RRT can be described by various terms: efficiency, intensity, frequency, and clinical efficacy.
53
Introduction
Dose adequacy and assessment CHAPTER 8
54
• Efficiency of RRT is represented by the concept of clearance (K), that is, the
volume of blood cleared of a given solute over a given time (it is generally expressed as volume over time: mL/min, mL/h, L/h, L/24 h, etc.). K does not reflect the overall solute removal rate (mass transfer) but rather its value normalized by the serum concentration: even when K remains stable over time, the removal rate will vary if the blood levels of the reference molecule change. During RRT, K depends on solute molecular size, transport modality (convection or diffusion), and circuit operational characteristics [blood flow rate (QB), ultrafiltration rate (QF), dialysate flow rate (QD), hemodialyzer type and size]. QB, as a variable in delivering RRT dose, is mainly dependent on vascular access and operational characteristics of utilized machines in the clinical setting. During convective techniques, QF is strictly linked to QB by filtration fraction (the fraction of plasma water that is removed from blood by ultrafiltration), because it is recommended to keep QF below 0.5 * QB. During diffusive techniques, when QD/QB ratio exceeds 0.3, it can be estimated that dialysate will not be completely saturated by blood diffusing solutes. In the absence of a specific solute, clearances of urea and creatinine blood levels are used to guide treatment dose. During ultrafiltration, the driving pressure jams solutes, such as urea and creatinine, against the membrane and into the pores, depending on membrane sieving coefficient (SC) for that molecule. SC expresses a dimensionless value and is estimated by the ratio of the concentration of the solutes in the filtrate divided by that in the plasma water or blood. An SC of 1.0, as is the case for urea and creatinine, demonstrates complete permeability and a value of 0 reflects complete rejection. Molecular size over approximately 12 kDa and filter porosity are the major determinants of SC. The K during convection is measured by the product of QF times the SC. Thus, there is a linear relationship between K and QF, the SC being the changing variable for different solutes. During diffusion, an analog linear relationship depends on the diffusibility of a solute across the membrane. As a rough estimate, we showed that during continuous slow efficiency treatments, urea K can be considered as a direct expression of QF and QD. K can be normally used to compare the treatment dose during each dialysis session, but it cannot be employed as an absolute dose measure to compare treatments with different time schedules. For example, K is typically higher in intermittent hemodialysis (IHD) than continuous renal replacement therapy (CRRT) and sustained low efficiency daily dialysis (SLEDD). This is not surprising, since K represents only the instantaneous efficiency of the system. However, mass removal may be greater during SLEDD or CRRT. For this reason, the information about the time span during which K is delivered is fundamental to describe the effective dose of dialysis (intensity). • Intensity of RRT can be defined by the product “clearance x time” (Kt: mL/ min * 24 h, L/h * 4 h, etc.). Kt is more useful than K in comparing various RRTs. However, it does not take into account the size of the pool of solute which needs to be cleared. This requires the dimension of efficacy.
Practical aspects of RRT dose Tables 8.1 and 8.2 show a potential flow chart that could be followed each time an RRT prescription is indicated. • Urea volume of distribution V (L): patient’s body weight (kg) * 0.6. • Estimated fractional clearance (Kt/VCALC): KCALC (mL/min) * prescribed treatment time (min)/V (mL).
Dose adequacy and assessment CHAPTER 8
administration of a given treatment dose to a given patient. It can be described as a fractional clearance of a given solute (Kt/V) where V is the volume of distribution of the marker molecule in the body. Kt/V is a dimensionless number (e.g., 50 mL/min * 24h/45 L = 3 L/h * 24h/45 L = 72 L/45 L = 1.6) and it is an established measure of dialysis dose correlating with medium term (several years) survival in chronic hemodialysis patients. Urea is typically used as a marker molecule in end-stage kidney disease to guide treatment dose (the volume of distribution of urea (VUREA) is generally considered as equal to patient total body water, which is 60% of patient body weight), and a Kt/VUREA of at least 1.2 is currently recommended for IHD treatments. However, Kt/VUREA application to patients with AKI has not been rigorously validated due to a major uncertainty about VUREA estimation. Some authors have suggested to express dose as K indexed to patient body weight as an operative measure of daily CRRT: it is now suggested to deliver no less than 20 mL/kg/h * 24 h: if the simplification discussed above (K = mL/h = QF or QD) can be considered acceptable, this CRRT dose might be expressed in a 70 kg patient as about 1500 mL/h or 36 L/day of continuous venovenous hemofiltration (CV VH: QF * kg * 24 h) or dialysis (CV VHD: QD * kg * 24 h). Interestingly, applying Kt/ VUREA dose assessment methodology in such a 70 kg patient, the dosage of 20 mL/kg/h * 24 h would be equivalent to a Kt/V of 0.8. Many authors showed the potential benefits of higher RRT doses. However, it has been shown that during a continuous therapy a K less than 2 L/h will almost definitely result insufficient in an adult septic (hypercatabolic) critically ill patient. Furthermore, it is usually necessary to proscribe a higher dose (e.g., 25–30 mL/kg/h) to ensure that delivery is never less than the 20 mL/kg/h floor. Nevertheless, so far, several clinical trials have failed to show a “one-size fits all” prescription for RRT, and dialysis dose should always be tailored to each patient. The most important point is to never “underdialize” patients. • Other parameters include acid-base control, tonicity control, potassium control, magnesium control, calcium and phosphate control, intravascular volume control, extravascular volume control, temperature control, and the avoidance of unwanted side effects associated with the delivery of solute control. These aspects of dose are not currently addressed by any attempt of measure, but should be considered when discussing the prescription of RRT.
55
• Efficacy of RRT is the effective solute removal outcome resulting from the
Dose adequacy and assessment CHAPTER 8
Table 8.1 RRT prescription Clinical variables Fluid balance
Adequacy and dose
Acid-base
56
Electrolyte
Timing Protocol
Operational variables Net ultrafiltration
Setting
A continuous management of negative balance (100–300 mL/h) is preferred in hemodynamically unstable patients. A complete monitoring (CVC, S-G, arterial line, EKG, pulse oxymeter) is recommended. Clearance/modality 2000–2500 mL/h K (or 25–30 mL/kg/h) for CRRT; consider first CVVHDF. If IHD is selected, a minimum dose of 1.2 Kt/V delivered at least 3 times per week. Note that a 4–5 hour prescription is usually necessary and monitoring of delivered Kt/V is recommended. Solution buffer Bicarbonate buffered solutions are preferable to lactate buffered solutions in case of lactic acidosis and/or hepatic failure. Dialysate/replacement Consider solutions without K+ in case of severe hyperkalemia. Manage accurately MgPO4. Schedule Early and intense RRT is suggested. Staff/machine Well-trained staff should routinely utilize RRT monitors according to predefined institutional protocols.
Note: CVC = central venous catheter; S-G = Swan Ganz catheter; EKG = electrocardiogram; CRRT = continuous renal replacement therapy; CVVHDF = continuous veno-venous hemodiafiltration; IHD = intermittent hemodialysis.
• 25 mL/kg/h roughly correspond to a Kt/V of 1.0. • Filtration fraction calculation (postdilution): QREP/QB * 100; filtration fraction
calculation (predilution): QREP/QB + QREP * 100. • QB: blood flow rate; QREP: replacement solution flow rate; QUF: ultrafiltration
flow rate (QUF: QREP + QNET); QNET: patient’s net fluid loss; QDO: dialysate solution flow rate.
RRT dose delivery: continuous or intermittent In its original conceivement, K is utilized to evaluate renal function among disparate individuals whose kidneys, however, are operating 24 hours per day and urea/creatinine blood levels are at steady state. For this reason, the concept of K is easily applicable to continuous treatments, and its utilization to describe intermittent therapies’ efficiency is a sort of “adaptation.” • K is typically higher in IHD than in CRRT and SLEDD. • However, mass removal may be greater during SLEDD or CRRT because the K is applied for 12/24 hours (Table 8.3).
CV VH predilution
Always keep filtration fraction < 20% (QB must be 5 times QREP) KCALC = QUF / Filtration fraction [1 + (QREP/QB)] computation changes (keep <20%)
CV VHD
KCALC = QDO
Keep QB at least thrice Qd
CV VHDF postdilution (~50% convective and diffusive K)
KCALC = QREP + QDO
Consider both notes of CVVH and CVVHD
Value of Q in order to obtain 25 mL/kg/h QREP: 25 mL/min or 2000 mL/h
For a QB of 180 mL/min: QREP: 30 mL/min or 2500 mL/h QDO: 25 mL/min or 2000 mL/h QREP: 15 mL/min + QDO: 10 mL/min
Value of Q in order to obtain a Kt/V of 1 QREP: 29 mL/min or 1750 mL/h
For a QB of 200 mL/min: QREP: 35 mL/min or 2100 mL/h QDO: 29 mL/min or 1750 mL/h QREP: 14 mL/min replacement solution + QDO: 15 mL/min
Table 8.3 Comparison of intermittent hemodialysis and continuous renal replacement therapy efficiency K (mL/min) Urea start (mg/dL) Urea end (mg/dL) Treatment time (min) Total K (K*time) Urea removed (g)
CRRT 35 110 90 1440 50.5 25
IHD 200 110 30 240 48 18
• From a physiological point of view, even if a continuous and an intermittent
therapy were prescribed in order to provide exactly the same marker solute removal, still they could not be comparable: during continuous treatments, where a relatively low K is applied, a slow but prolonged removal of solutes approaches a pseudosteady state slope (Figure 8.1). In highly intermittent therapies, the intensive K, limited to 4–6 hours per day, thrice a week, causes the saw tooth slope in solute removal and the eventual rebound during the time span without treatment: these peaks and valleys of solutes, bicarbonate, electrolytes, plasma osmolarity, and volemia are not physiological and might
Dose adequacy and assessment
Notes
CHAPTER 8
CV VH postdilution
Estimated urea clearance (KCALC) KCALC = QREP
57
Table 8.2 Example of a possible prescription for a continuous treatment in a 70-kg patient (VUREA: 42 L) during an ideal session of 24 hours (t: 1440 minutes). Net ultrafiltration (patient fluid loss) is considered zero in KCALC for simplicity
IHD 100 BUN (mg/dL)
Dose adequacy and assessment CHAPTER 8
120
80 60 CVVH
40 SLED
20 0
0
6
12
18 24 30 36 42 Hours of treatment
48
54
58
Figure 8.1 Blood urea nitrogen (BUN) patterns over time for intermittent hemodialysis (IHD), continuous venovenous hemofiltration (CVVH), and slow low-efficiency dialysis (SLED).
have a detrimental impact on patients’ hemodynamics as well as electrolyte, acid base, and other “osmoles” balance. • Furthermore, in the case of IHD, the intercompartmental transmittance (Kc), that is, the variable tendency of different tissues to “release” a solute into the bloodstream, is much more relevant than during slow efficiency treatments. Different prescriptions may lead to almost equivalent final daily delivery of K. Nonetheless, continuous therapies seem to achieve a final better urea control due to the different “physiology” of solute removal (slow, steady, prolonged, and independent from tissues intercompartmental transmittance). According to recent international surveys on clinical practice patterns, 80% centers administer CRRT, 17% use intermittent RRT (IRRT), and a few minority apply peritoneal dialysis (PD). Interestingly, in many centers intermittent techniques are utilized together with continuous ones, thus evidencing possibility of multiple prescriptions and practices. Nonetheless, after years of debate, scientific literature is not able to draw conclusions on how RRT delivery modalities may impact clinical outcomes. Many papers have been published on this issue and they must be analyzed critically. Many randomized controlled trials compared intermittent and continuous RRT, providing so far only conflicting and puzzling results. Basing on actual scientific evidence, the Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock recently concluded that, during AKI, CV VH and IHD should be considered equivalent.
Key references Lameire N, van Biesen W, Van Holder R, Colardijn F. The place of intermittent hemodialysis in the treatment of acute renal failure in the ICU patient. Kidney Int. 1998;53(suppl 66):S110-S119. Ricci Z, Bellomo R, Ronco C. Dose of dialysis in acute renal failure. Clin J Am Soc Nephrol. 2006;1:380-388. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26-30. The VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7-20. Uchino S, Bellomo R, Kellum JA, et al; BEST Kidney Investigators Writing Committee. Patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. Int J Artif Organs. 2007;30:281-292. Uchino S, Kellum JA, Bellomo R, et al; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients a multinational, multicenter study. JAMA. 2005;294:813-818.
Dose adequacy and assessment CHAPTER 8
As concluded by the Acute Dialysis Quality Initiative (ADQI) workgroup in 2001, delivered clearance should be monitored during all renal supportive therapies. No recommendations can be made for specific dialysis dosing for patients with specific diseases at this time. A minimum dose of RRT, however, needs to be delivered for AKI: • The best evidence to date supports the delivery of at least 20 mL/kg/h for CV VH, CV VHD, or CV VHDF. Usually this will require the prescribed dose of 25–30 mL/kg/h. At present, there is no evidence of harm in increasing the dose up to 35 mL/kg/h (2–2.5 L/h): this might be beneficial in terms of solute control in selected patients. • 1.2 Kt/V delivered IHD on alternate days—typically prescribed dose is approximately 1.4 Kt/V for alternate day dosing. • For alternate day IHD, isolated ultrafiltration can be used for volume control as needed on nondialysis days. • It should also be recommended that the prescription should exceed that calculated to be “adequate” because of the known gap between prescribed and delivered dose. • If a solute-based approach to the concept of dose seems too restrictive, although operatively relatively simple, other dimensions of adequacy of RRT or RRT dose remain unexplored but likely to be important: blood volume control, acid-base control, tonicity control.
59
Conclusions
This page intentionally left blank
Chapter 9
Acid-base and electrolyte disorders John A. Kellum
An important principle in the management of electrolytes with continuous renal replacement therapy (CRRT) is that “you get what you replace.” With hemofiltration, all electrolytes are freely removed (sieving coefficients near 1) and, thus, over time and assuming no large intake or other losses, plasma concentrations will approach those of the replacement fluid. The rate at which electrolytes change is determined by how different the plasma concentration is relative to that in the replacement fluid and the rate of fluid replacement delivered. Similar principles exist for continuous hemodialysis with one exception: phosphate. Although the phosphate molecule is not large, it behaves as if it were a much larger molecule. As a consequence, phosphate is removed much more slowly with dialysis (diffusion) compared to filtration (convection). For this reason, patients receiving dialysis may still require phosphate binders whereas those receiving hemofiltration frequently require phosphate replacement. It should be noted that plasma electrolyte concentrations often don’t reflect whole body stores, whereas high or low plasma concentrations still may induce symptoms and deleterious physiological and metabolic effects. In particular, K+, the primary intracellular cation, exhibits only a loose association between plasma and intracellular concentrations (see below). Plasma Mg2+ concentrations bear almost no relation to total body stores, and persistent hypokalemia may be the only clue to total body Mg2+ deficiency. Electrolyte losses, as well as electrolyte intake, should be considered in prescribing CRRT. An important source of exogenous K+ is from transfusions of banked blood. Blood transfusions are also an important cause of hypocalcemia owing to the citrate anticoagulation used in blood banking. Important sources of electrolyte loss are shown in Table 9.1. Specific fluid prescribing information for both continuous veno-venous hemofiltration (CVVH) and continuous veno-venous hemodialysis (CVVHD) is found in Chapter 14.
61
Electrolyte management
Acid-base and electrolyte disorders CHAPTER 9
62
Table 9.1 Electrolyte losses • Large nasogastric aspirate, vomiting • Sweating • Polyuria • Diarrhea • Ascitic drainage
Na+, Cl− Na+, Cl− Na+, Cl−, K+, Mg2+ Na+, Cl−, K+, Mg2+ Na+, Cl−, K+
Source: From Kellum JA, Gunn SR, eds. Oxford American Handbook of Critical Care. New York: Oxford University Press; 2008.
Dysnatremias Continuous renal replacement therapy (CRRT) is rarely required as primary therapy for dysnatremias, but patients with renal failure frequently develop dysnatremia, and care must be taken to correct sodium according to the rate at which the abnormality has developed and in response to the nature of the symptoms present. In general dysnatremias that develop slowly should be treated slowly, whereas rapidly occurring dysnatremias demand rapid correction. Severe symptoms also require rapid treatment, although correction will be partial, at first, in the case of chronic conditions. Finally volume status should be considered in the treatment plan.
Hypernatremia Hypernatremia is manifest by thirst, lethargy, coma, seizures, muscular tremor and rigidity, and an increased risk of intracranial hemorrhage. Thirst usually occurs when the plasma sodium rises 3–4 mmol/L above normal. Lack of thirst is associated with central nervous system disease (see Table 9.2). Rate of correction • If hyperacute (<12 h), correction should be rapid. • Otherwise, aim for gradual correction of plasma sodium levels (over 1–3 days), particularly in chronic cases (>2 days’ duration), to avoid cerebral edema through sudden lowering of osmolality. A rate of plasma sodium lowering <0.7 mmol/h has been suggested. Low or normal total body Na (water loss) • Reduce Na concentration in replacement fluid or dialysate (see Chapter 14 for specific fluids). • Give water replacement PO in addition to changes in CRRT fluids. • Even fluid balance (or even fluid gain with replacement fluid) until total body water is normalized. • In the case of central diabetes insipidus (CDI), restrict salt and give thiazide diuretics. Complete CDI will require desmopressin (10 µg bid intranasally or 1–2 µg bid IV), whereas partial CDI may require desmopressin but often responds to drugs that increase the rate of antidiuretic hormone (ADH) secretion or end-organ responsiveness to ADH, for example, chlorpropamide, hydrochlorthiazide.
Etiology
Urine
Low total body Na
Renal losses: diuretic excess, osmotic diuresis (glucose, urea, mannitol) Extra-renal losses: excess sweating
[Na+] >20 mmol/L iso- or hypotonic
Normal total body Na
Increased total body Na
Renal losses: diabetes insipidus Extra-renal losses: respiratory and renal insensible losses Conn’s syndrome, Cushing’s syndrome, excess NaCl, hypertonic NaHCO3
[Na+] <10 mmol/L hypertonic [Na+] variable hypo-, iso- or hypertonic [Na+] variable hypertonic [Na+] >20 mmol/L iso- or hypertonic
Acid-base and electrolyte disorders
Type
CHAPTER 9
Table 9.2 Causes of hypernatremia
• In the case of nephrogenic diabetes insipidus (DI), manage by a low salt diet
and thiazides. High dose desmopressin may be effective. Consider removal of causative agents, for example, lithium. Increased total body Na (Na gain) • Reduce Na concentration in replacement fluid or dialysate (see Chapter 14 for specific fluids). • Remove fluid to achieve even, or in the case of hypervolemia, net negative, fluid balance.
Hyponatremia Hyponatremia may cause nausea, vomiting, headache, fatigue, weakness, muscular twitching, obtundation, psychosis, seizures, and coma. Symptoms depend on the rate as well as the magnitude of fall in the plasma [Na+] (see Table 9.3). Rate and degree of correction • Rate and degree of correction depend on how rapidly the condition has developed and whether the patient is symptomatic. Hyponatremia that has developed over more than 48 h is considered “chronic.” • In CHRONIC ASYMPTOMATIC hyponatremia correction should not exceed 4 mmol /24 h and the rate of correction should not exceed 0.3 mmol/L/h. • In CHRONIC SYMPTOMATIC (e.g., seizures, coma) hyponatremia correction should be 1–1.5 mmol/L/h until symptoms resolve and then correction should be as per asymptomatic cases. • In ACUTE hyponatremia (<48 h) the ideal rate of correction is controversial, although elevations in plasma Na+ can be faster, but <20 mmol/L/day.
63
Source: Kellum JA, Gunn SR, eds. Oxford American Handbook of Critical Care. New York: Oxford University Press; 2008.
Acid-base and electrolyte disorders CHAPTER 9
64
• A plasma Na+ of 125–130 mmol/L is a reasonable target for initial correc-
tion of both acute and chronic states. Attempts to achieve eunatremia rapidly should be avoided. • Neurological complications, for example, central pontine myelinolysis, are related to the degree of correction and (in chronic hyponatremia) the rate. Premenopausal women are at highest risk for this complication. Extracellular fluid (ECF) volume excess • If symptomatic (e.g., seizures, agitation), 100 mL aliquots of hypertonic (1.8%) saline can be given, with plasma levels being checked every 2–3 h. • If symptomatic and edematous, fluid removal on CRRT can be done in addition to hypertonic saline. Plasma levels should be checked every 2–3 h. With custom replacement fluid or dialysate, the Na concentration can be increased somewhat, but hypertonic dialysis or replacement fluid is not recommended. • If not symptomatic, water should be restricted to 1–1.5 L/day. If hyponatremia persists, inappropriate ADH [syndrome of inappropriate antidiuretic hormone secretion (SIADH)] secretion should be considered. • If SIADH is likely, isotonic saline should be given and demeclocycline should be considered. Extracellular fluid (ECF) volume depletion • If symptomatic (e.g., seizures, agitation), give isotonic (0.9%) saline. Consider hypertonic (1.8%) saline initially especially if acute. • If asymptomatic, use isotonic (0.9%) saline. • Maintain even fluid balance on CRRT. General points • Equations that calculate excess water are unreliable. It is safer to monitor plasma sodium levels closely. • Hypertonic saline may be dangerous, especially in the elderly and those with impaired cardiac function. • Use isotonic solutions for reconstituting drugs, parenteral nutrition, and so on (i.e., avoid hypotonic fluids). • Hyponatremia may intensify the cardiac effects of hyperkalemia. • A true hyponatremia may occur with a normal osmolality in the presence of abnormal solutes, for example, ethanol, ethylene glycol, glucose.
Causes of inappropriate ADH secretion • • • • • • •
Neoplasm, for example, lung, pancreas, lymphoma Most pulmonary lesions Most central nervous system lesions Surgical and emotional stress Glucocorticoid and thyroid deficiency Idiopathic Drugs, for example, chlorpropamide, carbamazepine, narcotics
Urine [Na+]
Renal losses: diuretic excess, osmotic diuresis (glucose, urea, mannitol), renal tubular acidosis, salt-losing nephritis, mineralocorticoid deficiency Extra-renal losses, vomiting, diarrhea,: burns, pancreatitis Water intoxication (NB postoperative, TURP syndrome), inappropriate ADH secretion, hypothyroidism, drugs(e.g., carbamazepine, chlorpropamide), glucocorticoid deficiency, pain, stress. Acute and chronic renal failure
>20 mmol/l
Nephrotic syndrome, cirrhosis, heart failure
<10 mmol/l
Modest ECF volume excess (no edema)
ECF volume excess (edema)
<10 mmol/l >20 mmol/l
>20 mmol/l
Source: Kellum JA, Gunn SR, eds. Oxford American Handbook of Critical Care. New York: Oxford University Press; 2008.
Potassium and magnesium Both K+ and Mg2+ are primarily intracellular cations; their total body concentrations depend on the balance between intake and excretion, while their plasma concentrations are determined by total body stores as well as by their distribution across cell membranes. In the case of K+, plasma pH and [Na+] also affect the plasma concentration. Excretion is primarily controlled by the kidneys, although both cations are excreted in the feces as well.
Hyperkalemia Hyperkalemia may cause dangerous arrhythmias, including cardiac arrest. Arrhythmias are more closely related to the rate of rise of potassium than the absolute level. Clinical features such as paresthesia and areflexic weakness are not clearly related to the degree of hyperkalemia but usually occur after ECG changes (tall “T” waves, flat “P” waves, prolonged PR interval and wide QRS). Causes • Reduced renal excretion (e.g., renal failure, adrenal insufficiency, diabetes, potassium sparing diuretics) • Intracellular potassium release (e.g., acidosis, rapid transfusion of old blood, cell lysis including rhabdomyolysis, hemolysis, and tumor lysis • Potassium poisoning Management CRRT is effective in removing K+, although standard hemodialysis can remove K+ faster. Ancillary therapy may also be required particularly in emergency situations (see Chapter 6).
Acid-base and electrolyte disorders
Etiology
ECF volume depletion
CHAPTER 9
Type
65
Table 9.3 Causes of hyponatremia
Acid-base and electrolyte disorders CHAPTER 9
66
Hypokalemia Typical manifestations of hypokalemia include the following: • Arrhythmias (SVT, VT, and Torsades de Pointes) • ECG changes (ST depression, “T” wave flattening, “U” waves) • Constipation • Ileus • Weakness Causes • Inadequate intake • Gastrointestinal losses (e.g., vomiting, diarrhea, fistula losses) • Renal losses (e.g., diabetic ketoacidosis; Conn’s syndrome; secondary hyperaldosteronism; Cushing’s syndrome; renal tubular acidosis; metabolic alkalosis; hypomagnesemia; drugs including diuretics, steroids, theophyllines) • Hemofiltration losses • Potassium transfer into cells (e.g., acute alkalosis, glucose infusion, insulin treatment, familial periodic paralysis) Management Potassium replacement should be intravenous with ECG monitoring when there is a clinically significant arrhythmia (20 mmol over 30 min, repeated according to levels). Slower intravenous replacement (20 mmol over 1 h) should be used where there are clinical features without arrhythmias. Oral supplementation (to a total intake of 80–120 mmol/day, including nutritional input) can be given where there are no clinical features.
Hypomagnesemia Magnesium is primarily an intracellular ion involved in the production and utilization of energy stores and in the mediation of nerve transmission. Low plasma levels, which do not necessarily reflect either intracellular or whole body stores, may thus be associated with features related to these functions: • Confusion, irritability • Seizures • Muscle weakness, lethargy • Arrhythmias • Symptoms related to hypocalcemia and hypokalemia, which are resistant to calcium and potassium supplementation, respectively Normal plasma levels range from 1.7–2.4 mg/dL; severe symptoms do not usually occur until levels drop below 1.0 mg/dL. Causes • Excess loss, for example, diuretics, other causes of polyuria (including poorly controlled diabetes mellitus), severe diarrhea, prolonged vomiting, large nasogastric aspirates
Hypermagnesemia Symptomatic hypermagnesemia rarely occurs even in severe renal failure except as a consequence of a large magnesium load (in which it may occur even with intact renal function) (see Table 9.4). However, patients with renal failure may develop severe hypermagnesemia when exposed to magnesium containing antacids or laxatives, even in usual therapeutic dosages. Thus, these agents are contraindicated in patients with severe renal failure. Most cases of hypermagnesemia are mild (<3.6 mg/dL, or 1.5 mmol/L) and asymptomatic. However, three types of symptoms may be seen when the plasma magnesium concentration exceeds 4.8 mg/dL (2 mmol/L): neuromuscular, cardiovascular, and hypocalcemia. Causes • IV magnesium infusion (typically as treatment for preeclampsia) • Oral ingestion (e.g., laxative, epsom salts) • Magnesium enemas
Table 9.4 Relationship of plasma magnesium and clinical symptoms Plasma [Mg2+] 4.8–7.2 mg/dL (2–3 mmol/L) 7.3–12 mg/dL (3–5 mmol/L) >12 mg/dL (>5 mmol/L)
Deep tendon reflexes Diminished
Other symptoms/signs Nausea, flushing, headache, lethargy, and drowsiness
Absent
Somnolence, hypocalcemia, hypotension, bradycardia, and ECG changes
Absent
Muscle paralysis, respiratory paralysis, complete heart block, and cardiac arrest.
Acid-base and electrolyte disorders
Management • For severe, symptomatic hypomagnesemia, 10 mmol of magnesium sulphate can be given IV over 3–5 min. This can be repeated once or twice as necessary. • In less acute situations or for asymptomatic hypomagnesemia, 1–2 g MgSO4 solution can be given over 1–2 h and repeated as necessary, or according to repeat plasma levels. • A continuous IV infusion can be given; however, this is usually reserved for therapeutic indications where supranormal plasma levels (4–5 mg/dL) of magnesium are sought, for example, treatment of supraventricular and ventricular arrhythmias, preeclampsia, and eclampsia. • Oral magnesium sulfate has a laxative effect and may cause severe diarrhea.
CHAPTER 9
malabsorption syndromes
67
• Inadequate intake, for example, starvation, parenteral nutrition, alcoholism,
Acid-base and electrolyte disorders CHAPTER 9
Management Peritoneal dialysis, hemodialysis, and CRRT have been used effectively to lower the plasma magnesium concentration in patients with severe symptomatic hypermagnesemia, usually in the setting of renal failure complicated by exogenous magnesium loading. Hemodialysis with its higher flow rates works more rapidly, lowering magnesium levels to the nontoxic range usually within 3–4 h. CRRT is typically slower and peritoneal dialysis is usually reserved for milder cases in patients receiving chronic peritoneal dialysis. Exchange transfusion has been effective in neonatal hypermagnesemia. While awaiting dialysis in a patient with severe symptoms, intravenous calcium can be given as a magnesium antagonist. The usual dose is 100–200 mg of elemental calcium over 5–10 min.
Calcium and phosphate
68
Ca2+ and PO43– are often considered together in patients with renal failure as a common complication of chronic disease is renal osteodystophy or bone mineral disease, which leads to hypocalcemia and hyperphosphatemia.
Hypocalcemia Symptoms of hypocalcemia usually appear when total plasma calcium levels are less than 8 mg/dL and the ionized fraction is below 0.8 mmol/L. • Tetany (including carpopedal spasm) • Muscular weakness • Hypotension • Perioral and peripheral paresthesia • Chvostek and Trousseau’s signs • Prolonged QT interval • Seizures Causes • Associated with hyperphosphatemia: • Renal failure • Rhabdomyolysis • Hypoparathyroidism (including surgery), pseudohypoparathyroidism • Associated with low/normal phosphate: • Critical illness including sepsis, burns • Hypomagnesemia • Pancreatitis • Osteomalacia • Overhydration • Massive blood transfusion (citrate binding)
Management • If respiratory alkalosis is present, adjust ventilator settings or, if spontaneously hyperventilating and agitated, calm ± sedate. Rebreathing into a bag may be beneficial. • Administer 1 g of calcium chloride or 3 g of calcium gluconate (270 mg of elemental calcium) IV infusion over 30–60 min. • If symptomatic, give 5–10 mL 10% calcium chloride or 15–20 mL 10% calcium gluconate solution over 10–15 min. Repeat as necessary. • Correct hypomagnesemia or hypokalemia if present. • If asymptomatic and in renal failure or hypoparathyroid, consider enteral/ parenteral calcium supplementation and vitamin D analogues. • If hypotensive or cardiac output is decreased following administration of a calcium antagonist, give 5–10 mL 10% calcium chloride solution over 2–5 min.
Acid-base and electrolyte disorders
ized plasma calcium fraction and induce clinical features of hypocalcaemia
CHAPTER 9
• Hyperventilation and the resulting respiratory alkalosis may reduce the ion-
Among all causes of hypercalcemia, hyperparathyroidism and malignancy are the most common, accounting for greater than 90% of cases. Symptoms of hypercalcemia usually do not become apparent until the total (ionized + unionized) plasma levels >13 mg/dL (normal range 8.5–10.5 mg/dL). Symptoms depend on the patient’s age, the duration and rate of increase of plasma calcium, and the presence of concurrent medical conditions. Signs and symptoms of hypercalcemia may include the following: • Nausea, vomiting, weight loss, pruritus • Abdominal pain, constipation, acute pancreatitis • Muscle weakness, fatigue, lethargy • Depression, mania, psychosis, drowsiness, coma • Polyuria, renal calculi, renal failure • Cardiac arrhythmias Causes • Malignancy (e.g., myeloma, bony metastatic disease, hypernephroma) • Hyperparathyroidism • Granulomatous disease (e.g., sarcoidosis, tuberculosis) • Excess intake of calcium, vitamin A, or vitamin D • Drugs (e.g., thiazides, lithium) • Immobilization • Rarely, thyrotoxicosis, Addison’s disease Management • Identify and treat cause where possible.
69
Hypercalcemia
Acid-base and electrolyte disorders CHAPTER 9
Table 9.5 Drug dosage Diuretics Steroids Pamidronate Calcitonin
Furosemide 10–40 mg IV 2–4 h (may be increased to 80–100 mg IV every 1–2 h) Hydrocortisone 100 mg qid IV or prednisolone 40–60 mg PO for 3–5 days 15–60 mg slow IV bolus 3–4 U/kg IV followed by 4U/kg SC bd
• Carefully monitor hemodynamic variables, urine output, and ECG morphology •
• •
70
•
•
•
with frequent estimations of plasma Ca2+, PO43–, Mg2+, Na+, and K+. Intravascular volume repletion—this inhibits proximal tubular reabsorption of calcium and may lower plasma Ca2+ by 1–2 mg/dL. It should precede diuretics or any other therapy. Isotonic saline is typically used. Calciuresis—after adequate intravascular volume repletion, a forced diuresis with furosemide plus 0.9% saline (6–8 L/day) may be attempted. Steroids can be effective for hypercalcemia related to hematological cancers (lymphoma, myeloma), vitamin D overdose, and sarcoidosis (see Table 9.5). Calcitonin has the most rapid onset of action with a nadir often reached within 12–24 h. Its action is limited (usually does not decrease plasma Ca2+ by more than 2–3 mg/dL), usually short-lived, and rebound hypercalcemia may occur. Biphosphonates (e.g., pamidronate) and IV phosphate should only be given after other measures have failed in view of their toxicity and potential complications. CRRT or hemodialysis may be indicated particularly early on if the patient is in established oligoanuric renal failure ± fluid overloaded. • CRRT or hemodialysis without calcium in the dialysis or replacement fluid are both effective therapies for hypercalcemia, although are usually considered treatments of last resort. RRT may be indicated in patients with severe malignancy-associated hypercalcemia and renal failure or heart failure, in whom hydration cannot be safely administered. • The use of CRRT or hemodialysis in patients with hypercalcemia but without renal failure may require modification of the composition of dialysis solutions. In one case report, hemodialysis with a dialysis solution containing 4 mg/dL of phosphorus resulted in rapid correction of all abnormalities in a patient in whom medical therapy had failed to reverse hypercalcemia, mental status changes, and hypophosphatemia due to primary hyperparathyroidism.
Hypophosphatemia Hypophosphatemia is often asymptomatic even when severe (<1 mg/dL). Symptoms may include muscle weakness (including respiratory muscles and can be associated with inability to wean from mechanical ventilation) rhabdomyolysis, paresthesias, hemolysis, platelet dysfunction, and cardiac failure.
Hyperphosphatemia Hyperphosphatemia itself does not produce symptoms. The major concern for hyperphosphatemia is the high circulating levels of parathyroid hormone (PTH) that result, and, in turn, its role in the development of renal osteodystrophy and possibly in other uremic complications as well. High levels of plasma Ca2+, PO43– together may cause calcinosis (soft tissue calcifications) especially if the plasma Ca × PO4 product is chronically >70. Causes There are three general circumstances, alone or in combination, in which hyperphosphatemia occurs:
1. Massive acute phosphate load (e.g., tumor lysis, rhabdomyolysis) 2. Renal failure 3. Increased phosphate reabsorption (hypoparathyroidism, acromegaly, familial tumoral calcinosis, bisphosphonate therapy, vitamin D toxicity) Management The approach to therapy differs in acute and chronic hyperphosphatemia. Acute severe hyperphosphatemia with symptomatic hypocalcemia can be life-threatening. The hyperphosphatemia usually resolves within 6–12 h if renal function is intact. Phosphate excretion can be increased by saline infusion, although this can further reduce the serum calcium concentration by dilution. CRRT or hemodialysis is often indicated in patients with symptomatic hypocalcemia, particularly if renal function is impaired. Unlike other electrolytes, phosphate is removed more efficiently with CRRT (in hemofiltration mode) compared to hemodialysis. This is because PO43– acts in solution as a larger molecule and is more difficult to remove with diffusion (dialysis) compared to convection (filtration).
Acid-base and electrolyte disorders CHAPTER 9
Management Mild hypophosphatemia may be treated with PO phosphate supplements. In severe and symptomatic cases 20–40 mmol of NaPO4 or KaPO4 should be given by intravenous infusion over 6 h and repeated according to the plasma phosphate level.
71
Causes • Critical illness • Inadequate intake • Loop diuretic therapy (including low-dose dopamine) • Parenteral nutrition levels fall rapidly during high-dose intravenous glucose therapy, especially with insulin • Alcoholism • Hyperparathyroidism
Acid-base and electrolyte disorders CHAPTER 9
72
Pseudohyperphosphatemia Spurious hyperphosphatemia may result from interference with the analytical methods. Causes • Hyperglobulinemia, hyperlipidemia, hemolysis, and hyperbilirubinemia • Liposomal amphotericin B
Key Study Leehey DJ, Ing TS. Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus. Am J Kidney Dis. 1997 Feb;29(2):288-290.
General acid-base management Increased intake, altered production, or impaired/excessive excretion of acid or base leads to derangements in blood pH. With time, respiratory and renal adjustments correct the pH toward normality by altering the plasma levels of PCO2 or strong ions (Na+, Cl− ).
Increased intake • Acidosis: chloride administration (e.g., saline), aspirin overdose • Alkalosis: NaHCO3 administration, antacid abuse, buffered replacement fluid
(hemofiltration) Altered production • Increased acid production: lactic acidosis, diabetic ketoacidosis Altered excretion • Hypercapnic respiratory failure, permissive hypercapnia • Alkalosis: vomiting, large gastric aspirates, diuretics, hyperaldosteronism, corticosteroids • Acidosis: diarrhea, small bowel fistula, urethroenterostomy, renal tubular acidosis, renal failure, distal renal tubular acidosis, acetazolamide
General management principles • Correct (where possible) the underlying cause, for example, hypoperfusion • Use NaCl infusion for vomiting-induced alkalosis; insulin, Na+, and K+ in dia-
betic ketoacidosis • Correct pH in specific circumstances only, for example, NaHCO3 in renal
failure • Avoid large volume saline-based fluids. Consider lacted Ringer’s solution or
hetastarch in balanced electrolyte solution (Hextend) for fluid resuscitation.
citrate anticoagulation) and are amenable to correction with CRRT. • Correction of plasma pH occurs because of change in plasma strong ion differ-
ence and to a small extent, change in weak acid concentration. • “Rules of thumb” for pH correction with CRRT:
The standard base access (SBE) quantifies the change in plasma strong ion difference (SID) required to restore pH to 7.4 for a pCO2 of 40 mm Hg (e.g., SBE –10 indicates that the SID must be increased by 10 mEq/L to fully correct the acid-base abnormality). • To increase SID increase Na+ or decrease Cl– and or lactate. • To decrease SID decrease Na+ or increase Cl–. • Do not change Na+ beyond the normal range (135–145 mEq/L). • Use “buffer” (bicarbonate or lactate) to increase the difference between Na+ and Cl– in the dialysate or replacement fluid. • Typically, undertake correction of half the abnormality and then reassess. • Avoid “over correction” of acid-base abnormalities particularly in cases of metabolizable acid anions (e.g., lactate, ketones) (see metabolic acidosis).
73
•
Acid-base and electrolyte disorders
• Acid-base abnormalities may be caused by improper use of CRRT (e.g., during
CHAPTER 9
CRRT management
Metabolic acidosis A reduced arterial blood pH with a reduced strong ion difference and a base deficit > 2 mEq/L. Outcome in critically ill patients has been linked to the severity and duration of metabolic acidosis and hyperlactatemia.
Causes • Lactic acidosis. Can be due to tissue hypoperfusion, for example, circulatory
• • • •
shock. The anion gap (or strong ion gap) is increased with lactic and other organic acids and poisons. Anaerobic metabolism contributes, in part, to this metabolic acidosis; however other cellular mechanisms are involved and may be more important. May be seen with increased muscle activity (e.g., post seizure, respiratory distress). Lung lactate release seen in acute lung injury. High sustained levels suggest tissue necrosis, for example, bowel, muscle. Hyperchloremia, for example, excessive saline infusion. Ketoacidosis—high levels of β-hydroxybutyrate and acetoacetate related to uncontrolled diabetes mellitus, starvation, and alcoholism. Renal failure—accumulation of organic acids, for example, sulphuric. Drugs—in particular, aspirin (salicylic acid) overdose, acetazolamide (carbonic anhydrase inhibition), ammonium chloride. Vasopressor agents may be implicated, possibly by inducing regional ischemia or, in the case of epinephrine, accelerated glycolysis.
Acid-base and electrolyte disorders CHAPTER 9
• Ingestion of poisons, for example, paraldehyde, ethylene glycol, methanol. • Cation loss, for example, severe diarrhea, small bowel fistulae, large ileostomy
losses.
Causes of lactic acidosis Sepsis Acute lung injury Diabetes mellitus Drugs, for example, phenformin, metformin, alcohols Circulatory shock, for example, septic shock, hemorrhage, heart failure Glucose-6-phosphatase deficiency Hematological malignancy Hepatic failure Renal failure Short bowel syndrome (d-lactate) Thiamine deficiency
74
Clinical features • Dyspnea • Hemodynamic instability • A rapidly increasing metabolic acidosis (over minutes to hours) is not due to
renal failure. Other causes, particularly severe tissue hypoperfusion, sepsis, or tissue necrosis should be suspected when there is associated systemic deterioration
General management • The underlying cause should be identified and treated where possible. • Ventilation support (increase minute volume in controlled mechanical ventila-
tion) to help normalize the arterial pH. • Reversal of the metabolic acidosis is generally an indication of successful
therapy. An increasing base deficit suggests that the therapeutic maneuvers in operation are either inadequate or wrong. • The benefits of buffers such as Carbicarb and THAM (tris-hydroxymethylaminomethane) remain unproved.
CRRT management • Urgent CRRT/hemodialysis may be necessary, particularly if renal function is
also impaired. • Lactate and ketones are easily removed by CRRT, but they are also metabo-
lized rapidly once the underlying metabolic derangement is reversed. CRRT is rarely the primary therapy for lactic or ketoacidosis.
An increased arterial blood pH with an increased strong ion difference and base excess > 2 mEq/L caused either by loss of anions or gain of cations. As the kidney is usually efficient at regulating the strong ion difference, persistence of a metabolic alkalosis usually depends on either renal impairment or a diminished extracellular fluid volume with severe depletion of K+ resulting in an inability to reabsorb Cl– in excess of Na+. • The patient is usually asymptomatic, though, if spontaneously breathing, will hypoventilate. • A metabolic alkalosis will cause a left shift of the oxyhemoglobin curve, reducing oxygen availability to the tissues. • If severe (pH > 7.6), may result in encephalopathy, seizures, altered coronary arterial blood flow, and decreased cardiac inotropy.
Causes • Loss of total body fluid, Cl–, usually due to
diuretics large nasogastric aspirates, vomiting Secondary hyperaldosteronism with potassium chloride (KCl) depletion Use of hemofiltration replacement fluid containing excess buffer (e.g., lactate) Renal compensation for chronic hypercapnia. This can develop within 1–2 weeks. Although more apparent when the patient hyperventilates, or is hyperventilated to normocapnia, an overcompensated metabolic alkalosis can occasionally be seen in the chronic state (i.e., a raised pH in an otherwise stable long-term hypercapnic patient) Excess administration of sodium bicarbonate Excess administration of sodium citrate (large blood transfusion) Drugs, including laxative abuse, corticosteroids Rarely, Cushing’s, Conn’s, Bartter’s syndrome • •
• • •
• • • •
Acid-base and electrolyte disorders CHAPTER 9
Metabolic alkalosis
75
Use standard or slightly more alkaline dialysate or replacement fluid— avoid increasing SID by >5 mEq/L as rapid change in lactate or ketones will result in overshoot alkalosis. • Hyperchloremia does not self-correct in a patient with anuric renal failure. Apart from diet, GI losses, and intracellular shifts, the kidney is the primary regulator of plasma electrolytes. • CRRT is effective in correcting hyperchloremic acidosis. • Decrease Cl– in dialysate or replacement fluid by the same interval as the standard base excess (SBE), for example, for SBE-10, decrease Cl– by 10 mEq/L. •
Acid-base and electrolyte disorders CHAPTER 9
Management • Replacement of fluid, Cl– (i.e., give 0.9% saline), and K+ losses are often sufficient
to restore acid-base balance. • With distal renal causes related to hyperaldosteronism, addition of spironolac-
tone can be considered. • Active treatment is rarely necessary. If so, administer 150 mL of 1.0 N HCl in 1
L sterile water using a central line. Infuse at a rate not greater than 1 mL/kg/h. Alternatives include ammonium chloride PO or, if volume overloaded with intact renal function, acetazolamide 500 mg IV or PO q8h. • Compensation for a long-standing respiratory acidosis, followed by correction of acidosis, for example, with mechanical ventilation, will lead to an uncompensated metabolic alkalosis. This usually corrects with time though treatments such as acetazolamide can be considered. Mechanical “hypoventilation,” that is, maintaining hypercapnia, can also be considered.
CRRT management
76
• CRRT is not generally required for management of metabolic alkalosis itself
but in patients receiving CRRT principles of management of metabolic alkalosis mirror those described above for metabolic acidosis. • If hypernatremia, decrease Na+ in dialysate or replacement fluid. • Increase Cl– concentration in dialysate or replacement fluid (increase concentration by the interval of the SBE). • Metabolic alkalosis can result from regional citrate anticoagulation, particularly if the concentrations of Na+ and Cl– are not adjusted. The Cl– concentration should be increased; if using hypertonic sodium citrate, Na+ concentration in dialysate/replacement fluid should be decreased. • Avoid citrate and Ca2+ “dose spirals;” reduce citrate rather than increasing Ca2+ to avoid citrate overdosing.
Part 2
Practice
This page intentionally left blank
Chapter 10
Choosing a renal replacement therapy in acute kidney injury Jorge Cerdá and Claudio Ronco
Continuous renal replacement therapies (CRRT) are continuous forms of renal functional replacement used to manage acute kidney injury (AKI) in the critically ill patient. Depurative mechanisms include convection, diffusion, and membrane adsorption utilizing high-flux highly permeable biocompatible dialysis membranes. Simultaneous infusion of replacement fluid permits fluid removal without intravascular contraction and better hemodynamic stability, metabolic control to almost normal parameters, and removal of large-size toxins and cytokines. Moreover, CRRT allows better long-term clearance of small and middle molecules than other dialysis modalities. This chapter focuses on the different modalities of CRRT and briefly reviews both the basic concepts and the newest approaches to the management of the critically ill patient with AKI. Nowadays, most of AKI occurs in the intensive care units (ICU) and is associated with elevated morbidity and mortality. The following are characteristics of the “ideal” treatment modality of AKI in the ICU: • Preserves homeostasis • Does not increase comorbidity • Does not worsen patient’s underlying condition • Is inexpensive • Is simple to manage • Is not burdensome to the ICU staff CRRT has made possible the delivery of renal replacement therapy (RRT) to these hemodynamically unstable patients and has permitted a conceptual shift from “renal replacement” to “renal support” therapies, with “renal” and “nonrenal” [such as sepsis, acute respiratory distress syndrome (ARDS)] applications. The hemodynamic stability of the critically ill patient is the main determinant of the most appropriate dialysis modality (Table 10.1). When choosing the modality of RRT most appropriate for each patient, multiple considerations must be kept in mind (Table 10.2).
79
Introduction
Choosing a RRT in AKI CHAPTER 10
Table 10.1 Indications for specific renal replacement therapies Therapeutic goal
Hemodynamics
Preferred therapy
Fluid removal
Stable Unstable Stable Unstable
Intermittent isolated UF Slow continuous UF Intermittent hemodialysis CRRT Convection: CAVH, CV VH Diffusion: CAVHD, CV VHD Both: CAVHDF, CV VHDF Intermittent hemodialysis Intermittent hemodialysis CRRT CRRT CRRT
Urea clearance
Severe hyperkalemia Severe metabolic acidosis Severe hyperphosphoremia Brain edema
Stable/unstable Stable Unstable Stable/unstable Unstable
80
Table 10.2 Considerations in renal replacement therapy for AKI Consideration
Components
Varieties
Dialysis modality
Intermittent hemodialysis
Daily, every other day, SLED AV, VV
Continuous renal replacement therapies Dialysis biocompatibility Dialyzer performance Dialysis delivery
Peritoneal dialysis Membrane characteristics Efficiency Flux Timing of initiation Intensity of dialysis Adequacy of dialysis
Early, late Prescription vs. delivery Dialysis dose
In addition to the patient’s hemodynamic stability, the choice between the various renal replacement modalities rests on solute clearance goals, volume control, and anticoagulation (Table 10.3). This discussion will focus on CRRT modalities and review the basic concepts and the newest approaches to this technology and its application in the ICU. We intend to discuss convective and diffusive depurative mechanisms and address the use of membrane adsorption as an additional method of large molecule removal. Previous chapters have discussed the fundamental operational characteristics of CRRT. Recently, the Acute Dialysis Quality Initiative (ADQI) published a consensus on fluid and volume management, which is relevant to the present discussion.
Use in hemodynamically unstable patients
Solute clearance
Volume control
Anticoagulation
PD IHD IHF Intermittent IHF Hybrid techniques CV VH CV VHD CV VHDF
Yes Possible Possible Possible
++ ++++ +++ ++++
++ +++ +++ +++
No Yes/no Yes/no Yes/no
Possible
++++
++++
Yes/no
Yes Yes Yes
+++/++++ +++/++++ ++++
++++ ++++ ++++
Yes/no Yes/no Yes/no
Choosing a RRT in AKI
Modality
CHAPTER 10
Table 10.3 Advantages and disadvantages of various renal replacement modalities
Arterio-venous or veno-venous blood circuits Arterio-venous (AV) systems are not used except in emergent situations when veno-venous (VV) systems are not available. AV system limitations include arterial damage, blood flow dependency on systemic hemodynamics, and insufficient dialysis dose.
Choice of continuous renal replacement therapy modality The different modalities of CRRT (Figure 10.1) are defined by the main mechanism with which clearance is achieved: simple diffusion (continuous hemodialysis, CV VHD), convection (continuous hemofiltration, CV VH), or a combination of both (continuous hemodiafiltration, CV VHDF). These different modalities differ in the magnitude of the clearance achieved by convection or diffusion, as well as by the vascular access and the need for fluid replacement (hemofiltration) (Table 10.4). Given the absence of evidence of superiority among the different CRRT modalities, the choice rests on the available equipment (membranes, pump systems) and appropriate dialysate, cost, and conceptual considerations.
81
Notes: HDF = hemodiafiltration; CVVH = continuous veno-venous hemofiltration; CVVHD = continuous veno-venous hemodialysis; CVVHDF = continuous veno-venous hemodiafiltration; IHD = intermittent hemodialysis; IHF = intermittent hemofiltration; PD = peritoneal dialysis. Modified from Davenport.
82
CHAPTER 10
Choosing a RRT in AKI
Modalities of CRRT CVVH
SCUF Blood in
Blood in
V UFC
Uf
Uf
V
D
QB = 100–200 mL/min QF = 10 –30 mL/min QD = 10–30 mL/min K = 20 – 50 L/24 h
Blood in
V
Blood in Plasma
QB = 100–200 mL/min Can be coupled with CVVH or CVVHDF
Figure 10.1 Modalities of CRRT.
V
QB = 100–200 mL/min PF = 20–30 mL/min Can be coupled with CVVH or CVVHDF
CPFA
Adsorbent
Plasmafilter
D
QB = 100 – 200 mL/min QF = 2 – 8 mL/min QD = 50 – 200 mL/min K = 40 – 60 L/24 h Diffusion + Convection (Back Filtration)
CHP Blood in
QB = 100–200 mL/min QF = 2–4 mL/min QF = 10–30 mL/min K = 15–45 L/24 h
CPF–PE V
UFC
V D
CVVHDF–SLED
R Blood in
Blood in UF+D
Blood in
V
QB = 100–200 mL/min QF = 10–30 mL/min K = 15–45 L/24 h
QB = 100 mL/min QF = 2–8 mL/min
CVVHDF
CVVHD
R
Plasmafilter
HVHF V
Adsorbent
QB = 100–200 mL/min PF = 20 –30 mL/min Can be coupled with CVVH or CVVHD/F
R
Blood in
V Uf
QB = 200 –300 mL/min QF = 50 – 100 mL/min K = 60 – 120 L/24 h
Clearance
mechanism
Vascular access
Fluid replacement
SCUF CAVH CV VH CAVHD CV VHD CAVHDF CV VHDF CAVHFD CV VHFD
Convection + ++++ ++++ + + +++ +++ ++ ++
Diffusion ++++ ++++ +++ +++ ++++ ++++
Large vein Artery and vein Large vein Artery and vein Large vein Artery and vein Large vein Artery and vein Large vein
0 +++ +++ +++ +/0 ++ ++ +/0 +/0
Choosing a RRT in AKI
Technique
CHAPTER 10
Table 10.4 Modalities of continuous renal replacement therapy
Dialysis membranes for CRRT The main features of convective treatments are the following: • High-flux membranes • High permeability to water • High permeability to low and middle molecular weight (MW) solutes (1000–12,000 dalton) • High “biocompatibility” Dialysis devices are designated as the following: • “Dialyzers” working predominantly in diffusion with a countercurrent flow of blood and dialysate • “Hemofilters” working prevalently in convection • Newer designs allowing powerful simultaneous convection and diffusion (highflux dialysis, hemodiafiltration) It is a widespread opinion that convective treatments like high-flux hemodialysis, hemodiafiltration, and hemofiltration offer a clinical advantage over standard dialysis, when considering physiological outcomes. The crucial point is that up until now none of the studies have been able to demonstrate superiority of these techniques on morbidity, mortality, and quality of life.
83
Notes: CAVH = continuous arterio-venous hemofiltration; CAVHD = continuous arterio-venous hemodialysis; CAVHDF = continuous arterio-venous hemodiafiltration; CAVHFD = continuous arteriovenous high-flux hemodialysis; CV VH = continuous veno-venous hemofiltration; CV VHD = continuous veno-venous hemodialysis; CV VHDF = continuous veno-venous hemodiafiltration; CV VHFD = continuous veno-venous high-flux hemodialysis; SCUF = slow continuous ultrafiltration; 0 = not required; + = negligible; ++ = some; +++ = marked; ++++ = major.
Choosing a RRT in AKI CHAPTER 10
84
Comparison between CRRT and other renal replacement modalities Continuous renal replacement therapy techniques offer better long-term clearance of small and middle molecules than intermittent hemodialysis (IHD) or slow low efficiency dialysis (SLED): • An 8% and 60% higher small solute clearance comparing CV VH with SLED and IHD respectively. • Effective azotemic control with CRRT and SLED but pronounced concentration peaks and poor time-averaged azotemic control with IHD. • More pronounced differences in the middle-molecule range of solutes, with superior middle-molecule clearance with CV VH compared with SLED or IHD. • The superior middle and large molecule removal for CV VH is due to combination of convection and continuous operation. • While on CRRT beta-2 microglobulin plasma concentration achieved steady state after 3 days, using SLED or IHD plasma concentration actually increases steadily, thus reflecting the inability of the latter modalities to clear large and middlemolecular weight toxins. The importance of the clearance of larger compounds is suggested by two treatment trials (Ronco et al. [1] study and an earlier CRRT study) correlating convective dose (i.e., ultrafiltration rate) with survival. Large molecular clearance may have contributed substantially to the salutary effect of higher doses in these therapies. More recently, Saudan et al. [2] have shown that the addition of diffusion to convective clearance resulted in further improvement in patient outcome. Because the daily IHD versus every other day IHD study by Schiffl et al. [3] was performed with high-flux dialyzers, the clearance of compounds significantly larger than urea may have played a role in the improved survival among the patients dialyzed daily. In spite of these suggestive findings, there is no firm evidence that enhanced removal of mid or high molecular weight in patients leads to better patient outcomes (see below).
Convection and diffusion Convection-based replacement techniques (hemofiltration and hemodiafiltration) using high-flux membrane filters are aimed at maximizing the removal of so-called medium and high molecularweight solutes (higher than 1000 kDa up to several thousand kDa), as opposed to the so-called low molecular weight toxins.
Hemofiltration • Predominantly convective technique • Removes larger quantities of hydrophilic MW compounds than diffusion • Leads to greater cytokine removal by adsorption and convection
Hemodiafiltration • Utilizes partially hydrophilic high-flux membranes • Membranes that have high sieving coefficient and reduced wall thickness com-
bine diffusion and convection • Accurate ultrafiltration (UF) control systems make safe large-volume removal
possible • Newer machines permit separate control of dialysate and UF/reinfusion • Online production of ultrapure dialysate and replacement fluid has made it
Choosing a RRT in AKI
strated to benefit patient outcome
CHAPTER 10
• Removal of inflammatory mediators has been postulated but not demon-
With current CRRT machines, solute exchanges can be obtained by convection, diffusion, or both, with easier and more precise control over each component of the therapy. Blood (QB), dialysate (QD), and ultrafiltrate (QUF) flow rates can be controlled accurately with integrated pumps, and greater dialysate or convective flows—and therefore greater diffusive and convective solute fluxes can be achieved. During CRRT, diffusion is limited by QD, in contrast to IHD; the addition of convection may improve the clearances or middle molecular weight solutes.
Diffusion • The diffusivity of a solute, whether in solution or in an extracorporeal mem-
brane, is, inversely proportional to its molecular weight: as solute molecular weight increases, diffusion becomes a relatively inefficient dialytic removal mechanism and the relative importance of convection increases. • Diffusion occurs whenever a concentration gradient (dc) exists for solutes not restricted in diffusion by the porosity of the membrane. • Diffusion flux is also influenced by the characteristics of the membrane including the following: • Surface area (A) • Thickness (dx) • The temperature of the solution (T) • Diffusion coefficient of the solute (D) The diffusion flux of a given solute (Jx) will therefore result from the equation: Jx = D . T . A (dc/dx)
(1)
Other factors may influence the final clearance values, including protein binding or electrical charges in the solute. Increased convection may contribute to greater solute transport, especially in the higher molecular weight range.
85
possible to deliver safe and less costly treatments
Choosing a RRT in AKI CHAPTER 10
Convection Convection requires movement of fluid across the membrane driven by a transmembrane pressure gradient (TMP). The fluid transport is defined as ultrafiltration and can be described by the equation: Jf = Kf . TMP
(2)
where Kf is the coefficient of hydraulic permeability of the membrane and TMP = (PB – PUF) – S, where PB is the hydrostatic pressure of blood, PUF is the hydrostatic pressure of ultrafiltrate or dialysate, and S is the oncotic pressure of plasma proteins. The convective fluid of a solute x will therefore depend on the following: • The amount of ultrafiltration (Jf) • The concentration of the solute in plasma water (Cb) • The sieving characteristics of the membrane for the solute (S): Jx = Jf Cb (1–V) = Jf Cb S
(3)
86
The sieving coefficient (S) is regulated by the reflection coefficient of the membrane V according to the equation S=1–V
(4)
In clinical practice, however, because plasma proteins and other factors modify the original reflection coefficient of the membrane, the final observed sieving coefficient is smaller than expected from a simple theoretical calculation.
Predilution or postdilution In hemofiltration, replacement fluid can be infused either before the hemofilter (“predilution”) or after the hemofilter (“postdilution”). Postdilution CV VH is a purely convective therapy. The three primary determinants of solute clearance are as follows: 1. Ultrafiltration rate 2. Membrane sieving coefficient 3. Dilution mode Convection occurs by “solvent drag”: solutes are swept (dragged) across the membrane in association with ultrafiltered plasma water, such that K = QF . SC
(5)
where K is clearance (mL/min), QF is ultrafiltration rate (mL/min), and SC is sieving coefficient. For small solutes, as SC approaches unity, clearance equals the ultrafiltration rate in postdilution. In postdilution CV VH, filtration fraction (FF), the ratio of ultrafiltration rate (QUF) to plasma water flow rate is a limiting factor determined by blood flow (QB) rate and patient hematocrit (Htc): QUF FF = ___________ QB(1 – Htc)
(6)
Predilution mode has been introduced as an useful adjunct to prevent clotting of the extracorporeal circuit and to extend filter life, especially during high-volume CRRT, where filtration fraction would otherwise reach values greater than 0.3 and induce clotting and protein encroachment of the membranes. Predilution CRRT allows freedom from the constraints in blood flow and filtration rate imposed by predilution. For small solutes dissolved in the water of the blood passing through the hemofilter, clearance equals
Choosing a RRT in AKI
(7)
where QBW is blood water flow rate and QS is the substitution (replacement) fluid rate. At a given QF value, • predilution is always less efficient than postdilution CV VH with respect to fluid utilization, • while predilution attenuates hemoconcentration-related effects, it simultaneously reduces the efficiency of the treatment, • the larger the QS is relative to QBW, the smaller the entire fraction and the greater the loss of efficiency relative to postdilution.
Importance of achieving a high blood flow (QB) In CV VH, given the direct relationship between QS and QF, great efforts are needed toward increasing the blood flow beyond that used traditionally in CRRT, usually close to 150 mL/min or less. In predilution mode, to attain doses of 35 mL/kg/h as described by Ronco et al., it is necessary to achieve blood flows of 250 mL/min or higher, given that the decrease in efficiency inherent to predilution mode can be as high as 35% to 40%–45% for urea and creatinine respectively when QB is 125–150 mL/min and QS is fixed at 75 mL/min. Utilizing modeling analysis, Clark et al. [4] have shown that • as patient’s weight increases, for low blood flow rates substitution fluid rates required to achieve this dose are impractically high in the majority of patients weighing more than 70 kg, • to achieve the dose target, the high ultrafiltration required determines high replacement fluid infusion rates, which in turn have a substantial dilutive effect on solute concentrations at low blood flows,
87
K = QF . SC . [QBW/(QBW + QS)]
CHAPTER 10
Clinical practice indicates that an FF greater than 0.3 should be avoided because of hemoconcentration and protein-membrane interaction. • Greater ultrafiltration rates require larger blood flows to avoid elevated FF and filter clotting and coating with accumulated proteins. • As higher blood flows are usually difficult to reach with the temporary dialysis catheters and hemodynamic conditions commonly prevalent among critically ill patients, reaching the higher doses recently demonstrated to affect survival are difficult to reach in postdilution mode.
Choosing a RRT in AKI CHAPTER 10
Interaction between convection and diffusion
88
• conversely, higher blood flows allow the delivery of higher doses without loss
of efficiency. Brunet et al. [5] studied the diffusive and convective solute clearances during CV VHDF at various dialysate and ultrafiltration rates. They demonstrated that convection is more effective than diffusion in removing middle molecular weight solutes during CRRT, and that high convective fluxes should be applied if the goal is to remove middle molecules more efficiently. At the slow flow rates normally utilized in CRRT, there is no interaction between diffusive and convective clearances. Recent studies have shown that the addition of a diffusive component to dialysis “dose” resulted in improved survival. Up until recently, dose data were mainly limited to diffusion and convection [1]. The results of Ronco et al. led to the definition of a “standard dose” of CRRT of 35 mL/kg/h, which was applied indiscriminately to diffusive and convective continuous modalities. More recently, Palevsky et al. [6], utilizing a combined diffusive and convective modality (predilution CV VHDF) or IHD depending on hemodynamic stability, failed to demonstrate a beneficial effect of such dose, as discussed elsewhere (see Chapter 8). It must be emphasized that the study by Palevsky et al. was not designed to evaluate the different RRT modalities, but rather to evaluate the effects of dose on survival and renal recovery function. • The premise of those studies is that dose is a solute clearance-related parameter. • The studies were not designed to enable a determination of which toxin class increased clearance led to better survival. Although small solute clearance is a possible explanation, substantial clearance of relatively large molecular weight toxins may also explain the survival benefit in the high dose arm of the Ronco study. Based on the dosing scheme of normalizing effluent flow rate to body weight, other forms of CRRT such as CV VHD and CV VHDF may provide equivalent or nearly equivalent small solute clearances as postdilution CV VH, but for a given effluent flow rate, the diffusive component of these therapies limits their ability to clear larger molecular weight toxins relative to hemofiltration. Consequently, extrapolating Ronco’s data to other forms of CRRT, especially for dosing purposes, should be done with caution.
Nutrition and outcome Better management of volume and body fluid composition is easily achieved with CRRT. Given the importance of nutrition on the outcome of critically ill patients with AKI, CRRT could offer a theoretical advantage over IHD in this setting.
Choosing a RRT in AKI CHAPTER 10
Older and very recent studies have consistently shown that the main advantage of continuous modalities is greater hemodynamic stability. In their recently published study, Palevsky et al. [6] chose CRRT (CV VHDF) as the modality of choice for hemodynamically unstable patients, a decision that reflects current practice in the United States. In their study, although hemodynamically “stable” patients were allocated to IHD, hypotension occurred more frequently among patients treated with IHD than CRRT and may have had an impact on their lower rate of recovery of renal function. CRRT is associated with better tolerance to fluid removal because of the following reasons: • The rate of fluid removal is much slower in CRRT than in IHD. • The main determinant of hemodynamic instability during RRT is the maintenance of intravascular compartment volume. • The volume of that compartment is the result of the balance between convective removal of fluid (ultrafiltration) from plasma and the rate of replenishment from the interstitium. • Therefore, whenever the UF rate exceeds the rate of interstitium-toplasma flow (refilling), the patient will experience hypovolemia and hemodynamic instability. • In IHD rapid diffusion of urea creates a plasma-to-interstitium and interstitium-to-cell osmotic gradient that drives water to the interstitium and to the intracellular compartment, such that plasma volume decreases and cell edema (including neuronal edema) occurs. • With CRRT, the slower rate of urea clearance allows for equalization of urea concentrations between compartments and, therefore, lessened water shifts and cell edema. • This is particularly important in patients with intracranial hypertension, such as head trauma and severe liver failure. • A decrease in core temperature and peripheral vasoconstriction has been shown to decrease hypotensive episodes and may play a role in hemodynamic stability. • With either pre- or postdilution hemofiltration, the magnitude of sodium removal is less than the amount of sodium removed with hemodialysis, a factor that may contribute to better cardiovascular stability in hemofiltration. • Although hypovolemia is the first step in dialysis-related hypotension, the ultimate arterial pressure response to hypovolemia is the result of a complex interplay between active and passive mechanisms, including decreased venous vessel capacity to sustain cardiac filling, increased arterial vascular resistances to ensure organ perfusion, and increased myocardial contractility and heart rate to maintain cardiac stroke volume. Any factor interfering with one or more of these compensatory mechanisms may foster cardiovascular instability.
89
Hemodynamic stability
Choosing a RRT in AKI CHAPTER 10
90
In this context, it is possible that convective removal of inflammatory mediators could contribute to hemodynamic stability, especially in the early phases of septic shock (see below).
Hemofiltration of large molecules • Middle molecules
Mostly of peptides and small proteins with molecular weight in the range of 1000 to 600,000 daltons. • Accumulate in renal failure and contribute to the uremic toxic state. • Beta-2 microglobulin, with a molecular weight of 11,000 dalton, is considered representative of these middle molecules. • Cannot be well cleared by low-flux dialysis. • High-flux dialysis will clear middle molecules partly by internal filtration (convection); the convective component of high-flux dialysis can be enhanced in a predictable way by hemodiafiltration. In the past decade, it has been postulated that high convective dose therapies improve the management of sepsis. • Severe sepsis and septic shock are the primary causes of multiple organ dysfunction syndrome (MODS), the most frequent cause of death in intensive care unit patients. • Many water-soluble mediators with pro- and antiinflammatory action such as TNF, IL-6, IL-8, and IL-10 play a strategic role in septic syndrome. • In intensive care medicine, blocking any one mediator has not led to a measurable outcome improvement in patients with sepsis. • CRRT is a continuously acting therapy, which removes in a nonselective way pro- and antiinflammatory mediators. The “peak-concentration hypothesis” is the concept that cutting peaks of soluble mediators through continuous hemofiltration may help restore homeostasis. This latter development proposes to use increased volume exchanges in hemofiltration or the combined use of adsorbent techniques. • High-volume hemofiltration (HVHF): • A variant of CV VH that requires higher surface area hemofilters and ultrafiltration volumes of 35 to 80 mL/kg/h. • Provides higher clearance for middle/high molecular weight solutes than simple diffusive transport (CV VHD) or convection-based transport at lower volumes (CV VH). • Associated with practical difficulties including machinery, replacement fluid availability and cost, and accurate monitoring systems to maintain safety. • Studies utilizing this technique have shown preliminary evidence of benefit, but none of the studies are randomized trials of adequate statistical power to demonstrate effect conclusively. • Alternative technologies have utilized high cutoff hemofilters with increased effective pore size. •
Choosing a RRT in AKI
References
91
1. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26-30. 2. Saudan P, Niederberger M, DeSeigneux S, et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int. 2006;70:1312-1317. 3. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. New England Journal of Medicine. 2002;346:305-310. 4. Clark WR, Turk JE, Kraus MA, Gao D. Dose determinants in continuous renal replacement therapy. Artif Organs. 2003;27(9):815-220. 5. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. American Journal of Kidney Diseases. 1999;34:486-492. 6. Palevsky PM, Zhang JH, O’Connor TZ, et al., The VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359(1):7-20.
Suggested readings Cerda J, Bagga A, Kher V, Chakravarthi RM. The contrasting characteristics of acute kidney injury in developed and developing countries. Nat Clin Pract Nephrol. 2008;4(3):138–153.
CHAPTER 10
Drawbacks of such porous membranes include the loss of essential proteins such as albumin. • Plasmafiltration coupled with adsorption (CPFA) has been recently utilized in septic patients • In coupled plasma filtration adsorption (CPFA), plasma is separated from blood and the plasma is circulated through a sorbent bed; blood is subsequently reconstituted and dialyzed with standard techniques, thus achieving normalization of body fluid composition and increased removal of proteinbound solutes and high molecular weight toxins. • Recently, evidence has been obtained that very high-volume hemofiltration applied in pulses may improve the hemodynamic stability of septic patients in septic shock, but failed to show consistently improved survival. Larger multicentric evidence will be necessary before such techniques are widely implemented. If benefit is demonstrated, the use of very high volume hemofiltration will require special equipment and very capable nursing able to manage such large volumes (i.e., up to 5–6 L/h) of ultrapure replacement fluid without error. •
Choosing a RRT in AKI CHAPTER 10
92
Cerda, J, Cerdá M, Kilcullen P, Prendergast J. In severe acute kidney injury, a higher serum creatinine is paradoxically associated with better patient survival. Nephrol Dial Transplant. 2007;22(10):2781-2784. Cerda J, Lameire N, Eggers P. Epidemiology of acute kidney injury. Clin J Am Soc Nephrol. 2008;3(3):881-886. Clark WR, Ronco C. Continuous renal replacement techniques. Contrib Nephrol. 2004;144:264-277. Cruz D, Bellomo R, Kellum JA, de Cal M, Ronco C. The future of extracorporeal support. Crit Care Med. 2008;36(suppl 4):S243-252. Davenport A. Renal replacement therapy in acute kidney injury: which method to use in the intensive care unit? Saudi J Kidney Dis Transpl. 2008;19(4):529-536. Gibney N, Cerda J, Davenport A, et al. Volume management by renal replacement therapy in acute kidney injury. Int J Artif Organs. 2008;31(2):145-155. Kellum JA, Cerda J, Kaplan LJ, Nadim MK, Palevsky PM. Fluids for prevention and management of acute kidney injury. Int J Artif Organs. 2008;31(2):96-110. Lameire N, Biesen WV, Vanholder R. Dialysing the patient with acute renal failure in the ICU: the emperor’s clothes? Nephrol Dial Transplant. 1999;14(11):2570-2573. Murray P, Hall J. Renal replacement therapy for acute renal failure. Am J Respir Crit Care Med. 2000;162(3 Pt 1):777-781. Palevsky PM, Bunchman T, Tetta C. The Acute Dialysis Quality Initiative—part V: operational characteristics of CRRT. Adv Ren Replace Ther. 2002;9(4):268-272. Ronco C. Recent evolution of renal replacement therapy in the critically ill patient. Crit Care. 2006;10(1):123-131. Ronco C, Inguaggiato P, D’Intini V. The role of extracorporeal therapies in sepsis. J Nephrol. 2003;16(suppl 7):S34-41. Ronco C, Tetta C. Extracorporal blood purification: more than diffusion and convection. Does this help? Curr Opin Crit Care. 2007;13(6):662-667.
Chapter 11
Vascular access for continuous renal replacement therapy
Renal replacement therapy (RRT) remains a cornerstone for the management of patients with severe acute kidney injury (AKI). The efficacy of RRT depends on a reliable vascular access. In critically ill patients, continuous renal replacement therapy (CRRT) is usually performed with a temporary dialysis catheter (TDC), which can be employed in any patient, easily inserted at the bedside, and used immediately after insertion. Malfunction of the catheter is frequently due to insufficient blood flow rates, repeated clotting of the extracorporeal circuit, and shortened dialysis time.
Type of catheter The demands on TDC are manifold, including sufficient rigidity to insert the catheter and maintain patency, enough flexibility to prevent kinking, thromboresistent, and resistant to bacterial invasion. Different types of TDC are available, but CRRT is usually performed with a dual-lumen catheter inserted into a central vein (see Figure 11.1). A septum in the catheter separates the two lumina and prevents cross flow. The two lumina can be arranged side by side or in a concentric manner (coaxial). To minimize the recirculation rate, the tips on the catheter are staged. Frequently, the return tip will be longer than the intake tip with a gap of more than 3 cm separating the two orifices. The choice of the right catheter length is crucial for both upperbody (i.e., internal jugular vein) and lower-body (i.e., femoral vein) access sites, since recirculation will occur if the catheter length is not long enough. The two most frequently used blood-compatible materials for dialysis catheters are silicone and polyurethane. The advantage of silicone is that it is soft and flexible and resistant to most chemicals. However, due to the mechanical properties, silicone catheters are more difficult to insert and compression of the lumen may lead to mechanical failure. On the other hand the danger of endothelial damage or venous perforation is lower. Polyurethane is comparable to
93
Alexander Zarbock and Kai Singbartl
Vascular access for CRRT
B
C
D
94
CHAPTER 11
A
Figure 11.1 Type of catheters used for continuous renal replacement therapy (CRRT): (A) All catheters used for acute CRRT today have tapered tips. Blood is usually removed through the side holes, located at some distance from the tip (approx. 3 cm). (B) The Mahurkar acute dialysis catheter has a so-called “double-D design” that allows blood to be withdrawn through one side of the catheter (intake lumen, “dark grey”) and returned through the other side (return lumen, “light grey”). (C) The “Circle C” catheter represents a variation of the Mahurkar catheter. Blood is removed through the outer cylindrical lumen and later returned through the inner cylindrical lumen. Here, the internal surface area is greater than that of the double-D catheter, and therefore resistance to blood flow is greater. (D) Uldall concentric duallumen catheter. This catheter had an outer surface with side holes in all directions for intake of blood and a concentric inner lumen for blood return through the tip.
silicone with respect to biocompatibility but displays a higher tensile strength. Polyurethane catheter can be extruded with a thinner wall resulting in a larger inner diameter and subsequently a higher flow rate, compared to silicon catheters with the same outer diameter. The advantage of polyurethane catheters is that they have thermoplastic properties, being rigid during placement but softening when soaked at body temperature. The use of polyurethane catheters are often recommended, because it has been shown that this material is associated with reduced bacterial colonization [2].
Vascular access site and implementation General consideration • The insertion site of the catheter depends on the patient’s characteristics (e.g.,
previous surgery, local infection, coagulopathy, and body habitus), the availability of the insertion site, the skills/experience of the operator, and the risks of site-specific complications. • Due to catheter-related bloodstream infection, nontunneled and noncuffed catheters can be used for short-term RRT (<3 weeks), but tunneled (5–10 cm subcutaneous course) and cuffed catheters should be used if the duration of the RRT is anticipated to be more than 3 weeks [2].
Site of insertion Jugular vein Insertion in the right internal jugular vein (IJV) is preferred over the left IJV because of the increased blood flow and reduced complication rate. Femoral vein The femoral vein is often preferred because of easy and fast accessibility. Transient dialysis catheters in the femoral vein have for a long time been thought to be associated with the highest infection rate. However, a recently conducted multicenter study demonstrated that femoral catheterization is only associated with an increased infection rate in patients with a high body mass index (>28.4) [5]. However, femoral TDCs drastically limit patient mobilization and increase recirculation rates [6,7]. Subclavian vein In critically ill patients, the insertion of a central venous catheter (CVC) in the subclavian vein is preferred because of the low infection rate [8]. However, in patients who develop ESRF and may need permanent vascular access for dialysis, the insertion of a TDC in the subclavian vein is not recommended because it is associated with higher rates of central venous stenosis, excluding the ipsilateral arm for future dialysis access [9–11]. Therefore, the subclavian vein should be reserved for a very short-term use or if there is no other alternative [2,8].
Complications Primary complications • Insertion-related complications are arterial puncture, pneumothorax,
hemothorax, air embolism, arrhythmias, pericardial tamponade, and retroperitoneal hemorrhage. Most of these complications can be reduced by using ultrasound guidance. • A reduced blood flow, frequently indicated by increased intake and/or return pressures in the CRRT circuit, are often due to malpositioning, kinking during insertion, or other mechanical problems. Improper catheter tip placement is a common cause of reduced blood flow and malfunction. Femoral catheters
Vascular access for CRRT
tion whenever possible. This approach can increase the overall success rate while reducing the rate of complications, for example, hemothorax, pneumothorax, and catheter-related infections [2,3]. • Preexisting grafts and fistulae in patients with end-stage renal failure (ESRF) should not be used as vascular access sites for TDCs, as these catheters can lead to permanent vessel or graft wall damage [4].
CHAPTER 11
catheter-related bloodstream infections (CRBSI). • Ultrasound guidance is recommended to be used for central vein catheteriza-
95
• TDCs should be inserted using stringent sterile precautions in order to reduce
Vascular access for CRRT CHAPTER 11
should be inserted in the inferior vena cava, and jugular and subclavian catheters should be placed at the junction of the superior vena cava and the right atrium. Malfunction of catheters in the superior vena cava is further decreased when the tip of the catheters is located in the right atrium, which is safe only with silicone catheters. • Another problem is the inefficiency of CRRT due to recirculation of blood from the return to the intake part of the catheter. This problem arises when the flow generated by the extracorporeal circuit exceeds the flow in the vein. Recirculation rates are normally <5% and dependent on design, length, and insertion site of the catheter as well as the blood flow in the CRRT circuit.
Secondary complications • Infection •
96
•
• • • •
•
•
In ICU patients risk factors for CRBSI include the following: catheter material, elective versus urgent insertion, the frequency of manipulation, the number of infusion ports, the operator’s experience, insertion site, indwelling time, and the severity of the underlying illness. Contamination of TDCs can occur as follows: Extraluminal contamination (migration of skin flora along the external surface of the catheter into the bloodstream), hematogenous contamination (seeding from another focus of infection), and intraluminal contamination (dominant mechanism in longer-dwelling catheters, contamination of the catheter hub through contaminated infusate). The most frequent bacteria are coagulase-negative staphylococci, staphylococcus aureus, enterococci, gram-negative bacteria, and yeast. TDCs should be used for RRT only. The use of trisodium citrate compared to heparin as a catheter-locking solution reduces catheter-related infections [12]. The use of antibiotic-impregnated catheters prevents CRBSI [13], but a general recommendation for using these catheters cannot be given due to the emergence of allergic reactions and bacterial resistance. If a clinical suspicion of CRBSI exists, empiric systemic antibiotics appropriate for the suspected organisms should be started after cultures have been taken. After receiving the blood culture results, antibiotic treatment should be tailored to the specific organism. A positive result in the culture of the catheter tip necessitates the removal of the catheter and insertion of a new catheter at a new site. However, if an infection at the side of puncture, pocket infection of tunneled catheters, or CRBSI with clinical signs of sepsis exists, the catheter has to be removed immediately.
• •
• • •
97
•
Depending on the diagnostic method, the incidence of catheter-related thrombosis may be as high as 33%–67% [14]. Catheter-related thrombosis may occur as a thrombus adherent to the vessel wall or formation of a fibrin sleeve around the catheter. Catheter-related thrombosis can lead to life-threatening complications, such as right heart thromboembolism (RHTE) and pulmonary embolism. Nonmobile RHTE originate from the tip of a catheter in the right atrium. Mobile RHTE represent dislodged thrombi from deep venous thromboses in both upper and lower extremities. During interdialytic periods, the catheter can be filled with an anticoagulant (citrate or heparin) to prevent intraluminal thrombosis. Risk factors for catheter-related thrombosis are listed in Table 11.1. In critically ill patients the incidence of catheter-related thrombosis is higher for femoral and jugular than subclavian catheters. The risk of catheter-related thrombosis and subsequently the risk of catheter-related infection can be reduced by administering anticoagulants or using anticoagulant-bonded catheters.
Vascular access for CRRT
•
CHAPTER 11
• Thrombosis
Table 11.1 Risk factors for TDC thrombosis Patient-related Hypercoagulable statesa Thrombophilic statesa,b Age > 64b Underlying malignancya,b Dehydrationb Impaired tissue perfusionb Absent prophylaxis/ treatmentb
Catheter-related Polyurethane/polyvinyl cathetersb Additional central venous catheters simultaneouslyb Traumatic insertionb Distal placementa
Site-related Femoral or internal jugular siteb Subclavian sitea
Source: Modified after Burns KEA, McLaren A. A critical review of thromboembolic complications associated with central venous catheters. Can J Anesth. 2008;55:532–541. Notes: a Associated with RHTE; bAssociated with central venous thrombosis.
98
CHAPTER 11
Vascular access for CRRT
References 1. Wentling AG, Hemodialysis catheters: materials, design and manufacturing. Contrib Nephrol. 2004;142:112-127. 2. NKF-K/DOQI. Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis. 2001;37(suppl 1):S137-S181. 3. Karakitsos D, Labropoulos N, De Groot E, et al. Real-time ultrasound-guided catheterisation of the internal jugular vein: a prospective comparison with the landmark technique in critical care patients. Crit Care. 2006;10:R162. 4. Davenport A, Mehta S. The Acute Dialysis Quality Initiative—part VI: access and anticoagulation in CRRT. Adv Ren Replace Ther. 2002;9:273-281. 5. Parienti JJ, Thirion M, Megarbane B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA. 2008;299:2413-2422. 6. Leblanc M, Fedak S, Mokris G, Paganini EP. Blood recirculation in temporary central catheters for acute hemodialysis. Clin Nephrol. 1996;45(5):315-319. 7. Little MA, Conlon PJ, Walshe JJ. Access recirculation in temporary hemodialysis catheters as measured by the saline dilution technique. Am J Kidney Dis. 2000;36:1135-1139. 8. Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol. 2002;23:759-769. 9. Cimochowski GE, Worley E, Rutherford WE, Sartain J, Blondin J, Harter H. Superiority of the internal jugular over the subclavian access for temporary dialysis. Nephron. 1990;54:154-161. 10. Schillinger F, Schillinger D, Montagnac R, Milcent T. Post catheterisation vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. Nephrol Dial Transplant. 1991;6:722-724. 11. Trerotola SO, Kuhn-Fulton J, Johnson MS, Shah H, Ambrosius WT, Kneebone PH. Tunneled infusion catheters: increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access. Radiology. 2000;217:89-93. 12. Weijmer MC, van den Dorpel MA, Van de Ven PJ, et al; CITRATE Study Group. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol. 2005;16:2769-2777. 13. Chatzinikolaou I, Finkel K, Hanna H, et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. Am J Med. 2003;115:352-357. 14. Burns KEA, McLaren A. A critical review of thromboembolic complications associated with central venous catheters. Can J Anesth. 2008;55:532-541.
Chapter 12
The circuit and the prescription Rinaldo Bellomo and Ian Baldwin
The prescription of continuous renal replacement therapy (CRRT) requires an understanding of the circuit and the filter and their properties in order to deliver physiologically logical treatment. It also requires an understanding of the different processes of solute removal (diffusion and convection) and the importance of filtration fraction on filter performance and filter life. Finally, it requires an understanding of the different patterns of solute removal achieved with continuous hemofiltration compared with hemodiafiltration and, in turn, compared with hemodialysis. This understanding allows the application of a particular circuit setting, which, in turn, defines a significant component of the final prescription. Both physician and nurses need to understand these principles to practice CRRT safely and effectively.
Key terms Hemofiltration (CV VH): This term refers to the removal of plasma water (the solvent) across a semipermeable membrane by means of the application of a transmembrane pressure (Figure 12.1). This transmembrane pressure can derive form the rate of blood flow through the filter containing the membrane or from a negative pressure (typically generated by a peristaltic pump) applied to the nonblood side of the membrane. This process leads to solute removal as it follows the solvent across the membrane (solvent drag). This process is known as convection. Hemodialysis (CV VHD): This term refers to the removal of solute across a semipermeable membrane by means of the application of a concentration gradient. This concentration gradient derives form the relationship between the rate of blood flow through the filter and the rate of flow of a toxin-free electrolyte containing fluid (dialysate) on the nonblood side of the membrane (Figure 12.2). This process leads to solute removal as solutes move from plasma water (high
99
Introduction
The circuit and the prescription CHAPTER 12
100
CAVH–CVVH CAVH A
QB = 50 – 100
R
High perm.
V
QF = 8–12 mL/min
CVVH V
QB = 150–200 High perm.
R V
QF = 20–25 mL/min
Figure 12.1 Diagram of a continuous arterio-venous hemofiltration (CAVH) or continuous veno-venous hemofiltration (CV VH) circuit. A = artery; V = vein; R = replacement fluid; QB = blood flow; QF = ultrafiltrate flow; high per = high permeability filter.
CAVHD–CVVHD CAVHD A
QB = 50 – 100 Low perm.
V
Do Di QD = 8–15 mL/min QD = 2–3 mL/min CVVHD V
QB = 150–200 Low perm. Do
V
Di
QD = 20–35 mL/min QF = 2–5 mL/min Figure 12.2 Diagram of a continuous arterio-venous hemodialysis (CAVHD) or continuous veno-venous hemodialysis (CV VHD) circuit. A = artery; V = vein; R = replacement fluid; QB = blood flow; QF = ultrafiltrate flow; QD = dialysate flow rate; DO = dialysate outflow port; DI = dialysate inflow port; low perm = low permeability filter.
CAVHDF–CVVHDF CAVHDF A
QB = 50 – 100
R
High perm.
Do
V
Di
QD = 15–20 mL/min QF = 8–12 mL/min CVVHDF V
QB = 150–200 High perm.
Do
R V
Di
QD = 10 –20 mL/min QF = 10–20 mL/min Figure 12.3 Diagram of a continuous arterio-venous hemodiafiltration (CAVHDF) or continuous veno-venous hemodiafiltration (CVVHDF) circuit. A = artery; V = vein; R = replacement fluid; QB = blood flow; QF = ultrafiltrate flow; QD = dialysate flow rate; DO = dialysate outflow port; DI = dialysate inflow port; high perm = high permeability filter.
The circuit and the prescription
Filtration fraction (FF): This term refers to the fraction of plasma that is filtered across the semipermeable membrane. For example, if blood flow through the filter is 150 mL/min and the hematocrit is 33%, plasma flow is 100 mL/min. If the filtration rate is 25 mL/min (1.5 L/h), then the FF is 25%. FF above 25% are associated with increased hemoconcentration (significant increases in hematocrit, platelet count, and concentration of proteins within the filter) which, in turn, increase the likelihood of filter clotting and lead to the formation of layers of protein on the filtering membrane (“caking” or “concentration polarization”). These changes decrease membrane permeability.
CHAPTER 12
Hemodiafiltration (CV VHDF): This term refers to the removal of solute across a semipermeable membrane by means of the application of both a concentration gradient and a transmembrane pressure (Figure 12.3). This treatment combines hemofiltration and hemodialysis (convection and diffusion) in a way that can be determined by prescription.
101
concentration) to the dialysate (concentration equal to zero). This process is known as diffusion. Middle-sized molecules (>500 daltons) are not removed by diffusion as effectively as they are by convection. This may affect antibiotic clearance (e.g., vancomycin, which is approximately 1100 daltons in molecular weight, is removed with convection but not diffusion).
The circuit and the prescription CHAPTER 12
102
Replacement fluid: It is an electrolyte-containing, buffer-containing fluid that is given to replace the losses of plasma water induced by hemofiltration or hemodiafiltration. Dialysate: It is an electrolyte-containing, buffer-containing fluid that is given to provide a concentration gradient across the membrane to enable diffusive solute clearance. Typically, the same fluid can be used as dialysate and as replacement fluid. Predilution: This term refers to the administration of replacement fluid into the circuit before the filter. This choice of prefilter administration has two effects. First it dilutes the concentration of solutes entering the filter in a way that is proportional to the relationship between fluid administration and plasma flow (if the replacement fluid flow rate is 25 mL/min and the plasma flow rate is 100 mL/min, the dilution effect is 25% and the serum creatinine and urea will be 25% less when entering the filter. This will decrease the efficiency of solute removal) and, second, it will stop any hemoconcentration. This effect on hemoconcentration has been shown to prolong filter life and thereby decrease “off-time.” As a consequence, despite its diminished efficiency, predilution leads to similar solute control and decreased filter clotting. Postdilution: This term refers to the administration of replacement fluid into the circuit after the filter. This choice of postfilter administration has two effects. First it avoids any dilution of the concentration of solutes entering the filter and, second, it will lead to hemoconcentration as described under the term FF. This effect on hemoconcentration has been shown to decrease filter life and, thereby, increase “off-time.” As a consequence, despite its greater efficiency, postdilution does not appear to have significant advantages. Effluent: This term refers to the waste fluid generated by CRRT. This fluid can be straight ultrafiltrate in CV VH, spent dialysate in CV VHD, or a combination of both in CV VHDF. Circuit pressure measurements: The functioning of the circuit can be monitored by the measurements of pressures at various points along it. Pressure can be monitored before the filter, after the filter, and on the ultrafiltrate/spent dialysate side of the membrane. At blood flows of 200 mL/min, common prefilter pressures of 130–160 mm Hg can be expected (depending on filter size, design, hematocrit etc.). The pressure fall across the filter would typically be expected to be 30–40 mm Hg with a postfilter (or “inflow”) pressure of 110–120 mm Hg. The ultrafiltrate/dialysate side of the membrane may initially register a positive pressure as the peristaltic pump retards spontaneous filtration in a new filter. Over time, as the filter “ages” and the membrane clots, a negative pressure develops as the pump now actively “sucks” fluid across the membrane. The transmembrane pressure (average pressure on the blood side of the membrane minus the pressure on the ultrafiltrate side of the membrane) can be used as a measure of progressive filter clotting. If pressure is measured before the blood pump, this is typically negative (usually in the range of 50–70 mm Hg) and
Practical considerations For many machines, CRRT circuits are typically already set up for a particular modality. Thus, once an intensive care unit (ICU) clinician group has chosen a machine and the modality they wish to apply to patients, then the appropriate circuit is used during the machine setup. When this is not the case, appropriately designed tubing is typically provided that can be connected to achieve the necessary circuit design inclusive of pressure pod connections. The circuit is then primed with a crystalloid solution (in neonates or small children the circuit prime might require blood or a blood-albumin mix) and connected with the vascular access catheter. The outflow lumen of the access catheter (“arterial” lumen) is typically labeled in red. The inflow lumen of the catheter is typically labeled in blue (“venous” lumen). If CV VHDF is being implemented, the bag containing fluid is connected with peristaltic fluid pumps, which can deliver some of the fluid in the predilution position as replacement fluid (typically 50%) and also deliver some of the fluid (the other 50%) in a countercurrent direction to blood on the nonblood side of the membrane. However, some machines and circuit design prohibit predilutional CV VHDF because of the reduced diffusive clearance. Finally, the effluent port of the filter is connected with tubing to another peristaltic pump that sets the effluent flow rate. This is typically greater than the sum of the replacement fluid flow rate and the dialysate flow rate to ensure
The circuit and the prescription
There is no evidence to suggest that choosing CRRT based on hemofiltration over hemodiafiltration or over hemodialysis leads to clinically important differences in outcomes. There is a clear difference, however, in terms of the nature of solute removal with convection (filtration) leading to essentially equal small solute removal but much greater middle molecular weight solute removal. It is unclear, however, whether this effect matters pathophysiologically or clinically. Because of such uncertainty, physicians and nurses choose a particular approach in a given unit (typically based on local tradition, comfort, ease of operation etc.) and apply it consistently to all patients. Epidemiological data suggest that continuous veno-venous hemodiafiltration (CV VHDF) with replacement fluid delivered in predilution mode may be the most common approach to CRRT worldwide, followed by continuous veno-venous hemofiltration (CV VH) also with predilution. The delivery of the actual dose is more important than the choice of modality (see Chapter 8). The dose depends not only on modality but also on the size of the patient and the rate of effluent generation.
CHAPTER 12
Methods and approach
103
reflects the suction pressure applied to the outflow lumen of the vascular access catheter by the blood pump. High negative (>100 mm Hg) pressures suggest vascular access malfunction.
The circuit and the prescription CHAPTER 12
104
Table 12.1 Prescription for CVVHDF (100 mL/h negative fluid balance) Patient
H. Jones
Technique Med. record no. 678945 CVVHDF
Replacement fluid rate 900 mL/h
Dialysate flow rate
Effluent flow rate
Comments
900 mL/h
2000 mL/h (25 mL/kg/h) 100 mL/h fluid loss
Start pump at 20 mL/min and increase to 200 mL/ min over >5 min.
some fluid removal, which will compensate for additional fluids (nutrition, drugs, blood products) that the patient may be receiving. Once all tubing is connected, the blood pump can be started. This is best done at low flows (especially for patients who require vasopressor support) because, at the start, blood is removed and crystalloid administered to replace it. This results in the equivalent of acute venesection or “bleed” equal to the volume of the circuit (close to 150 mL in adults) before blood can both leave and enter the patient at an equivalent rate. Accordingly, the blood pump is best set at 20–30 mL/min until the full circuit is primed with blood. Once that has happened, gentle increases of 20–30 mL/min are appropriate until the target flow is achieved. After the blood path has been “set,” the therapy (dialysate flow, replacement fluid flow, and effluent generation) can begin. A possible prescription for such therapy is summarized in Table 12.1.
Expected outcomes, potential problems, cautions, and benefits If the principles of circuit design and function are understood and if the consequences of different techniques are appreciated and if the impact of choosing predilution versus postdilution are clear, then the physician can prescribe a logical approach to starting and delivering CRRT and the nurse can conduct CRRT with insight and expertise. This combination of knowledge and expertise inevitably leads to safe and effective delivery of CRRT. This leads to the following benefits: (1) reliable and safe control of uremia; (2) adequate filter life and costing; (3) full control of fluid balance; and (4) minimal technical problems. The clinical outcome is a patient in whom CRRT goes on silently and problem-free in the background in a way that is similar to successful mechanical ventilation. Problems may appear to arise in specific circumstances. However, understanding of the basics will help to deal with the problems successfully and rapidly. For example, filter life may be short. If so, assessment of the circumstances surrounding filter loss should allow prevention of similar events: Was the patient
The extracorporeal circuit used for CRRT has key components that, if understood clearly, allow physicians to prescribe physiologically logical therapy and nurses to conduct smooth, safe, and problem-free treatment. Appreciation of the consequence of choosing a particular technique is important. Understanding of the impact of predilution and postdilution on solute clearance and filtration fraction is similarly important. A clear and logical understanding of pressure measurements along the CRRT circuit is extremely useful in troubleshooting and in making the correct etiological diagnosis when the circuit fails. To conduct CRRT without such knowledge and understanding will likely make the treatment less safe for the patient, less effective in terms of uremic control, and a burden for nurses to develop expertise.
Key references Baldwin I, Bellomo R, Koch B. A technique for the monitoring of blood flow during continuous hemofiltration. Intensive Care Med. 2002;28:1361-1364. Baldwin I, Tan HK, Bridge N, Bellomo R. Possible strategies to prolong filter life during hemofiltration: three controlled studies. Ren Fail. 2002;24:839-848. Bellomo R. Choosing a therapeutic modality: hemofiltration vs. hemodialysis vs. hemodiafiltration. Semin Dial. 1996;9:88-92. Fealy N, Baldwin I, Bellomo R. The effect of circuit “down-time” on uraemic control during continuous veno-venous haemofiltration. Crit Care Resuscitation. 2002;4:170-172. Tan HK, Bridge N, Baldwin I, Bellomo R. Ex-vivo evaluation of vascular catheters for continuous hemofiltration. Ren Fail. 2002;24:755-762. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous is not Continuous: The Incidence and Impact of Circuit “Down-time” on Uremic Control during Continuous Veno-Venous Hemofiltration. Intensive Care Med. 2003;29:1672-1678.
The circuit and the prescription CHAPTER 12
Summary
105
agitated and flexing the hip in the presence of a femoral vascular access catheter? If so, acute blockage to flow may have been responsible. Was the outflow pressure very negative (–120 mm Hg) from the very start of the therapy ? If so, vascular access dysfunction/clotting should be suspected. Was the transmembrane pressure low (90–100 mm Hg) at the start but increased progressively over 4–5 hours of therapy? If so, rapidly progressive filter clotting should be suspected and the circuit anticoagulation approach reviewed. Did the postfilter pressure rise while the transmembrane pressure did not change much? If so, one should suspect postfilter obstruction in the air chamber, where clot can frequently form. All of these diagnostic thoughts are logical and derive from understanding the circuit and its components.
This page intentionally left blank
Chapter 13
The membrane: size and material Zhongping Huang, Jeffrey J. Letteri, Claudio Ronco, and William R. Clark
The filter membrane in a continuous renal replacement therapy (CRRT) extracorporeal circuit is vitally important for several reasons. Because it has the largest degree of exposure to blood of all circuit components, the membrane is the most important determinant of the circuit’s overall biocompatibility. In addition, membrane characteristics determine both the solute removal and water permeability properties of a CRRT filter. This chapter addresses the key clinical issues related to CRRT membrane performance and biocompatibility.
Hollow fiber membranes used for CRRT: biometrical considerations As opposed to chronic hemodialysis, for which cellulosic membranes continue to be used commonly, membrane comprising CRRT filters are almost exclusively synthetic. Synthetic membranes were developed essentially in response to concerns related to the narrow scope of solute removal and the pronounced complement activation associated with unmodified cellulosic dialyzers. The AN69 membrane, a copolymer of acrylonitrile and an anionic sulfonate group, was first employed in flat sheet form in a closed-loop dialysate system in the early 1970s for chronic hemodialysis. Since that time, a number of other synthetic membranes have been developed, including polysulfone, polyamide, polymethylmethacrylate, polyethersulfone, and polyarylethersulfone/polyamide. As is the case in chronic hemodialysis, all of these membranes either have been used or currently are being used in a CRRT application. Synthetic membranes are manufactured polymers that are classified as thermoplastics. In fact, for most of the synthetic membranes, the renal market represents only a small fraction of their entire industrial utilization. Having wall thickness values of at least 20 µm, synthetic membranes tend to be thicker than their cellulosic counterparts and, from a structural perspective, they may be
107
Introduction
The membrane: size and material CHAPTER 13
108
symmetric (e.g., AN69, polymethylmethacrylate) or asymmetric (e.g., polysulfone, polyamide, polyethersulfone, polyamide/polyarylethersulfone). In the latter category, a very thin “skin” (approximately 1 µm) contacting the blood compartment lumen acts primarily as the membrane’s separative element with regard to solute removal. The structure of the remaining wall thickness (“stroma”), which determines the thermal, chemical, and mechanical properties, varies considerably among the different synthetic membranes. Although biocompatibility encompasses several different considerations, complement activation traditionally has been the primary parameter used for comparisons of different membranes. As suggested earlier, synthetic membranes as a class result in less complement activation than do cellulosic membranes. Because complement activation is roughly proportional to the balance between hydrophilicity (which promotes complement activation) and hydrophobicity (which attenuates complement activation), the relatively hydrophobic nature of synthetic membranes is a benefit in this regard. Another distinguishing feature of synthetic membranes is their propensity to adsorb plasma proteins. As discussed in more detail below, exposure of an extracorporeal membrane to blood results in the instantaneous adsorption of a protein layer (“secondary membrane”), which modifies the native membrane’s permeability properties. The composition of this secondary membrane is dominated by relatively high molecular weight proteins that have the highest plasma concentrations, such as albumin, immunoglobulins, and fibrinogen. However, certain membranes also possess the specific capability to remove low molecular weight (LMW) proteins, such as anaphylatoxins and other inflammatory mediators including cytokines, in significant amounts by adsorption. With respect to adsorptive removal of LMW proteins, the AN69 membrane (a component of extracorporeal circuits used with the Prisma and Prismaflex CRRT systems) has been studied most widely. Previous investigations have had several findings. First, while overall secondary membrane formation occurs at the “nominal” (nonpore) membrane surface, the bulk of LMW protein adsorption occurs within the membrane’s internal pore structure. Second, the removal of some LMW proteins by AN69 filters occurs exclusively by adsorption, even though the molecular weights of such compounds theoretically would allow transmembrane removal. Third, adsorptive removal of LMW proteins by AN69 filters is a saturable phenomenon, usually within the first 60–90 minutes of use of a particular filter. Subsequent to saturation, the removal of a specific compound may effectively cease or continue to occur by a “breakthrough” transmembrane mechanism.
Relationship between ultrafiltration rate and transmembrane pressure in CRRT Extracorporeal membranes used for dialysis are classified according to their ultrafiltration coefficient as high flux or low flux. However, considerable
Region of TMP–independent filtration (concentr. polarizat. control)
Filtration rate
Pure water filtration
Region of formation of concentration polarization
Region of TMP–independent filtration (membrane control)
Transmembrane pressure
Figure 13.1 Fundamental relationship between ultrafiltration rate and transmembrane pressure during ultrafiltration under different operating conditions. Reprinted from Goehl H, Konstantin P. Membranes and filter for hemofiltration. In: Henderson LW, Quellhorst EA, Baldamus CA, Lysaght MJ, eds. Hemofiltration, 1st ed. Berlin: Springer-Verlag Publishers; 1986,73-85. With kind permission of Springer Science and Business Media.
The membrane: size and material CHAPTER 13
109
confusion currently exists regarding the exact meaning of flux. The hydraulic flux of a membrane is the volumetric rate (normalized to surface area) at which ultrafiltration occurs. The clinical parameter used to characterize the water permeability of a specific dialyzer is the ultrafiltration coefficient (KUF: mL/h/mm Hg). The KUF of a filter is usually derived from in vitro experiments in which bovine blood is ultrafiltered at varying transmembrane pressure (TMP). The membrane characteristic having the largest impact on water permeability is the pore size, such that ultrafiltrate flux is roughly proportional to the fourth power of the mean membrane pore radius. As such, small changes in pore size have a very large effect on water permeability. The method by which KUF is determined can be derived from Figure 13.1, in which the relationship between ultrafiltration flow rate (QUF) and TMP is shown for a particular CRRT filter operated under different conditions. The line in the left part of the figure represents the relationship between these two parameters for a “virgin” filter (i.e., no prior exposure to blood or other protein-containing solution) when the test fluid is also an aqueous solution. The slope of the line represents the KUF of the filter for these operating conditions. This strictly linear relationship can be contrasted with the nature of the curve in the right part of the figure. The curved line in the right part of the figure defines a filter’s QUF versus TMP relationship under the condition of ultrafiltration of blood. As the figure indicates, two distinct regions of this curve can be identified: a region controlled by the permeability of the filter membrane itself (“membrane control”)
The membrane: size and material CHAPTER 13
110
and a region controlled by the effects of the secondary membrane on filter performance. (Note that the term “concentration polarization,” which is used in the figure, is essentially synonymous with secondary membrane for the purpose of this discussion.) The membrane control region of the curve occurs at relatively low TMP values and is linear. Similar to the situation of aqueous ultrafiltration with a virgin filter, the slope of the line in this region is the KUF of the filter. The lower slope (i.e., lower KUF) of the right-hand curve is a direct result of the permeability reduction resulting from the secondary membrane. As TMP increases, the curve eventually plateaus in the region of secondary membrane control at a certain maximum QUF where further increases in TMP result in no further increase in QUF. In terms of clinical operation of a filter, the plateau portion of the curve is to be avoided because of the high likelihood of impaired performance or premature clotting of the filter. As mentioned previously, filter KUF is a value that is specific to a certain set of flow operating conditions, including blood flow rate (QB). Blood flow rate influences the nature of the right-hand curve in two ways. First, as QB increases, the slope of the curve in the linear (low TMP) region increases. Effectively, this means to achieve a certain QUF, a lower TMP is required. The second way in which QB influences the nature of these curves is its effect on the maximum achievable (plateau) QUF such that an increase in QB results in a corresponding increase in plateau QUF. The explanation for these phenomena is related to the effect of higher QB in preserving filter membrane function. Specifically, as QB increases, a greater shear force is applied to the proteins comprising the secondary membrane. In this way, the secondary membrane is disrupted and its negative impact on membrane permeability is blunted.
Effect of secondary membrane formation on solute permeability in CRRT The adsorbed protein layer comprising the secondary membrane also reduces the effective solute permeability of a CRRT membrane by “plugging” or blocking of a certain percentage of membrane pores. The effect of this process on solute permeability for a polyamide membrane is shown in Figure 13.2. In this figure, percent rejection (which is essentially equal to 1—sieving coefficient), is plotted against solute molecular weight. Results for both a protein-containing fluid (plasma) and a protein-free fluid (saline) are shown. For a test solute with a molecular weight of 5000 daltons, the percent rejection in saline is 0% (i.e., the sieving coefficient is 1.0). On the other hand, for that same solute, the percent rejection in plasma is approximately 60% (sieving coefficient of 0.4). The adsorptive tendency of a particular membrane varies according to the operating conditions employed. Postdilution tends to promote protein adsorption
% Rejection
80
Plasma
60 Saline
40 20 0 0
2000 3000
5000
10,000
20,000
Figure 13.2 Effect of secondary membrane formation on the sieving properties of a polyamide filter membrane. From Feldhoff P, Turnham T, Klein E. Effect of plasma proteins on the sieving spectra of hemofilters. Artif Organs. 1984;8:186-192, copyright © 1984 International Center for Artificial Organs and Transplantation. Reproduced with permission of Blackwell Publishing Ltd.
CHAPTER 13
because protein concentrations are higher within the membrane fibers (due to hemoconcentration). On the other hand, as mentioned previously, higher blood flow rates work to attenuate this process because the shear effect created by the blood disrupts the binding of proteins to the membrane surface.
111
Log [molecular weight]
The membrane: size and material
100
Membrane surface area effects in CRRT Early in the era of veno-venous CRRT, typical blood and effluent flow rates were less than 150 mL/min and 1.5 L/h, respectively. In this context, filters with surface areas in the range of 0.3–0.5 m2 could generally provide desired solute clearances at acceptable filter operating conditions. However, as blood and fluid flow rates have increased substantially over the years with the goal of increasing delivered CRRT dose, filter membrane surface area requirements have also increased. For adequate filter operation, the surface area required to provide an effluent-based CRRT dose target of 35 mL/kg/h is approximately 1.0 m2 and may be as high as 1.5 m2 in some larger size patients treated with effluent rates greater than 4 L/h.
Continuous hemofiltration As discussed above, the choice of operating conditions for a hemofiltration procedure should avoid operation of the filter in the secondary membrane-limited region of the QUF versus TMP curve. The clinical corollary of this is the need to select a filter with a surface area that is adequate to support the operating conditions chosen. In Figure 13.3, the relationship between QUF and QB for three theoretical hemofilters of 0.3 m2, 1.0 m2, and 1.5 m2 at constant TMP is shown. In general, these curves have similar contours with an initial linear region at
Ultrafiltration rate (L/hr)
The membrane: size and material CHAPTER 13
112
Membrane surface area (m2) 1.5
1.0 B
High QUF
C 0.3
Low QUF
A
Blood fow rate (mL/min) Figure 13.3 Relationship between ultrafiltration rate and blood flow rate for theoretical hemofilters of different surface area. (See text for explanation of operating conditions corresponding to points A, B, and C.)
relatively low blood flow rates followed eventually by a plateau or quasi-plateau region at relatively high blood flow rates. Both the slope of the linear phase and the maximum (plateau) QUF for each curve are directly proportional to membrane surface area at a given TMP. At a low blood flow rate (e.g., 75 mL/min), all three filters can generate a relatively low QUF (e.g., 1.5 L/h) at the same TMP, as denoted by point A on the graph. However, when the clinical goal is a higher QUF (e.g., 4.0 L/h), a 0.3 m2 filter is not adequate as the plateau QUF for this filter falls below the desired value. On the other hand, the higher QUF is in the operating range of both of the larger filters for the TMP that has been chosen. However, the 1.5 m2 filter can achieve this filtration rate at a lower blood flow rate (point B) compared to the 1.0 m2 filter (point C). An analogous point is that, for a given blood flow rate, filter membrane surface area is inversely proportional to the TMP required to achieve a certain ultrafiltration rate. The general relationship between ultrafiltration rate and blood flow rate during hemofiltration, as described in Figure 13.3, is explained by the phenomenon of filtration pressure equilibrium. In this situation, hydrostatic pressure driving filtration out of the blood compartment is balanced by the oncotic pressure opposing filtration in this direction. When a scenario of filtration pressure equilibrium situation occurs for a filter, surface area is relatively unimportant since the additional surface area is not used for filtration. The corollary is that the benefit of higher surface area on filtration rate can only be achieved if higher blood flow rates are used.
Clearance or effluent rate (mL/min)
Effluent Urea Cr Ur P
45 40 35 30 25 20 15 10 5 0
B2-M
0
500
1000
1500
2000
2500
Dialysate flow rate (mL/h) Figure 13.4 Relationship between solute clearance and dialysate flow rate for a 0.9 m2 filter in continuous veno-venous hemodialysis. Abbreviations: Cr: creatinine; Ur: urate; P: phosphate; and B2M: beta2-microglobulin. Reprinted from Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999;34:486-492, copyright 1999, with permission from Elsevier.
The membrane: size and material CHAPTER 13
Relative to conventional hemodialysis, in which solute clearance is primarily dictated by blood flow rate and membrane surface area, effluent dialysate flow rate is the primary determinant of solute clearance in continuous veno-venous hemodialysis (CV VHD). At least with respect to small solute clearance, saturation of the effluent indicates optimal utilization of the prescribed dialysate volume. If such saturation is not achieved, the most likely explanation is a filter of inadequate membrane surface area. When CV VHD is performed with a relatively small surface area filter (< 0.5 m2), saturation of the dialysate is only achieved at relatively low dialysate flow rates. For a 0.4 m2 AN69 filter, Bonnardeaux et al. showed saturation of the effluent dialysate for urea, and creatinine is preserved only up to a dialysate flow rate (QD) of approximately 16.7 mL/min (1 L/h). For QD values in the 2–3 L/h range (33.3–50 mL/min), although an increase in QD resulted in an increase in clearance, a divergence between the urea/creatinine clearance and the effluent flow rates was observed, indicating nonsaturation of the effluent dialysate. Of course, the greater the degree of nonsaturation, the more inefficient is the procedure. A more contemporary study involving a larger surface area AN69 filter (0.9 m2) demonstrates clearly the important effect of surface area on preserving dialysate saturation (Figure 13.4). For this larger filter, preservation of effluent dialysate saturation was achieved essentially over the entire QD range, the only exception being B2M. The high molecular weight of this compound (approximately 200 times that of urea) severely limits its diffusive capabilities and, therefore, its ability to saturate the dialysate.
113
Continuous hemodialysis
The membrane: size and material CHAPTER 13
114
Summary In this chapter, an overview of membranes used for CRRT has been provided. The major characteristics of hollow fiber membranes influencing both biocompatibility and solute and water removal have been discussed. It is hoped that this information will help provide clinicians with a rational approach to the prescription of CRRT from the perspective of the extracorporeal membrane.
References Bonnardeaux A, Pichette V, Ouimet D, Geadeh D, Habel F, Cardinal J. Solute clearances with high dialysate flow rates and glucose absorption from the dialysate in continuous arteriovenous hemodialysis. Am J Kidney Dis. 1992;19:31-38. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999;34:486-492. Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on performance and biocompatibility in hemodialysis. Kidney Int. 1999;56:2005-2015. Clark WR, Macias WL, Molitoris A, Wang NHL. Plasma protein adsorption to highly permeable hemodialysis membranes. Kidney Int. 1995;48:481-488. Feldhoff P, Turnham T, Klein E. Effect of plasma proteins on the sieving spectra of hemofilters. Artif Organs. 1984;8:186–192. Goehl H, Konstantin P. Membranes and filter for hemofiltration. In: Henderson LW, Quellhorst EA, Baldamus CA, Lysaght MJ, eds. Hemofiltration. 1st ed. Berlin: SpringerVerlag; 1986:73.
Chapter 14
Fluids for continuous renal replacement therapy Paul M. Palevsky and John A. Kellum
Considerable variability exists in the prescription of fluids for continuous renal replacement therapy (CRRT), both dialysate and replacement fluid. In general, since electrolytes will diffuse across the dialysis membrane in both directions, there is little practical difference in the composition of dialysate and replacement fluid, and many commercial dialysis fluids are used off-label as replacement fluid. When using both dialysis and hemofiltration (CVVHDF), it is usually convenient to use standard dialysate and customize the replacement fluid as necessary. The Acute Dialysis Quality Initiative (ADQI) has published a series of recommendations of fluids for CRRT. These recommendations are summarized below.
Electrolyte composition Available evidence shows the following: 1. Sodium is generally kept at an isonatric (physiologic) concentration except when special prescriptions are used in combination with some citrate anticoagulation protocols or during management of hypo- or hypernatremia. 2. Chloride, potassium, magnesium, and anion needs are variable in different clinical situations. 3. Phosphate—Hypophosphoremia due to increased clearance and intracellular shifts due to refeeding are common in CRRT, and may place patients at risk of complications including rhabdomyolysis. 4. Glucose—Maintenance of normoglycemia has been shown to be associated with lesser mortality in the critically ill patient. 5. Trace elements, including water-soluble metals, micronutrients, aminoacids, and folate are lost during CRRT. Recommendations from ADQI: 1. Sodium: Physiological concentrations should be used except when using citrate anticoagulation. In the latter circumstances, adjustments may be
115
General considerations
Fluids for CRRT CHAPTER 14
2.
3.
4.
116
5.
6.
necessary, given the variable contents of sodium in different citrate solutions. Adjustment of the sodium concentration of fluids may also be necessary in patients with hypo- or hypernatremia in order to achieve an appropriate controlled correction of the serum sodium concentration. Chloride, potassium, magnesium, and anions: These should be present in replacement fluid and/or dialysate in concentrations tailored to patient need and anticoagulation procedures. Calcium: It should be present in replacement fluids and dialysate. It should be at approximately physiological concentrations (corresponding to the normal blood ionized calcium). Augmented levels may be necessary in the setting of severe hypocalcemia and reduced levels in the setting of hypercalcemia. Very low or no calcium should be used when citrate is used as an anticoagulant, although intravenous calcium infusion to maintain normal serum ionized calcium concentration is then necessary. Phosphate: To avoid hypophosphoremia, phosphate should be provided either as a supplement in the CRRT fluids (replacement fluid or dialysate) or as a nutritional supplement once hyperphosphatemia, if present, has resolved. Glucose: To avoid hyperglycemia, glucose can either be absent or present at physiological concentration in replacement fluids and dialysate. The use of fluids with supraphysiological glucose concentrations should be avoided. Trace elements: Losses of trace elements (water-soluble metals, micronutrients, aminoacids, and folate) must be appropriately replaced.
Buffer composition Lactate versus bicarbonate Both lactate and bicarbonate ions have been used in replacement fluid and dialysate for CRRT. Historically, lactate has been preferentially used as a buffer due to the instability of bicarbonate-based solutions when stored over prolonged periods of time. This problem has recently been overcome, allowing commercial availability of bicarbonate-based fluids. Controlled (though not all randomized) trials have suggested that lactate and bicarbonate buffered solutions have a similar efficacy for correction of metabolic acidosis during CRRT. However, recent studies showed better control of metabolic acidosis with bicarbonate as compared to lactate. Blood levels of lactate are generally higher when lactate is used as a buffer and may confuse the clinical interpretation of these measurements. It is not clear whether this hyperlactatemia is associated with morbidity. Depending on tissue redox status and substrate availability, lactate is either metabolized back to pyruvate and into the citric acid cycle, resulting in proton buffering, or into glucose by gluconeogenesis. Potential concerns with excessive lactate accumulation are hemodynamic compromise, increased urea generation, and cerebral
Acetate
Fluids for CRRT CHAPTER 14
dysfunction. Hyperlactatemia may develop in situations of impaired lactate clearance including liver failure and tissue hypoperfusion. This hyperlactatemia can be expected to be more pronounced if lactate-buffered solutions are used during high-volume hemofiltration. Accumulation of the d-isomer of lactate may also be a concern as the d-isomer constitutes 50% of the total lactate contents of racemic mixtures. As d-lactate is nonmetabolizable by humans, it may accumulate, contributing to severely elevated lactatemia and associated with neurologic impairment. In the intermittent hemodialysis (IHD) literature, acetate has been shown to be associated with impaired myocardial contractility and decreased cardiac function. This anion has been rarely used as a buffer in CRRT. Used primarily for its anticoagulant properties, citrate serves as an effective buffer. Scant evidence is available on the use of citrate exclusively as a buffer in CRRT. Importantly, citrate metabolism is often impaired in liver failure or muscle hypoperfusion, both situations posing risk of hypercitratemia when citrate is utilized. Hypercitratemia carries the risk of decreased ionized extracellular calcium concentration. Importantly, blood products contain citrate as an anticoagulant; massive blood or plasma product transfusions are associated with high citrate loads, which accumulate when citrate is simultaneously used as an anticoagulant and/or a buffer. Low concentrations of citrate are present in some commercial dialysate solutions for IHD. Complications of citrate toxicity have not been associated with these agents. Recommendations from ADQI: 1. Bicarbonate is an effective buffer and is currently the preferred organic buffer in commercially manufactured solutions. 2. Lactate-buffered solutions are safe and efficacious in the majority of patients, but these solutions may be hazardous whenever lactate clearance is impaired, such as in liver failure patients or patients with severe tissue hypoperfusion. d-lactate should be removed from lactate-containing solutions, which should consist almost exclusively of l-Lactate. 3. There is insufficient data to evaluate the use of acetate-buffered solutions in CRRT. However, limited evidence does not support its use compared to lactate or bicarbonate, given the risks of cardiac depression. 4. The metabolism of sodium citrate used for regional anticoagulation during CRRT generates three moles of bicarbonate per mole of citrate and functions as an efficacious organic buffer. Use of citrate in the setting of decreased citrate clearance or when patients receive large doses of citrate during massive transfusions should be done with individualized adjustment of citrate dose and with close monitoring of plasma ionized calcium levels.
117
Citrate
Fluids for CRRT CHAPTER 14
Fluid prescriptions during permissive hypercapnia In patients with acute respiratory distress syndrome (ARDS)/acute lung injury (ALI) on lung protecting ventilator strategies, the resulting respiratory acidosis can be partially or completely compensated by elevation of plasma bicarbonate with CRRT. The decision about the level to which acidemia should be corrected is controversial, but most authors recommend avoiding severe acidosis (pH < 7.20).
118
Example fluid orders for CRRT Keeping in mind that, after a period of equilibration, plasma composition will approach the electrolyte composition of the dialysate or replacement fluid used (with the exception of bicarbonate) the standard composition of CRRT fluids will be physiological. Table 14.1 shows that the usual range of composition for a standard dialysate or replacement fluid is close to the usual range for plasma electrolytes. Bicarbonate is higher in these fluids compared to plasma because plasma contains albumin, a weak acid, which serves as an endogenous buffer. The same solutions can be used for either dialysis or hemofiltration. Example A might be appropriate for a patient with relatively stable electrolyte and acidbase status. Example B might be more appropriate for a hyperkalemic patient. Occasionally severe abnormalities in electrolyte and acid-base balance call for more drastic changes in fluid prescription from the standard composition. For example, a patient with severe acidosis and hyperkalemia might require a potassium-free solution with higher concentration of bicarbonate. One liter of sterile water with three “ampoules” of sodium bicarbonate (each ampoule of 8.4% solution contains 50 mEq both sodium and bicarbonate) produces a near isotonic solution of 150 mEq/L of sodium and 150 mEq/L of bicarbonate. If this solution is used as replacement fluid, it should only be temporary and should be done only with close monitoring. In continuous veno-venous hemodiafiltration (CVVHDF) mode, it is often Table 14.1 Example fluids for CRRT
Sodium Potassium Chloride Calcium Magnesium Bicarbonate Lactate Glucose
Custom dialysate/replacement fluid 140–150 mEq/L 0–5 mEq/L As needed to achieve charge balance 0–3.5 mEq/L 0.5–1.5 mEq/L 22–45 mEq/L 0–5 mEq/L 100–120 mg/dL
Example A
Example B
140 mEq/L 4 mEq/L 113 mEq/L 2.5 mEq/L 1.5 mEq/L 32 mEq/L 3 mEq/L 110 mg/dL
140 mEq/L 2 mEq/L 112 mEq/L 3.5 mEq/L 1.0 mEq/L 32 mEq/L 3 mEq/L 110 mg/dL
Correct electrolyte formulation by repeat testing as needed should be assured, given that serious errors have been reported when local pharmacies compound without regular monitoring of composition. When dialysis fluids are compounded locally, appropriate monitoring of RRT fluid composition must be assured. Most established CRRT programs are switching to commercially prepared fluids.
Fluids for CRRT
Fluid compounding
CHAPTER 14
convenient to choice a standard solution for dialysate (e.g., Example A) and, when necessary, a custom solution for replacement fluid. After the patient’s metabolic status stabilizes, the replacement fluid can be switched to standard as well.
Both lactate and bicarbonate are able to correct metabolic acidosis in most CRRT patients; however, correction of acidosis may not be as efficient with lactate as with equimolar bicarbonate. Worsening hyperlactatemia has been noted when lactate was used in patients with lactic acidosis or liver failure. The clinical relevance of this finding is unknown. Thus, bicarbonate is the preferred buffer, especially in patients with lactic acidosis and/or liver failure and in high-volume hemofiltration. However, lactate is an effective buffer in most CRRT patients. Citrate used as an anticoagulant has also been effectively used as a buffer in CRRT. When citrate is used as an anticoagulant, the concentrations of other buffers need to be adjusted or eliminated, depending on the specific regimen used, to minimize the risk of iatrogenic metabolic alkalosis. Monitoring of plasma pH and ionized calcium is required.
Key references Davenport A. Replacement and dialysate fluids for patients with acute renal failure treated by continuous veno-venous haemofiltration and/or haemodiafiltration. Contrib Nephrol. 2004;144:317-328. Kellum JA, Cerda J, Kaplan LJ, Nadim MK, Palevsky PM. Fluids for prevention and management of acute kidney injury. Int J Artif Organs. 2008; 31(2):96-110. Kellum JA, Mehta R, Angus DC, Palevsky P, Ronco C; ADQI Workgroup. The First International Consensus Conference on Continuous Renal Replacement Therapy. Kidney Int. 2002; 62(5):1855-1863. Kierdorf H, Leue C, Heintz B, Riehl J, Melzer H, Sieberth HG. Continuous venovenous hemofiltration in acute renal failure: is a bicarbonate- or lactate-buffered substitution better? Contrib Nephrol. 1995;116:38-47. Leblanc M, Moreno L, Robinson OP, Tapolyai M, Paganini EP. Bicarbonate dialysate for continuous renal replacement therapy in intensive care unit patients with acute renal failure. Am J Kidney Dis. 1995;26(6):910-917.
119
Summary
This page intentionally left blank
Chapter 15
Alarms and troubleshooting Zaccaria Ricci, Ian Baldwin, and Claudio Ronco
Technical expertise is mandatory for administration and management of continuous renal replacement therapy (CRRT), which is conceived to run for 24 hours a day in the intensive care unit (ICU). Routine clinical practice of CRRT may challenge physicians and nurses with several practical problems that can be of clinical and technical nature. Circuit pressure monitoring, setting and responding to alarms, and default safety features of modern CRRT machines allow effective and safe therapy delivery in critically ill patients. It should be never forgotten, however, that the human-machine interface can fail and is not a perfect system.
Training Intensive care unit (ICU) physicians and nurses involved in prescription and delivery of CRRT operate safely and best with protocols and defined procedures. The following is a list of key aims for training and education: • An educational program providing theoretical content is necessary. • A training program for practical skills specific to using CRRT is also necessary with a connection to the theory. • All training should be sequenced, providing a logical flow to embrace the cycle of use from preparation of a CRRT machine, patient connection and management during use, and then cessation of treatment—disconnection. • Programs need to be continuous and repeated owing to the ongoing technological developments and high staff turnover. • A simple simulator can be achieved by placing a double lumen access catheter into a 5 L saline bag—simulating the patient. • It is desirable to have the majority of staff working at a “competent” level with small groups at the “novice” and “expert” levels. Novice practitioners can also be assisted and supervised by expert colleagues.
121
Introduction
Alarms and troubleshooting CHAPTER 15
122
Vascular access Veno-venous CRRT rely on the use of a temporary double lumen catheter, typically inserted into one of the central veins (femoral, subclavian, or jugular). Ideal catheter type, size, and site of insertion are determined by local hospital policies; however, success can be achieved with many variations, and no controlled data are available to reflect “best” practice. Catheters should be easy to insert and remove or be guide wire exchanged, allow a wide range of blood flows, minimize recirculation phenomena, and reduce decubitus and infection episodes. Key considerations for access catheter use are as follows: • Catheter type and size: Double lumen catheters as a general rule can be classified into short (about 15 cm) and long (more than 20 cm), small (less than 11 Fr) and big (more than 13 Fr). The catheter lumen design profile varies, but all designs can obstruct by contact with vessel walls and/or kinking due to body positional changes during nursing. • Catheter site: Jugular venous catheterization access does not appear to reduce the risk of infection compared with femoral access, except among adults with a high body mass index, and may have a higher risk of hematoma. The site of catheter placement should depend on clinician skill, the presence of other central venous catheters, and the risk of bleeding. Insertion of the catheter to the right atrium promotes reliable and higher blood flow rate use. • Catheter trouble-shooting: a malfunctioning catheter is suspected when CRRT monitor pressure alarms occur as low “arterial” or high “venous.” The catheter could be guide-wire exchanged; however this is not always successful to resolve the problem and a new site insertion is necessary. Swapping over the connections to the CRRT circuit may also resolve the catheter malfunction but creates a recirculation of blood. This may not be of clinical consequence when solute levels are in control and can allow treatment to continue when fluid balance is the key goal, and a new access catheter insertion is not easily done.
Circuit pressures Modern technology CRRT machines allow continuous pressure measurement and display for both operator (human) and “smart software” (machine) interpretation. This requires measurement from several different points in the circuit. • Machine inlet (negative) pressure and return (positive) pressure depends mostly on the performance of vascular access relative to programmed blood flow rate and patient position. • Inlet of the filter: This pressure indicates the resistance of blood that is pumped into the filter. The gradient of filter inlet and catheter return is defined as “drop pressure” (DP) and is generally automatically calculated by all modern monitors. DP indicates the capacity of blood to flow through the membrane.
CHAPTER 15
new or spontaneous UF occurs. When the filter pores are reduced in size and number due to clotting, UF starts being sucked by the pump and the UF port pressure value becomes negative. • Inlet of filter pressure, catheter return pressure, and UF port pressure are used in software calculation of transmembrane pressure (TMP) indicating the capacity of the filter ultrafiltering blood. • This amount of information, integrated with friendly user operator interface, are optimized in different monitors with different setups and displays: in our opinion, the optimal machine keeps record of circuit pressures during the last 24 hours of the treatment (or more) and possibly provides graphs and trends of all recorded pressures, and a “log file” of alarms or errors when they occurred, along with the remedy or operator response at the time. This information is a useful audit of the system in use.
Alarms and troubleshooting
• Ultrafiltration (UF) port pressure: Its value can be positive when the filter is
Understanding how alarms systems work on CRRT machines is useful for troubleshooting. In general, alarms used in biomedical equipment are classified according to severity of problem and urgency for attention. They range from “advisory” messages, with no immediate error to “crisis” indicating danger and automatic shutdown. In addition, alarms can be “latched,” where, if a measured parameter is breached. despite self-correction, the machine will pause operation with the alarm sounding until resetting. Or, the alarm can be “unlatched,” where, if a breached parameter creates an alarm but the situation self corrects, the alarm stops and the machine restarts automatically. For example, with CRRT machine technology, low arterial pressure alarm is an unlatched alarm, but air detection is latched, representing the potential severity of each. Most new machines provide default settings for many alarms; sometimes these can be altered. It is useful for the staff to know the default settings or the policy within the ICU for where common alarms are set. Alarms set too widely will create unsafe use of the machine. Figure 15.1 outlines this concept of alarm classification.
The clogging circuit All circuits clot, sooner or later, and they generally need change of all the components of the extracorporeal circuit. The first issue to address in order to optimize management of circuit clotting is prevention: performing an “elective” change, before the circuit clots completely, leading to progressive anemia. A scheduled change to a new extracorporeal circuit also allows a reduced time off therapy (downtime).
123
Alarm systems
Alarms and troubleshooting CHAPTER 15
Latched
Requires correction, will not reset, use alarm silence
Unlatched
Self correction, then reset without intervention
Advisory alarm
Message to operator, futrue intervention
Warning alarm
Message to operator, intervention now:
Crisis alarm
Message to operator, machine stop
124
Figure 15.1 Classification of biomedical devices and alarms.
In order to identify and recognize circuit clotting the following “signs” are proposed: • Dark streaks through the hollow fibers of filters indicates a degree of filter clotting that is proportional with the total amount of clotted fibers. This sign should be kept under constant observation but does not herald imminent filter failure. • TMP rapid increase (before it reaches machine alarm threshold) is an important sign of hollow fibers failure, especially during hemo/ultrafiltration. There is not an absolute value to be aware of but >250 mm Hg is commonly considered indicative of substantial membrane clotting; however, this also depends on machine setup and filter size. The trend curve of TMP should be observed by the operators because a rapid increase in a short time frame suggests a threshold of membrane surface area clotting and total failure imminent. • DP rapid increase (before it reaches machine alarm threshold) is another important sign of filter clotting, and it works as a reliable indication either during dialysis and hemo/ultrafiltration. Again, there is not an absolute value to be aware of (it generally depends on machine setup and filter size), whereas the trend curve of DP should be monitored by the operators. • Experience can also teach the ICU staff that different components in different machines are particularly susceptible to early clotting and should be strictly monitored. • The venous drip chamber (bubble trap) may be a site of circuit clotting during continuous runs. Two mechanisms seem to be responsible for clot formation: blood-air interface and blood stagnation in the chamber. Modifications of these chambers, derived from traditional intermittent therapies, have been
Fluid balance errors The possibility of making fluid balance errors during CRRT has been identified since the beginning of this modality of treatment. The advent of automated
Alarms and troubleshooting
Treatment failure due to circuit clotting has been acknowledged as the major problem in CRRT delivery. Some general measures can be recommended in order to increase filter life and to achieve an average session length of at least 20 hours. • Blood flow should be ideally prescribed and maintained between 150 and 200 mL/min. If poor vascular access does not allow such flow rate, blood flow below 100 mL/min should not be accepted and vascular access should be optimized. • Administration of replacement fluids before the filter may prolong filter function. Alternatively, if postdilution hemofiltraiton is the institutional preferred CRRT modality, when TMP is rapidly increasing, a switch to predilution hemofiltration, hemodialysis, or hemodiafiltration can be tried (if the utilized machine allows such intra-therapy changes). • If heparin is the administered anticoagulant, the infusion of dilute solutions (10 IU/mL) at a greater rate will improve the efficacy of anticoagulation. In these patients, antithrombin III levels should be monitored, and maintained at supernormal levels (> 100%). Activated clotting time or other methods of bedside anticoagulation measure are strongly recommended and, if necessary, small heparin boluses might be indicated. • Flushing circuits with normal saline once per shift or when clogging is suspected may allow better visual detection of clot formation in the circuit and sometimes small decreases of circuit pressures. However, the routine flushing of the circuits is not recommended in all cases because of the limited efficacy and because of the fluid administered to patients when doing this frequently. Troubleshooting for specific events, however, must be decided at the moment and the rapidity of intervention is based on adequate staff training, optimal material choice, and correct CRRT machine setup and/or therapy prescription. Quick interventions reduce circuit failure and downtime, increase system accuracy, and especially prevent prolonged cessation or slowing of blood flow, which is the most common cause of clotting.
CHAPTER 15
Management of clogging circuit
125
designed and new deareation chambers without air-blood contact are now available. Keeping the chamber full with a small air space and stopping foaming or splashing of blood flow may also be preventative of clotting.
Alarms and troubleshooting CHAPTER 15
126
machines has partially overcome this problem. Nevertheless, there are conditions and operation modes in which the potential for fluid balance errors is still present. The precision of delivery of the prescribed renal replacement therapy is dependent on the training of the operators, the clarity of the orders, the familiarity with the equipment, and its fluid measurement accuracy. Third-generation machines control fluid flows by accurate pump-scales feedback: 30 gm (30 mL) per hour is the accepted error for each pump, and an alarm warns the operator if this limit is exceeded; furthermore, some monitors are designed to correct a previous error in the next 60 minutes, further increasing accuracy of the system. When the therapy is interrupted by a pressure alarm, it automatically restarts if the pressure level normalizes within few seconds. In spite of several educational efforts, however, misunderstandings are still possible on common terms such as “fluid exchange rate,” “ultrafiltration,” “fluid loss,” “fluid balance,” “weight loss rate,” and “patient negative.” Improvements in commercial machines for safety and accuracy of fluid balance, the way alarms can be overridden, or the occasional addition of external components to the overall fluid balance can easily affect the final result and make fluid balance significantly different from that prescribed. In particular, users who override scale alarms without solving the cause of the alarm (possible error in fluid balance typically occurs when a replacement fluid bag is clamped) may dramatically impact patient fluid balance. In fact, if an alarm appears on the machine, one can override it without major problems: these may occur when multiple override commands are operated without identifying the problem and solving it adequately. For this reason some monitors, by default, accept a limited numbers of overrides per hour, automatically stopping the therapy if the limit is exceeded. In general, fluid balance errors can easily be avoided not only by a correct and careful adherence to the protocols of use of the current CRRT machines, but also by the compliance to prescriptions and programmed controls during therapy. Potential fluid balance errors, not detected by the machine or due to inadvertent prescription of additional fluids (diluted drugs, nutrition increase, need for high volumes of blood derivates) should be always considered. • Physical assessment of the patient and hemodynamic monitor should be constant (especially when CRRT is delivered in semi-intensive care (high dependency units). • A fluid balance chart should be updated hourly. This will help to correctly interpret patients’ total fluid balance. • Never forget to check and possibly record machine information on “effectively delivered net UF” and not just reporting on clinical chart the “prescribed UF”: they can differ significantly due to systematic small errors of the machine (after 24 hours they can be highly multiplied) but, above all, they are caused by all unreported interruptions needed for troubleshooting.
Alarm/problem Too low arterial pressure alarm
Possible causes 1. Kinked or clamped line 2. Clotted line 3. Access device against vessel wall 4. Hypovolemia
High venous pressure alarm
1. Kinked or clamped line 2. Clotted line 3. Positional vascular access obstruction 1. Line separation or disconnection from patient (very rare!) 2. Circuit kinked or clamped before pressure sensor 3. Clot excluding pressure sensor 4. Blood pump speed relatively too slow with respect to catheter performance 1. Clogging hemofilter 2. Kinked or clamped hemofiltration/ dialysis line 3. Blood flow too slow for UF setting 1. Presence of small air bubbles (often due to bicarbonate - CO2 coming from hemofiltration bags) 2. Line disconnection at arterial access 3. Turbulence close to air sensor 1. Effluent or hemofiltration/dialysis bags moving or incorrectly hanged. 2. Kinking in effluent or hemofiltration/dialysis bags 3. Machine occasional error 4. Machine systematic error (if more than 10 times without reason in 3 hours)
Arterial (or venous) line disconnection alarm
Increasing TMP
Air in the circuit
Fluid balance error
Actions 1. Remove kinking 2. Declot access 3. Consider limbs switching 4. Stop UF, decrease blood flow rate 1. Remove kinking 2. Declot access 3. Consider limbs switching 1. Check circuit and patient and, if no disconnection is present, override alarm 2. Declamp line 3. Evaluate for circuit change 4. Increase set blood flow rate
1. Evaluate for circuit change 2. Declamp line 3. Increase blood flow speed, check UF setting 1. Follow instruction for degassing 2. Stop session 3. Override alarm
1. Wait for bags, stop or reposition them on scales 2. Remove line kinking 3. Override 4. Change machine and do not reuse it before technical assistance
Alarms and troubleshooting
Table 15.1 Troubleshooting checklist
CHAPTER 15
With any health care technology, it is easy to focus on management of the machinery and lose sight of the patient. It is, therefore, invaluable to always have a problem-oriented approach to patients. Constant technical training and checklists are useful for all users and considered mandatory for novice practitioners (Table 15.1).
127
Conclusions
Alarms and troubleshooting CHAPTER 15
128
It should be noted that modern CRRT machines include, for each occurring alarm during treatment, an online “real time” alarm page with clear and simple explanations describing the causes and remedy for alarms. This is very useful to operators, but rarely read and used as a learning tool due to the hurry and perceived urgency of the event.
Suggested readings Acute Dialysis Quality Initiative, www.adqi.org (accessed July 10, 2009) Baldwin I. Training, Management and Credentialing for CRRT in ICU. Am J Kidney Dis, 1997;30(5)(suppl 4):S112-S116. Bellomo R, Baldwin I, Ronco C, Golper T. Atlas of hemofiltration. WB Saunders, Philadelphia, PA: Harcourt Publishers Limited; 2002. Parienti JJ, Thirion M, Mégarbane B, and the Members of the Cathedia Study Group. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA. 2008;299:2413-2422. Ricci Z, Bonello M, Salvatori G, et al. Continuous renal replacement technology: from adaptive technology and early dedicated machines towards flexible multipurpose machine platforms. Blood Purif. 2004;22:269-276. Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Contributions to Nephrology. Karger Publishers; 2007. Ronco C, Bellomo R, La Greca G. Blood Purification in Intensive Care. Contributions to Nephrology. Basel: Karger Publishers; 2002. Ronco C, Bellomo R. Critical Care Nephrology. Dordrecht: Kluwer Academic Publishers; 1st ed.; 1998. Ronco C, Ricci Z, Bellomo R, Baldwin I, Kellum J. Management of fluid balance in CRRT: a technical approach. Int J Artif Organs. 2005;28:765-776.
Chapter 16
Nonanticoagulation strategies to optimize circuit function in renal replacement therapy Ian Baldwin
Anticoagulant drugs such as heparin and citrate can be effective in preventing clotting in the extracorporeal circuit. Not all patients can be administered these agents due to risk of bleeding. Renal replacement therapies can be done without anticoagulation. In centres with a large surgical case load, anticoagulation may only be used in approximately 50% of all treatments. In all treatments, and particularly when anticoagulation is not used, strategies to maintain blood flow in the renal replacement therapy (RRT) circuit are useful in preventing clotting.
Definitions—key terms associated with optimising circuit function in renal replacement therapy Filter life: The “filter life” is defined as the time (hour, minute) from the commencement of blood flow through the hemofilter until the time when the blood is unable to pass through the hemofilter due to clot formation and obstruction in the hemofilter. Predilution: The administration of replacement fluid into the blood pathway prior to its entry into the hemofilter (prefilter delivery, see Figure 16.1). Access catheter: Often referred to as a Vascath (vascular access catheter), which is also a trade name; Vascath. A plastic tubing device with two lumens placed percutaneously in a large vein of the body for the purpose of drawing blood into an RRT circuit and returning it to the patient. Access failure: Obstruction in the catheter such that blood aspiration and or flush is not adequate for RRT to function.
129
Introduction
Nonanticoagulation strategies CHAPTER 16
CVVH predilution Membrane
Replacement fluid Blood pump
Waste pump
Pump
Heater
Waste collection Patient
130
Figure 16.1 Schematic diagram for continuous veno-venous hemofiltration indicating premembrane fluids administration or predilution.
Blood Pump speed: Flow of blood setting for RRT in mL/min. Filtration fraction: Describes a relationship between the blood flow through the hemofilter and the amount of plasma water removed from the blood within the hemofilter. An increased filtration fraction means hemoconcentration and potential clotting and cell clogging of the hemofilter fibers. P-in: Pressure (mm Hg) measured in the RRT circuit before the hemofilter. An increase in this pressure reflects hemofilter clotting. Transmembrane Pressure (TMP): A measure of pressure across the hemofilter as a result of pressure measurements taken before (P-in), after the hemofilter (P-venous), and in the filtration pathway (P-Uf). P-venous – P-in/2 + P-Uf = TMP. Arterial pressure: Pressure in the RRT circuit between the access catheter outflow connection and the blood pump is a negative pressure reflecting blood being drawn from the patient. Blood flow reduction: A blood flow less than set or prescribed, related to access catheter outflow failure and insufficient stroke volume of the roller pump tubing. It is associated with increasing negative arterial pressure, and often without operator awareness as pump rotations remain stable. Venous chamber clotting: Clot formation in the circuit bubbles trap chamber, found in the section of tubing between the hemofilter and the access catheter return line. Air-blood interface: A pocket of gas above the level of blood in the venous chamber. This provides an exposure of blood to this gas thought to promote clotting. The gas is initially air on starting RRT, but becomes carbon dioxide when
The access catheter type and site: Large size, 13.5–15.0 Fg, side-by-side lumen configuration (see Figure 16.2). Tip placement close to the right atrium on chest X-ray. Femoral site functions well in most patients. Test access patency by aspiration and flush for each circuit connection. Access failure can cause reduced blood flow with pump failure due to inadequate pump tubing segment refill (see Figure 16.3). The operator will be unaware this is occurring and premature clotting will result. Blood flow rate setting: 150–200 mL/min. Flow must be adequate for the fluid removal rate (see filtration fraction error). Incorrect blood flow and fluid removal rate ratio (filtration fraction) causes membrane hemoconcentration with an increase in clotting and cell clogging of the membrane. Flow too fast can cause turbulence at resistance points, cell and plasma separation, and clot formation. Flow too slow causes cell slugging and sticking to surfaces. Membrane size and type: The membrane needs to be adequate for the blood flow and fluids removal settings. In adults it is commonly between 1.0 and 1.4 m2. Different membrane composition may affect clot potential. Where clotting occurs frequently with one type of membrane composition, use an alternative.
Vascular access catheter design profiles Side by side: Double ‘‘D’’
Inner and outer lumen: Coaxial
Side by side: Double ‘‘O’’ Figure 16.2 Schematic diagram indicating three different vascular access catheter profiles. Side-by-side profile can provide best blood flow.
Nonanticoagulation strategies
Circuit preparation: Use saline solution to expel all air; avoid excessive tapping to remove air bubbles. Use of bicarbonate fluids may increase bubbles during priming. Addition of heparin may prevent clotting by coating plastic and membrane surfaces.
CHAPTER 16
Key areas for attention to maintain blood flow and reduce clotting
131
bicarbonate fluids are used as substitution solution and heated liberating carbon dioxide gas.
Nonanticoagulation strategies
After forward compression, the tubing behind the rotating wheel will reexpand and refill with blood from the access catheter (A).
Patient access catheter (A)
If patient access restricts flow, the tubing may not adequately refill and may remain partially collapsed. Output of the next pump stroke is reduced. Blood may also pass backwards through the occlusion gap before the compression stroke of the alternate wheel.
QB
Gap QF
QB backwards flow
Flow reduction is therefore related to patient access, the revolutions per min. of the roller, (affecting refill time) the occlusion gap, and tubing reexpansion properties. QF backwards flow
Figure 16.3 Schematic diagram with description for how blood flow may fail when the access catheter is inadequate and pump tubing fails to recoil and refill reducing stroke volume. From Tamari Y, Lee-Sensiba K, Leonard EF, Tortolani A. A dynamic method for setting roller pumps nonocclusively reduces hemolysis and predicts retrograde flow. ASAIO J. 1997;43:39-52. Reprinted with permission of Wolters Kluwer Health.
132
CHAPTER 16
Roller pumps. Why they may not deliver the desired blood flow!
Substitution fluids administration site: Replacement fluids given before the membrane dilute the blood and reduce clot development in the membrane (predilution). Understanding the “air-bubble trap” chamber: The bubble trap collects bubbles that enter the circuit before blood returns to the patient. CO2 bubbles cause most of this and occur frequently when using heated bicarbonate solutions. The gas and blood interface, along with surface movement, causes cell smearing on the chamber walls. Adjustment of the blood level high in the chamber may reduce this by reducing blood splashing on the surface. Postdilution fluids into the chamber can create a fluid layer on top of the blood level, possibly reducing clot development (see Figure 16.4). Training and education for staff: Staff training and education has a direct relationship to success and therefore circuit life. Machine alarms “troubleshooting,” recognizing access failure, and use of anticoagulation are the key areas for education and training.
Summary Clotting in the circuit during continuous renal replacement therapy (CRRT) can be prevented by paying attention to circuit preparation with air and bubble removal and addition of heparin into the circuit with priming, circuit connection to a large Fg vascular access catheter with side-by-side lumen configuration,
Gas space
Clot: cross-section Keep level to here
CHAPTER 16
Splashing of blood on entry to chamber causing clotting as cells stick to chamber walls
Nonanticoagulation strategies
Blood entry
133
Figure 16.4 Schematic diagram of a typical bubble trap on the return or venous limb of the RRT circuit. Blood level needs to be high to reduce gas and blood interface and minimize cell splashing on surface of blood level. Cells stick to chamber walls and create clot development.
pumping blood at 200 mL/min, use of a larger surface area membrane in the adult, premembrane substitution fluids administration, and keeping the blood level in the venous bubble trap high. Nursing training and “troubleshooting” ability is also vital to prevent clotting due to delayed alarms correction and skilled use of technology.
Key references Baldwin I, Tan HK, Bridge N, Bellomo R. Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Ren Fail. 2002;24(6):839-848. Baldwin I, Bellomo R. The relationship between blood flow, access catheter and circuit failure during CRRT; a practical review. Contributions to Nephrology. 2004;144:203-213. Baldwin I, Bellomo R, Koch W. Blood Flow reductions during continuous renal replacement therapy and circuit life. Intensive Care Med. 2004;30:2074-2079. Baldwin I. Training management and credentialing for CRRT in critical care. Am J Kidney Dis. 1997;30(5)(suppl 4):S112-S116. Baldwin IC, Elderkin TD. CV VH in intensive care. Nursing perspectives. New Horiz. 1995;3(4):738-747. Canaud B, Formet C, Raynal N, et al. Vascular access for extracorporeal renal replacement therapy in the intensive care unit. Contributions to Nephrology. 2004;144:291-307. Egi M, Naka T, Bellomo R, et al. A comparison of two citrate anticoagulation regimens for continuous veno-venous hemofiltration. J Artif Organs. 2005;28(12):1211-1218.
Nonanticoagulation strategies CHAPTER 16
134
Lavaud S, Paris B, Maheut H, et al. Assessment of the heparin-binding AN69 ST hemodialysi membrane: II. clinical studies without heparin administration. ASAIO J. 2005;51(4): 348-351. Oudemans-Van Straaten HM, Wester JPJ, de Pont ACJM, Schetz MRC. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med. 2006;32:188-202. Schetz M. Anticoagulation for continuous renal replacement therapy. Current Opinion in anaesthesiology. 2001;14:143-149. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control. Nephron Clin Pract. 2003;94(4):94-98. Webb AR, Mythen MG, Jacobsen D, Mackie IJ. Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation. Intensive Care Med. 1995;21:84-93.
Chapter 17
Anticoagulation Rinaldo Bellomo and Ian Baldwin
Continuous treatment suggests extracorporeal blood flow without clotting. This is not a realistic aim. However, drugs blocking normal coagulation pathways can prevent or delay clotting such that sufficient treatment time is achieved, and importantly patient blood is returned before complete circuit obstruction. Anticoagulation primarily refers to the use of agents that prevent blood from clotting after contact with the plastic and artificial surfaces in the extracorporeal circuit (EC). Heparin is most commonly used as an anticoagulant for renal replacement therapy (RRT). Citrate is routinely used to prevent clotting by chelating calcium and preventing its action as a cofactor. Administration of anticoagulant drugs during RRT requires specific knowledge and the application of monitoring protocols to ensure safety and effectiveness. This chapter provides a brief clinical guide to such treatments.
Definitions and key terms associated with anticoagulation during continuous renal replacement therapy Filter life: The term “filter life” refers to the time from the commencement of blood flow through the filter until the time when the blood is unable to pass through it due to clot formation and obstruction. Circuit life: An equivalent term for filter life. It is probably a more correct term as some circuits develop obstruction to adequate blood flow because of clot elsewhere in the circuit and not in the filter itself. Air trap (or bubble trap): A component of circuit, which is typically located after the filter and which aims to prevent air entering the circuit and embolizing into the blood of the patient.
135
Introduction
Anticoagulation CHAPTER 17
Anticoagulant: A term used to describe any agent given with the aim of decreasing the tendency of blood to clot. Heparin: The most common drug used to prevent blood clotting within the circuit. Heparin is administered to prevent clot formation when extracorporeal blood flow is required. It can be administered at various doses, from “low dose” (5 units/kg/h) to simply decrease the coagulability of the circuit to “full dose” [to achieve an activated partial thromboplastin time (APTT) between 1.5 to 2.5 times the normal value] to achieve both circuit and patient anticoagulation. Low molecular weight heparin (LMWH): A drug that is a modification of the heparin molecule and that can also be used to achieve circuit anticoagulation during CRRT. It can be given as a single subcutaneous dose once a day. Various types of LMWH exist and some can accumulate in patients with kidney failure. LMWH can only be partially reversed by protamine.
136
Protamine: A drug given to bind heparin and reverse its anticoagulant effect. The typical effective ratio for full blockade is 1 mg of protamine to 100 international units of heparin. Protamine can be given to reverse the effect of heparin within the circuit before blood is returned to the patient. Warfarin (coumadin): A drug used to anticoagulate blood in the chronic setting. Although uncommon in the ICU, several patients may be admitted to the ICU with acute kidney injury and require CRRT while still under the effects of this agent. In some of these cases, such effects may be used to advantage as a form of circuit anticoagulation. INR: International normalized ratio for the prothrombin time. This test is used to measure and monitor the degree of anticoagulation achieved with warfarin. It is frequently prolonged in patients with liver disease and may be used to guide the (lack of) need for additional anticoagulant treatment in such patients. Prostacyclin: A drug that interferes with platelet aggregation and can be used as a continuous infusion to retard circuit clotting during CRRT. Activated partial thromboplastin time (APTT): A laboratory test used to monitor the degree of anticoagulation achieved with heparin. Citrate: (See Chapter 18 for details.) A molecule administered to chelate (bind) calcium in the EC blood and make it unavailable as a cofactor to the clotting process. Citrate is then metabolized by the liver into CO2. The calcium lost into the dialysate or ultrafiltrate together with citrate is then replaced by a separate infusion of calcium. Citrate acts as both an anticoagulant and a buffer. The amount given is sufficient to inhibit clotting within the circuit but, typically, does not have an effect on systemic anticoagulation. Bolus dose: Drug administration aimed at achieving therapeutic blood levels quickly. A continuous infusion at a lower dose is then provided to maintain this level.
Anticoagulation
Newer anticoagulants: More recently new anticoagulants have been developed and found to be effective and safe for human use. They include the pentasaccharides and the thrombin inhibitors. There is limited information on their use for circuit anticoagulation. In patients receiving invasive cardiac procedures, glycoprotein IIb/IIIa inhibitors are often used to prevent coronary vessel clotting. These agents may also affect the lack of need for circuit anticoagulation in some patients. In Japan, circuit anticoagulation is commonly achieved with a protease inhibitor called nafamostat mesylate, which is not available in other countries.
CHAPTER 17
Heparin coating: Administering the drug heparin into the circuit priming solution with the aim of preventing clotting due to blood contact with plastic surfaces where the heparin has coated the surface.
Orgaran: This drug is a low molecular weight glycosaminoglycan, which can be used to anticoagulate the circuit in the presence of the heparin-induced thrombocytopenia thrombosis syndrome (HITTS).
Regional anticoagulation: Any anticoagulation of the circuit but not of the patient. This might include the use of citrate with separate administration of calcium and the use of heparin with the administration of protamine to reverse its effect before the blood is returned to the patient.
Key areas for attention when administering an anticoagulant for the prevention of circuit clotting • Develop a bedside protocol for anticoagulant use. Keep this simple and read-
ily available for reference as a chart or computer page. • Develop your own expertise with this protocol. • If the circuit clots, this can be replaced. If the patient bleeds, a more seri-
ous and adverse outcome may occur. To lose a filter to protect a patient is entirely acceptable. To lose a patient in order to protect a filter is not. • Often the circuit clots not because anticoagulation is suboptimal or inadequate but rather because of poor quality vascular access, poor attention to optimal machine operation, and sudden changes in patient position that alter catheter function, decrease blood flow, and induce clotting through stasis. To respond to such events by increasing anticoagulant dose is dangerous and unwise. For every clotting event, an appropriate diagnostic assessment is necessary in order to implement rational measure to prevent it the next time around.
137
No anticoagulation: In patients considered at high risk of bleeding because of recent major surgery, low platelet count, abnormal clotting tests or any combination of these can receive CRRT without the administration of any anticoagulant drug.
Anticoagulation CHAPTER 17
Practical considerations using heparin anticoagulation • It is not necessary to use full heparin anticoagulation to perform CRRT; many
patients have altered clotting as a result of critical illness. • After major surgery and with epidural use, no anticoagulation for the first
24–48 hours postoperatively or citrate anticoagulation may be a safer option. • CRRT machines include a syringe device for concentrated anticoagulant drug
• • • •
138
• •
• • • •
•
preparation. If a dilute preparation is used, an intravenous pump used widely in the ward promotes safety as all staff will be familiar with its operation. Use of dilute preparation administered by volumetric pump minimizes accidental bolus and syringe “lag” when changing syringe once it is empty. Make the heparin infusion preparation simple in terms of calculation of dose. Heparin at 10,000 IU in a 1000 mL bag = 10 IU/mL. Label and identify this infusion as “for CRRT only.” Use a heparin preparation different to those used for other anticoagulation prescriptions (e.g., following thrombosis or embolism). Use a dosing chart or table (see Table 17.1) based on body weight for initial bolus dose and consideration of the daily clotting profile for the patient. Start the treatment using the dosing table as a guide, then increase heparin if circuit life is poor. If filter life is less than 8 hours for the first circuit consider increasing the dose. A filter life of 20–24 hours is common using heparin. A dose of 5–10 IU/kg/h given prefilter is a common starting dose for the first treatment circuit. The fluid volume used to administer the anticoagulation must be included in the fluid balance calculations. Administer the anticoagulant into the circuit before blood enters the membrane in “prefilter” position. Check and assess the patient for evidence of spontaneous bleeding, urine, faeces, wounds, punctures sites, and mucus membranes. Do not check the patient clotting time (APPT) too frequently and make inappropriate infusion adjustments. Check after the first 6 hours. After that, 12 hourly monitoring is probably adequate in most cases unless significant clinical changes have taken place. After stabilization, daily monitoring is adequate. If patient anticoagulation is the goal, APTT monitoring may need to be more frequent. If circuit anticoagulation is the goal, APTT monitoring is performed not to titrate heparin infusion but rather to ensure there is no unnecessary or excessive patient anticoagulation. Chart the dose of heparin given each hour on bedside observation charts/ computers and the filter consecutive hours of function next to this. This provides an instant ability to assess filter life associated with heparin dosing (see Table 17.2).
Anticoagulation
Table 17.1 Heparin dosing guide for bolus and infusion Heparin anticoagulation
• All circuits primed with 5000 U heparin (1st bolus) • Patients to have at least two of the following: INR
APTT
Plts
d1.5
d40s
t150
Heparin 35 IU/kg*5 U kg/h
t1.5 d2.5
t40s
d150 t60
No bolus
t2.5
t60s
d60
CHAPTER 17
2nd bolus Heparin 70 IU/kg*10 U kg/h
Nil other
Table 17.2 ICU charting aligning heparin dose each hour with accompanying filter “life” 500 7
500 8
500 9
500 10
// clotted
750 1
750 2
Summary Anticoagulants can delay or prevent circuit clotting. However, they increase the risk of bleeding. Accordingly, their use should be based on a careful assessment of the likely risks and benefits in a given patient. Heparin is commonly used in hospitals. Typically, doctors and nurses understand its risks and benefits well and have established expertise with this drug. Heparin, however, is not always necessary and CRRT can be done without using it, particularly in the patient at high risk of bleeding. Heparin can be reversed with protamine if necessary. Use of a standard dilute preparation, administration prefilter via a common infusion device, reference to a dosing chart specific for CRRT, ongoing review of the patient and of his/her clotting profile all promote safe circuit anticoagulation. No other approaches to circuit anticoagulation have yet been convincingly shown to be superior to heparin, although citrate anticoagulation is also highly effective. Whatever the choice of approach to anticoagulation, the physician and nurse must remain vigilant of changes in the patient’s risk profile and make a frequent and thoughtful assessment of what approach to circuit anticoagulation is best at any given time in a given patient.
Key references Fealy N, Baldwin I, Johnstone M, Egi M, Bellomo R. A pilot controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. Int J Artif Organs. 2007;30:281-292.
139
Heparin dose Filter hour
Anticoagulation CHAPTER 17
Naka T, Egi M, Bellomo R, et al. Commercial low-citrate anticoagulation haemofiltration in high risk patients with frequent filter clotting. Anaesth Intensive Care. 2005;33:601-608. Tan HK, Baldwin I, Bellomo R. Hemofiltration without anticoagulation in high-risk patients. Intensive Care Med. 2000;26:1652-1657. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous hemofiltration without anticoagulation. ASAIO J. 2004;50:76-80.
Other suggested readings
140
Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care. 2007;11(4):218. Mehta RL. Anticoagulation during continuous renal replacement therapy. ASAIO J. 1994 Oct-Dec;40(4):931-935.
Chapter 18
Regional citrate anticoagulation Nigel Fealy
An alternative to systemic methods of extracorporeal circuit anticoagulation is the application of a “regional technique” using citrate. A regional technique such as citrate anticoagulation reduces the hemorrhagic risk of systemic anticoagulation by providing selective anticoagulation within the extracorporeal system. Regional citrate anticoagulation (RCA) involves the infusion of citrate into the blood circuit, which combines (chelates) with ionized calcium to form citrate– calcium complexes. This decreases the level of circulating calcium in the circuit and prevents coagulation of blood. Ionized calcium is an important cofactor in multiple steps of the clotting cascade. Calcium, therefore, that is bound to citrate will not participate in the clotting cascade, leading to clotting inhibition.
Definitions Extracorporeal circuit (EC)—The path for blood flow outside the body. Includes the plastic tubing carrying the blood to the hemofilter from the access catheter and from the hemofilter back to the body via the access catheter. Filter life or functional life of the EC—The passage of blood through the EC, particularly the hemofilter, initiates blood clotting. The clotting of blood is a slow but inevitable process delayed by factors known and unknown. Blood coagulation is thought to be a main factor in this process. The time period before the blood is unable to pass through the hemofilter due to clot formation and obstruction in the hemofilter is the filter life. This is generally synonymous with EC life or circuit life. Anticoagulation—It is the administration of a substance that prevents coagulation, that is, it stops blood from clotting. Anticoagulant therapies interfere with humoral coagulation or platelet activation and have varying impact on systemic coagulation.
141
Introduction
Regional citrate anticoagulation CHAPTER 18
142
Systemic anticoagulation—Where an anticoagulant is administered and has a direct effect on the patient’s ability to activate the clotting cascade within the body. The agent leads to increased clotting times of the patients themselves. Some anticoagulants are administered into the EC circuit but also have a direct effect on the patient’s ability to clot blood. Circuit anticoagulation—The aim of anticoagulation is to prevent clot formation within the EC circuit and hemofilter, with little or no impact on the patient’s ability to start the clotting process. Regional anticoagulation–Where a high level of anticoagulation is provided to the EC circuit only while the patient receives no drug. Usually the anticoagulant is administered into the circuit and an “antidote” is administered to reverse the effects of the anticoagulant before blood returns to the body.
Method It is important to understand some aspects of calcium physiology and distribution in blood (Figure 18.1). When citrate is infused into the blood circuit, it combines with ionized calcium (IC) to form citrate–calcium complexes (nonionized). This reduces the level of ionized calcium in the extracorporeal circuit, which in turn leads to the inhibition of clotting in the circuit. The target for circuit ionized calcium level to prevent or retard clotting is generally between 0.25 and 0.4 mmol/L. There is no systemic anticoagulation because of the following reasons: • There is significant loss of the citrate–calcium complexes as they cross the semipermeable membrane of the hemofilter (dialyzer) into the ultrafiltrate (UF).
(IC) Ionized calcium, (~ 50%) 1.1–1.3 mmol/L (TC) Total calcium 2.2–2.6 mmol/L (PBC) Protein bound calcium (~ 40% 0.95–1.2 mmol/L
(CC) Complex calcium (~ 10%) Calcium phosphate, salts ~ 0.05 mmol/L Figure 18.1 Calcium distribution in plasma and normal lab ranges.
Practical considerations Key areas that need attention to maintain metabolic and electrolyte balance are as follows: • In addition to acting as an anticoagulant, citrate acts as a buffer following liver metabolism. One mmol of citrate yields three mmol of bicarbonate when metabolized. Potentially, when higher doses of citrate are administered, this could lead to an increase in serum bicarbonate levels (metabolic alkalosis). • The amount of citrate lost in the ultrafiltrate will vary with filtrate flow (both UF rate and amount of fluid removal), and, therefore, the amount of buffer entering the systemic circulation may vary (metabolic acidosis). • When trisodium citrate is used, there is an increase in the sodium load to the patient, increasing the risk of hypernatremia. • If the patient is not able to metabolize citrate–calcium complexes due to liver dysfunction or via the skeletal muscle pathway, then citrate may accumulate and no buffer is generated. In addition, hypocalcaemia may also result.
Regional citrate anticoagulation CHAPTER 18
are delivered to the patient are diluted with the patient’s blood and rapidly metabolized by liver, kidney, and muscle cells to form bicarbonate (1 citrate ion = 3 bicarbonate ions). • During this metabolism of the citrate–calcium complexes, calcium liberated from the complex contributes to the normalization of calcium levels. • Serum ionized calcium levels lost in the UF are replaced by the administration of a calcium infusion systemically to restore normal levels (normal serum ionized calcium level ~ 1.1–1.3 mmol/L) A variety of citrate protocols or regimens exist for the prescription for continuous renal replacement therapy (CRRT) using both continuous venovenous hemofiltration (CV VH) and continuous veno-venous hemodiafiltration (CV VHDF) as the mode of therapy. Often protocols are hospital specific requiring pharmacy or custom-made solutions (substitution and dialysate) to implement the technique. These prescriptions vary according to mode, pre- or postdilution, different citrate solutions, and different approaches for monitoring and adjustment of acid-base balance. In CRRT, there are three major forms of citrate administration. First is 4% trisodium citrate, second is acid citrate dextrose solution (ACD-A), and third is citrate-containing replacement solution. These different approaches can also vary with respect to the mode of CRRT—a pure diffusive method (CV VHD), a diffusive and convective method (CV VHDF), and pure convective method (CV VH). As previously described, there are many descriptions and protocols for the delivery of citrate anticoagulation in the clinical setting. A description of protocols for CV VHDF and CV VH can be seen in Figures 18.2 and 18.3.
143
• Any citrate or citrate–calcium complexes that remain in the venous line and
Regional citrate anticoagulation CHAPTER 18
144
QE = QR + QFR + QD
QB 100–150 mL/min
Dialysate: 4L bag Na+ 140 mmol/L Cl– 118.5 mmol/L HCO3– 25 mmol/L K+ 4.0 mmol/L Mg 0.58 mmol/L Rate: 1000–2500 mL/h QD Patient iCa2+ 1.1–1.3 mmol/L
QR PF iCa2+ (0.25–0.5mmol/L) Prefilter fluid: 4L bag 0.5% Trisodium citrate Citrate 18 mmol/L Na+ 140 mmol/L Rate: 1000–2000 mL/h
Ca2+ Gluconate 38.75 mmol/L Initial rate: 60 mL/h
Figure 18.2 Continuous veno-venous hemodiafiltration (CV VHDF). University of Alabama at Birmingham CV VHDF protocol (A. Tolwani, 2005). QB = blood flow; QE = effluent flow; QR = replacement; QFR = fluid removal; QD = dialysate flow. Modified from Tolwani A, Prendergast M, Speer R, Stofan B, Willie K. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clinical Journal of the American Society of Nephrologists. 2005;1:79-87.
• In addition to binding calcium to form calcium–citrate complexes, magnesium
is also bound and freely filtered across the membrane, potentially leading to a reduction in serum magnesium levels. Therefore, when prescribing a citrate-based anticoagulation regimen, metabolic monitoring should be a priority. Regular monitoring of pH, serum and circuit iCa, serum bicarbonate, and sodium and magnesium levels should be an essential element of any unit based protocol. Depending on the method used a local protocol should be developed to monitor, report, and treat any metabolic derangements that may occur as a result of utilizing a citrate-based anticoagulation regimen. There are numerous descriptions and reports available for the monitoring of electrolytes, acid-base balance, and anticoagulation in RCA.
Summary With regional citrate anticoagulation, filter life is prolonged or equal to that of standard systemic heparin anticoagulation. The major advantage is that adequate
Patient iCa2+ 1.1–1.3 mmol/L
Prefilter fluid: 5 L bag Sodium citrate Citrate 14 mmol/L Na+ 140 mmol/L Rate: 2000 mL/h
Ca2+ Chloride + Mg+(210 mL) Ca2+ 70 mmol/L Mg+ 35 mmol/L Initial rate: 12mL/h (Ca2+ = 4 mmol/h)
Regional citrate anticoagulation
QB 200 mL/min
CHAPTER 18
QE = QR + QFR
anticoagulation can be achieved for CRRT without the need for systemic anticoagulation and the associated risks of bleeding in critically ill patients. The choice of citrate protocol will depend largely on the citrate solution available, mode of therapy used (CV VH, CV VHDF), and method chosen for citrate delivery (infusion, replacement solution). RCA requires, however, the development of unit-based protocols that are easy, safe, and practical in the clinical setting. With these protocols in place, RCA is a safe and practical alternative strategy for anticoagulation in CRRT.
Key references Abramson S, Niles J. Anticoagulation for continuous renal replacement therapy. Current Opinion in Nephrology and Hypertension. 1999;8:701-707. Amanzadeh J, Reilly Jr R. Anticoagulation for continuous renal replacement therapy. Seminars in Dialysis. 2006;19(4):311-316. Cointault O, Kamar N, Bories P, et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrology Dialysis Transplantation. 2003;19(1):171-178. Fealy N, Baldwin I, Johnstone MJ, Egi M, Bellomo R. A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs. 2007;30(4):301-307.
145
Figure 18.3 Continuous veno-venous hemofiltration (CV VH). Department of intensive care, Austin hospital CV VH protocol. QB = blood flow; QE = effluent flow; QR = replacement; QFR = fluid removal.
Regional citrate anticoagulation CHAPTER 18
146
Kutsogiannis DJ, Mayers I, Chin W, Gibney R. Regional citrate anticoagulation in continuous venovenous hemofiltration. American Journal of Kidney Diseases. 2007;35:802-811. Oudemans-van Straaten HM, Wester J, de Pont A, Schetz M. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Medicine. 2006;32:188-202. Tolwani A, Prendergast M, Speer R, Stofan B, Willie K. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clinical journal of the American Society of Nephrologists. 2005;1:79-87.
Chapter 19
Drug dosing in continuous renal replacement therapy
The use of continuous renal replacement therapy (CRRT) in intensive care patients is increasing. Typically, CRRT is used in the critically ill patient because it provides continuous removal of solutes and fluid, which results in decreased fluctuations in electrolytes and fluid balance with reduced hemodynamic instability as compared to conventional intermittent hemodialysis (IHD). While there is still debate regarding the optimal use and application of renal replacement therapy (RRT) in the intensive care unit (ICU), it is important to recognize the impact that RRT may have on medications used to treat the critically ill. More precisely, it is important to understand the numerous variables that affect drug dosing in the critically ill patient receiving RRT. Among those variables are differences between available renal replacement therapies, pharmacokinetic and pharmacodynamic changes that occur in the critically ill, and physiochemical properties that affect drug dosing and clearance in this patient population.
Continuous renal replacement therapy properties As discussed in Chapter 10 and 12, CRRT can be applied utilizing various techniques and methods. Differences among CRRT techniques that affect solute and medication clearance include mechanism of solute clearance, vascular access, filter membrane properties, and flow rates for blood, ultrafiltration, and dialysis fluid.
CRRT techniques The three main techniques of clearance utilized are hemodialysis, hemofiltration, and hemodiafiltration. Each technique varies in mechanism of solute clearance (i.e., convection or diffusion) and need for fluid replacement (see Table 19.1). In addition, each technique can be applied using either arterio-venous or veno-venous access. However, veno-venous methods are generally preferred, given the reduced risk of complications and the ability to generate consistent and higher solute clearance rates.
147
Kimberly A. Maslonek, Kelly A. Killius, and John A. Kellum
Drug dosing in CRRT CHAPTER 19
Table 19.1 CRRT techniques Technique
Clearance mechanism
Replacement fluid 0
SCUF
Convection +
Diffusion
CV VH
++++
CV VHD
+
++++
+/0
CV VHDF
+++
+++
++
+++
Note: SCUF = slow continuous ultrafiltration; CV VH = continuous veno-venous hemofiltration; CV VHD = continuous veno-venous hemodialysis; CV VHDF = continuous veno-venous hemodiafiltration
148
• Hemodialysis utilizes passive diffusion of solutes across a concentration gra-
dient with countercurrent dialysis fluid. Only molecules of small molecular weight (<500 dalton) are readily removed during diffusion. Replacement fluid is not required. • Hemofiltration utilizes convection, where solutes and plasma water are driven through a membrane with a pressure gradient, resulting in higher solute removal and the formation of an ultrafiltrate. As long as the solute is smaller than the pore size cutoff for the membrane used, particle size or molecular weight has little influence on solute removal during convection methods. However, replacement fluid, which can be administered before or after blood filtration, is required due to the large volume of ultrafiltrate formed during this process. • Hemodiafiltration is a combination of diffusion and convection. Solute and volume removal involve a countercurrent dialysis fluid and pressure gradient. Replacement fluids are required to support higher ultrafiltration rates. • Slow continuous ultrafiltration (SCUF) is a method of fluid removal without dialysis or replacement fluid. SCUF is not appropriate for patients with renal failure since it provides only very limited solute clearance. SCUF is usually employed for temporary volume removal in patients with at least some renal function (e.g., congestive heart failure). As such drug dosing does not typically require adjustment for patients receiving SCUF. In general, drug removal may be expected to be greater with CRRT compared to IHD, and when replacement fluids are administered after filtration. Drug clearance with CRRT may vary greatly depending on the particular physicochemical properties of each compound and the CRRT device characteristics and operating conditions.
Filter properties Filters used in RRT differ in a number of properties including, but not limited to, permeability, membrane composition, and surface area. While no one membrane is recommended, it is important to note their differences and to understand that different filters may result in significant differences in solute or drug removal.
Membrane composition Intermittent hemodialysis (IHD) filters are composed of cellulose or syntheticbased materials, while the most common materials employed in CRRT filters are synthetics, including polyacrylonitrile, polyamide, and polysulfone. Again, while no one filter is considered optimal, filters composed of synthetic material are favored over those that are cellulose based because they are generally considered more biocompatible. Other considerations include differences in permeability and their varying effect on the SC of many drugs. In general, larger pore sizes or “high-flux” membranes generally result in greater drug clearances especially for larger molecules.
Flow rates Although variation exists depending on which mode of therapy is provided (e.g., CV VH vs. CV VHD) and which membranes are used, in general, higher flow rates (blood flow, dialysate flow, ultrafiltration flow) result in increased solute removal. Hence, for medications removed by CRRT, increased flow rates will result in a need to increase drug dosing or to shorten dosing intervals.
Patient properties Critically ill patients may have alterations in their pharmacokinetic parameters that can affect drug clearance and disposition (see Table 19.2). With regard to medication dosing in IHD and CRRT, the most relevant patient changes can occur in volume of distribution, protein binding, metabolism, and elimination.
Drug dosing in CRRT CHAPTER 19
SC = CUF/CP SC = 0; no passage through filter SC = 1; pass freely through filter SC = Sieving coefficient, CUF = concentration of medication in ultrafiltrate, CP = concentration of medication in plasma The SC is available for some medications in published literature. Otherwise, it can be calculated by obtaining medication concentrations.
149
Membrane permeability Membrane permeability differs on the basis of the type of RRT used. Conventional low-flux dialysis (IHD) filters have smaller pore size and are inefficient at removing molecules > 500 dalton. Conversely, filters that are used in CRRT have increased pore size and are effective in removing molecules up to 50,000 dalton. The ability of a drug or solute to pass through a filter membrane is expressed as the sieving coefficient (SC). Medications with SC that approach unity (SC = 1) are able to freely pass through the filter and will require increased dosing or interval changes.
Drug dosing in CRRT CHAPTER 19
150
Table 19.2 Patient factors affecting drug levels Factor Hypervolemia Hypoalbuminemia Organ dysfunction
Effects Increases Vd and decreases absorption Increases unbound fraction Decreases drug clearance
Effect on drug levels Decreases Increases Increases
• Volume of distribution: It may be altered in critically ill patients, with either an
•
•
• •
increase or decrease in total body water and intravascular volume. Increases in volume of distribution have been reported in patients with edema, ascites, pleural effusions, mediastinitis, hypoalbuminemia, and postsurgical drainage. Hypervolemic patients may require higher doses for medications with large volumes of distribution, with the opposite being true for hypovolemic patients. As fluid removal is accomplished with CRRT, volume of distribution will decrease for many drugs. This may paradoxically result in a need to decrease dosing as severely volume overloaded patients are brought back toward their premorbid weight. Drug absorption: In the case of transdermal, subcutaneous, and oral administration drug absorption can also be significantly affected by volume overload and by peripheral and intestinal edema. As edema is reduced with CRRT, drug absorption may increase. Protein binding: In the critically ill patients may be affected by several variables including, but not limited to, acid-base disturbances and alterations in protein concentrations. Acid-base abnormalities will adversely affect protein binding. Studies performed in the critically ill show that a decrease in the concentration of albumin or an increase in the concentration of alpha-1-acid glycoprotein can occur. Given that only the unbound fraction of a medication is able to diffuse across a filter membrane, shifts in protein concentrations or acid-base status can affect the amount of unbound drug (active drug) available in the body. These changes can ultimately affect the amount of drug available for removal by RRT. Importantly, protein binding is in dynamic equilibrium. Because of its continuous nature, CRRT results in significantly greater removal of drugs with increased protein binding compared to IHD. Metabolism: Assessment of other organ function is essential to determine the potential for accumulation of metabolites as well as parent compounds. Elimination: The application of CRRT is more likely to increase the clearance of renally eliminated medications than those that undergo nonrenal clearance mechanisms. In addition, the existence of residual renal function must also be considered as this may further enhance drug clearance in a patient undergoing CRRT. Furthermore, fluid removal by CRRT may result in changes in drug elimination by other organs.
Molecular weight Medications with a small molecular weight (<500 dalton) are effectively cleared by conventional low-flux hemodialysis and CRRT, while only CRRT is capable of removing larger molecules (up to the pore size cutoff of the membrane, typically 20,000–50,000 dalton). Drugs of larger molecular size, therefore, are more likely to be removed by CRRT methods and may require increased or more frequent dosing. For example, vancomycin (1400 dalton) is not easily removed by IHD but has significantly greater clearance through more open membranes even during diffusive therapy (continuous hemodialysis).
Drug dosing in CRRT
There are a number of intrinsic properties that affect the ability of any drug to be removed by RRT. These properties include molecular size, volume of distribution, protein binding, and elimination mechanisms (renal vs. nonrenal clearance).
CHAPTER 19
Drug properties
The degree to which any drug is bound to protein will affect its ability to be cleared by CRRT or dialysis (see Table 19.3). Drugs that are bound to proteins form large complex molecules (>50,000 dalton) and are not readily removed by IHD or CRRT. Unbound medications are more likely to pass through a dialysis filter and require increased dosing or dosing interval changes.
Volume of distribution Drugs that have a small volume of distribution are generally hydrophilic and limited to vascular space since they are unable to pass through plasma membranes. Most hydrophilic agents are renally eliminated as unchanged drug. Therefore, Table 19.3 Relative sieving coefficients and protein binding of select drugs Drug Acyclovir Amphotericin Ampicillin Cefoxitin Ceftazidime Ciprofloxacin Cyclosporine Diazepam
SC +++ + ++ ++ +++ ++ ++ 0
PB Very low Very high Low High Very low Low Very high Very high
Drug Digoxin Ganciclovir Gentamicin Imipenem Oxacillin Phenytoin Piperacillin Vancomycin
SC +++ +++ ++ +++ 0 + ++ ++
PB Low Very low Very low Low Very high High Low Very low
Note: SC = sieving coefficient; PB = protein binding; Drugs with high SCs and low protein binding are easily removed by CRRT. Drugs with low or near 0 SCs cannot be removed by RRT; drugs with high protein binding will be removed only to a small extend with CRRT and not at all with IHD.
151
Protein binding
Drug dosing in CRRT CHAPTER 19
medications with a low volume of distribution are more readily removed by RRT and may require increased or more frequent dosing. Examples include beta-lactams, glycopeptides, and aminoglycosides, with the exception of ceftriaxone and oxacillin. Both undergo primary biliary elimination and are therefore largely unaffected by CRRT despite their hydrophilic status. Conversely, lipophilic medications, which are able to freely cross plasma membranes and sequester into tissues, typically have high volumes of distribution and undergo hepatic metabolism. Medications with large volumes of distribution are less available to pass through the RRT circuit for clearance and are less affected by renal clearance changes (extracorporeal or residual). Dose adjustments are generally not necessary for drugs with large volumes of distribution in IHD. However, CRRT may have a greater impact on drug removal because the increased duration of therapy increases the likelihood that drug will redistribute from tissue to vascular space and be available for clearance. Examples include macrolides, fluoroquinolones, tetracyclines, chloramphenicols, and rifampins, with the exception of levofloxacins and ciprofloxacins. Both undergo renal elimination and may be removed by RRT despite their lipophilic nature.
152
Elimination Medications that are cleared renally will likely require increased dosing during RRT. In addition, dosing requirements may be further increased in patients with residual renal function receiving CRRT.
Pharmacodynamic principles Appropriate dosing of antimicrobial agents in patients receiving RRT is imperative in order to avoid therapeutic failure, increased resistance, or adverse effects, and must include pharmacodynamic considerations. In brief, antimicrobial efficacy has been defined in pharmacodynamic terms to be either time dependent or concentration dependent.
Concentration-dependent antimicrobial The efficacy of concentration-dependent antimicrobials is primarily related to the peak of minimum inhibitory concentration (MIC) (Cmax/MIC) and the area under the curve (AUC) to MIC (AUC/MIC) ratios. Concentration-dependent antimicrobials include fluoroquinolones, metronidazole, and aminoglycosides. AUC/MIC ratios >100 have been suggested for gram-negative organisms and >30 for gram-positive organisms. Cmax/MIC ratios of 10–12 have been shown to provide clinical efficacy and prevent the development of resistance. Concentration-dependent agents exhibit postantibiotic effects against grampositive and gram-negative organisms; therefore, allowing concentrations to fall below the MIC is permissible. Concentration-dependent medications typically require increased doses to achieve adequate peak or area under the curve MIC ratios (see Figure 19.1).
MBC
Drug dosing in CRRT
Bacterial regrowth
CHAPTER 19
Bacteriostatic
Plasma concentration
Bactericidal
B MIC C
A
Figure 19.1 Time-varying plasma concentration and relation to minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Curve A represents a typical relationship while B represents a decreased clearance and C represents increased clearance. Time-dependent killing is most affected by increasing drug clearance. When possible, medication adjustments based on appropriately drawn serum levels is desired.
Time-dependent antimicrobial The efficacy of time-dependent antimicrobials is primarily related to the duration of time that the drug concentration exceeds the MIC (T>MIC ratio) or by maintaining the minimum plasma concentration above the MIC (Cmin>MIC). Time-dependent agents include beta-lactams, glycopeptides, oxazolidinones, and azole antifungals. Maximum efficacy is thought to be achieved by maintaining the Cmin at 4 to 5 times the MIC. Troughs below the MIC must be avoided in time-dependent agents as the majority (with the exception of carbepenems) lacks a postantibiotic effect against gram-negative organisms. Time-dependent medications will require more frequent dosing to achieve adequate time above the MIC.
Dosing recommendations There are multiple limitations with regard to dosing recommendations for CRRT. Included is the limited number of studies available that evaluate the effect of CRRT on drug disposition in the critically ill. Those studies that do exist primarily involve the investigation of antimicrobial agents and vary in their study design, method of CRRT, and study population, making it difficult to generalize
153
Time
Drug dosing in CRRT CHAPTER 19
Table 19.4 Antibiotic dosing recommendations Dosing for CrCl 30 mL/min but not on RTT 500 mg–1 g Q 24 h
Conventional IHD (Kt/V 1.2 QOD)
Ciprofloxacin
500 mg oral or 400 mg IV Q 24 h
Gentamicina
24-hour dosing
250–500 mg oral or 200–400 mg IV after* each dialysis 30% removal occurs during 4 hours of HD; administer dose after* dialysis and follow levels
Piperacillintazobactam
Decrease dose by 30% and administer every 6 h 15–20 mg/kg Q 24 h
2.25 g every 8–12 h with additional dose of 0.75 g after each dialysis 10–15 mg/kg after each treatment
Drug
Cefepime
154
Vancomycinb
1 g load; 500 mg Q 24 h (given after dialysis)
CRRT (CVVH at 25 mL/ kg/h) 1–2 g Q 12 h (consider continuous infusion of 2–4 g/24 h) 250–500 mg oral or 200–400 mg IV Q 12 h 24-hour dosing
4.5 g every 8 h
15–20 mg/kg Q 24 h
Notes: a Should always be guided by therapeutic drug levels; b For concentration-dependent antimicrobials some authorities recommend higher IV dosing administered 1 hour before IHD.
data to all patients. In addition, there exists inconsistency across drug information resources. Many of the drug information resources offer adjustments for IHD or early forms of CRRT that are not applicable to the newer forms of CRRT that provide higher clearance rates. Table 19.4 provides dosing recommendations for some common antimicrobial agents based on available literature. Limitations to these recommendations are as cited above. Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacological response, signs of adverse reactions due to drug accumulation, as well as drug levels in relation to target trough (if appropriate). The following are general recommendations only (for a typical sized adult patient) and should not supersede clinical judgment: When available, therapeutic drug monitoring should be applied to optimize drug therapy and limit adverse effects.
Key references Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998;32:362-375. Pea F, Viale P, Falanut M. Antimicrobial therapy in critically ill patients. Clin Pharmacokinet. 2005;44(10):1009-10034.
Drug dosing in CRRT CHAPTER 19
155
Pea F, Viale P, Pavan F, Falanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007; 46(12):997-1038. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41:1159-66.
This page intentionally left blank
Part 3
Special situations
This page intentionally left blank
Chapter 20
Renal replacement therapy in children Michael L. Moritz
There are various options for renal replacement therapy (RRT) in children. The type of RRT largely depends on the child’s size, the reason for initiating therapy, and the equipment and expertise available at an institution. Acute RRT is not nearly as often performed in children as it is in adults, and not all RRT’s are available at each pediatric center. Peritoneal dialysis is the most widely available RRT, performed at almost all pediatrics centers. Hemodialysis is also widely available, but many centers do not have the expertise or equipment to dialyze infants or neonates. Continuous veno-venous hemofiltration (CV VH) is becoming more available at pediatric center, but is primarily offered at large pediatric tertiary care centers. RRT in the large child or adolescent (> 50 kg) is no different than in adults. The focus of this section will be to discuss RRT, as it pertains to infants and small children. A complete discussion of renal replacement therapies can be found elsewhere in this manual.
Indications The most common reasons for initiated acute RRT in children are similar to adults: acute renal failure, sepsis, multisystem organ failure, solid organ transplants, and bone marrow transplants There are some reasons for initiating RRT in children that are different than adults, such as postoperative congenital heart disease repair, urea cylcle disorders, and hemolytic uremic syndrome.
Peritoneal dialysis Peritoneal dialysis (PD) remains an attractive form of RRT for a variety of reasons. PD catheters are relatively easy to insert and can be placed in, virtually, any sized child. It is an inexpensive therapy that does not require sophisticated dialysis equipment or highly trained personnel. Acute PD is primarily performed following postoperative complex congenital heart disease repair. PD is a better
159
Renal replacement therapy in children
Renal replacement therapy in children CHAPTER 20
160
option than CV VH in these children due to their small size and also because PD does not require vascular access or systemic anticoagulation. Many cardiac centers will place a PD catheter at the time of cardiac repair and initiate PD if there is oliguria, fluid overload, or metabolic derrangements.
Contraindications to PD There are only a few contraindications to PD. A gastrostomy tube, ileostomy, colostomy, and vesicostomy are not contraindications to PD. A ventriculo-peritoneal shunt is a relative contraindication to PD, but should only be initiated by experienced dialysis personnel. Contraindications to PD: • Recent abdominal surgery ( 5–7 days) • Abdominal drains • Abdominal wall defects • Communication between abdomen and thorax • Extensive abdominal adhesion • Peritoneal membrane failure • Ventriculo-peritoneal shunt
PD access A single-cuff acute Tenckoff catheter is the most common catheter used for acute PD in children. The catheters can be either straight or coiled. The catheters come in three sizes—infant, pediatric, and adult. Pediatric and adult catheters have the same internal diameter, but only differ in length. Selection of acute Tenckoff PD catheter: • <3 kg infant catheter • >3 and <20 kg pediatric catheter • 20 kg adult catheter
Apparatuses for PD Acute PD is easy to initiate. Manual PD can be initiated with a “Y-set” that connects to the PD catheter. One end of the Y is connected to the dialysate solution and the other end is connected to a drain bag. Manual PD can then be initiated. A burretrol will be required to deliver small dwell volumes in such cases. A specially manufactured manual dialysis set called “Daily-Nate” is available for performing manual PD in small infants. Dialy-Nate is a closed system with a graded burretrol to deliver small volumes, a drain bag, multiple connectors for dialysate, and an optional heating coil. An automated “cylcler” can be used in large sized infants. The minimal volume that can be delivered by a cylcler is 60 mL. It is best to use a cylcler when a dwell volume of 100 mL or greater is used.
Acute PD prescription There are various components to writing an acute PD prescription. The list below describes a typical prescription to initiate PD. Below is an explanation of each component of the dialysis prescription.
The dialysate solution is referred to by the dextrose concentration as 1.5%, 2.5%, or 4.25%. Dialysate is hyperosmolar in relationship to the plasma. Uremic toxins, electrolytes, and water are removed from the patient via diffusion into the peritoneum. • A 1.5% dialysate solution is the standard concentration for initiating PD. • The dextrose concentration can be increased if additional fluid removal is required. • 200 units of heparin per liter are usually added to the dialysate to prevent fibrin clots. • Heparin does not cross the peritoneal. • 2–4 mEq/L of heparin can be added to the dialysate if hypokalemia develops.
Renal replacement therapy in children
Dialysate
CHAPTER 20
Initial PD prescription: • 1.5% Dextrose + 200 units of heparin per liter • 10 mL/kg dwell volume • Continuous hourly exchanges
Acute PD is initiated at a low dwell volume to prevent leakage of dialysate around the catheter from higher intraperitoneal volume. The dwell volume can be progressively increased over time to improve clearance. • PD is initiated at a dwell volume of 10 mL/kg. • The dwell volume can be progressively increased over 2 weeks to up to 40 mL/kg.
Dwell time • Acute PD is usually initiated with hourly exchanges • 20–30 minute exchanges can be used if
PD is initiated within 24 hours of catheter placement, aggressive fluid removal is needed, • there is severe hyperkalemia. • Acute PD is usually continuous. • Intermittent PD of 8–10 hours can be done when dwell volumes > 30 mL/kg are achieved. • •
Complications There are a variety of complications associated with peritoneal dialysis. Below are the key aspects to a variety of complications: • Leakage of fluid around the PD catheter • Interrupt PD for 24–48 hours. • Resume at a reduced dwell volume. • Consider administering fibrin glue to the exit site.
161
Dwell volume
Renal replacement therapy in children CHAPTER 20
162
• Peritonitis: Cloudy fluid, abdominal pain, fever; peritoneal cell count: >100 µL,
>50% neutrophils • Send peritoneal fluid for culture. • Treat with intraperitoneal antibiotics. • PD does not have to be discontinued. • Problems with filling and draining • Check catheter placement on abdominal X-ray. • Treat constipation. • Consider increasing dwell volume. • Change position of the patient. • Add heparin to dialysate if fibrin is present. • Consider using tissue plasminogen activator (TPA) in PD catheter. • Omentum may be wrapped around catheter.
Hemodialysis Hemodialysis (HD) is a widely available RRT in most pediatric centers. It can be successfully performed in infants 2 kg, and in even smaller neonates by very experienced personal. Infant and neonatal HD requires special equipment and modifications in the dialysis prescription due to the small blood volume of these patients. An adult dialysis prescription with adult lines and dialyzers are not appropriate for children < 40 kg.
Acute hemodialysis access Reliable vascular access is critical for doing HD or CV VH in children. Various sizes of HD catheters are available for children (Table 20.1). Dialysis is usually performed through a double lumen hemodialysis catheter. In neonates, HD can be performed through umbilical lines or through a radial arterial line and a single lumen central venous catheter.
Dialysis blood lines and dialyzers Dialysis blood lines and dialyzers come in a variety of sizes. The exact blood volume differs between manufacturers. Selecting an appropriate blood line and dialyzer is critical to dialyzing children (Table 20.2). • The surface are of the dialyzer should be approximately the same as the body surface area of the child. • The extracorporeal volume (ECV) of the blood line and dialyzer should not exceed 10% of the patients blood volume (8 mL/kg). • If the ECV exceeds 10% of the blood volume, prime the lines with 5% albumin or whole blood (hematocrit 30%–35%).
3–6 kg 6– 30 kg > 30 kg
Table 20.2 Examples of appropriate dialysis prescriptions for children Patient size Wt (kg), BSA (m2) 4.0, 0.3 10.0, 0.5 30.0, 1.0
Blood lines, volume (mL) Neonatal, 20 Small pediatric, 44 Large pediatric, 79
Dialyzer, volume (mL), surface ares (m2) a F3, 28, 0.4 F3, 28, 0.4 a F5, 63, 1.0
QB (mL) Priming volume (mL), blood volume (%) 48, 15 12–40 48, 6 30–100 142, 6 100–300
Note: aF3 and F5 are manufactured by Fresenius.
Blood flow (QB) • First dialysis treatment should be 3–5 mL/kg. • Subsequent dialysis treatments can be as much as 10 mL/kg.
Time Dialysis is extremely efficient in small children due to the small volume of distribution. • A 3-hour dialysis treatment is usually sufficient for children < 50 kg.
Ultrafiltration • Ultrafiltration should not exceed 5%–7% of body weight in a 3-hour treatment.
Anticoagulation • • • •
30–50 units/kg loading dose 10 units/kg hourly Heparin-free dialysis can be done with high blood flows and saline flushes. Lock catheters with 1:1000 unit of heparin per liter.
Renal replacement therapy in children
Catheter size 3.5 Fr or 5 Fr umbilical artery catheter 5 Fr umbilical venous catheter 5 Fr single lumen venous catheters Radial arterial line 7 Fr double lumen dialysis catheter 7 Fr double lumen dialysis catheter 8, 9 Fr double lumen dialysis catheter 10, 11, 11.5 Fr double lumen dialysis catheter
CHAPTER 20
Patient size Neonate < 3 kg
163
Table 20.1 Vascular access in children
Renal replacement therapy in children CHAPTER 20
164
Continuous veno-venous hemofiltration (CV VH) The principles of CV VH are the same for children as adults. CV VH is technically more difficult in small children than hemodialysis due to the larger priming volume of the system. The minimum priming volume for the Aquarius system by Baxter, the System One by NxStage, and the Prisma system by Gambro is 75 mL, 83 mL, and 93 mL respectively. CV VH should not be attempted in children < 10 kg unless the center has significant experience with children of this size. Initiating CV VH in small children and infants can produce significant hemodynamic instability. Below are general principles to follow when initiating CV VH.
Blood pressure The initiation of CV VH should be delayed if there is severe hypotension and hemodynamic instability. CV VH can usually be initiated successfully if the mean arterial pressure is >50 mm Hg.
Vascular access At least a 7 Fr double lumen hemodialysis catheter should be used for CV VH in children as the minimum blood for most CV VH machines is 30 mL/h. The 7 Fr catheters are prone to kinking and may need to be replaced often (Table 20.1).
Extracorporeal volume The priming volume (PV) for the CV VH system usually exceeds 10% of the blood volume in children < 10 kg. • Calculate the ECV of the CV VH circuit. • The child’s hematocrit should be 30% prior to initiating CV VH. • If the PV exceeds 8 mL/kg, prime the system with whole blood.
Blood flow • 3–5 mL/kg/h
Dialysate-replacement fluid flow rate The choice of using CV VH or CV VHD is center specific and there is no clear advantage of one over the other in pediatrics. There are no specific CV VH solution for children. Accusol, Prismasate, Normocarb, Nxstage, or a pharmacy made solution have all been used successfully. The dialysis flow in children has been adapted from what has been used in adults and adjusted to body surface area (BSA). The most widely accepted dialysate rate is 2L/1.73 m2/h. In the authors opinion, excellent clearance and metabolic control can be obtained with flow rates much lower than this.
Anticoagulation Both heparin and citrate anticoagulation have been used successfully in children and the principles are the same as those for adults. Heparin anticoagulation typically requires a 30– 50 units/kg loading dose followed by a 10–20 units/kg/h
Renal replacement therapy in children CHAPTER 20
165
maintenance dose to keep to the activated clotting time (ACT) 180–240 seconds or an activated partial thromboplastin time (APTT) of 60–80 seconds. Heparin anticoagulation should be avoided if the patient is immediately postoperative, if there is active bleeding, or if the patient is systemically anticoagulated. The protocol for regional citrate anticoagulation is mostly same as that for adults. The ACD-A citrate flow rate is 1.5 times the blood flow rate to keep the postfilter ionized calcium 0.2–0.4 mm. The calcium chloride (20 mg/mL) infusion rate is 0.1 times the ACD-A flow rate to keep the systemic ionized calcium 1. 0–1.3. The adjustments made to the ACD-A and calcium chloride flow rate to maintain the appropriate ionized calcium will be 50% less for children less then 20 kg.
This page intentionally left blank
Chapter 21
Therapeutic plasma exchange in critical care medicine Joseph E. Kiss
Therapeutic plasma exchange (TPE) is the automated removal of a patient’s plasma and its replacement (exchange) with a suitable alternative fluid such as a solution containing albumin or fresh frozen plasma. Its intended use is not only depletion of pathogenic, large molecular weight substances (>30–50,000 daltons) present in blood plasma, but also replacement of depleted normal/ beneficial substances. Smaller molecular weight compounds are not efficiently removed by TPE, but may be effectively removed by alternative extracorporeal techniques such as hemofiltration (<20–30,000 daltons) or dialysis (<500–600 daltons).
The decision to utilize TPE The rational use of TPE is based on the following considerations: • What is the pathophysiological role of the target macromolecule in the clinical disorder? Is there an evidence of acute toxicity caused by the substance? Is the patient resistant to the usual medical and/or pharmacologic therapy or does the clinical urgency demand more immediate action? • Can the substance be efficiently removed by TPE? Generally, this applies to large molecules with relatively long half-lives (reduced synthetic rate). • Is there evidence that reduction in levels of the offending substance is associated with improved clinical outcomes? Clinical consultation with the appropriate provider of TPE services is recommended to address these issues and to provide management guidance, as outlined in Table 21.1. Note, the American Society for Apheresis (ASFA) has published comprehensive evidence-based indications on the use of TPE in specific disease categories (Szczepiorkowski ZM. Clinical applications of therapeutic apheresis: an evidence-based approach. 4th ed. J Clin Apher. 2007;22:96-105). The classification system and examples of substances removed are shown in Table 21.2 and 21.3.
167
Principles
Therapeutic plasma exchange CHAPTER 21
Table 21.1 Decision making in therapeutic plasma exchange Rationale Technical issues Management plan Endpoint
Considerations Disease pathogenesis, published efficacy, and quality of evidence Vascular access, volume of plasma to process, replacement solution Timing (emergent, urgent), number, and frequency of treatments Clinical and/or laboratory response
Table 21.2 Consensus indications for plasma exchange ASFA category I
Interpretation Standard acceptable therapy
Remarks Proven in controlled trials
II
Available evidence supports efficacy
III
Available evidence suggests efficacy but is inconclusive Ineffective in controlled trials
Case series, second line, adjunctive therapy Anecdotal data, for example case reports
IV
168
Table 21.3 Clinical examples where plasma exchange is used Substances removed Autoantibodies Alloantibodies Immunoglobulins causing hyperviscosity Cryoglobulins Protein-bound toxins
Clinical examples Goodpasture’s syndrome (antiglomerular basement membrane autoantibodies) Solid organ transplant (e.g., anti-HLA) Waldenstrom’s macroglobulinemia
ASFA category I
Cryoglobulin-associated skin ulceration, renal dysfunction Amanita (mushroom) poisoning
I
Substances replenished Thrombotic thrombocytopenic ADAMTS13 purpura (TTP) (von-Willebrand factor cleaving protease) Coagulation factors Hepatic failure
II I
II I III
Management guidelines for TPE The extent of removal of a substance during TPE depends on the volume of the patient’s plasma removed in relation to total plasma volume, the distribution of the substance between the intravascular and extravascular compartments, and how rapidly the substance reequilibrates between compartments. The plasma volume (PV) is calculated as PV = total blood volume x [1–hematocrit (HCT)]. In adults, the total blood volume may be estimated as 70 mL/kg. Therefore, for a 70-kg man with HCT of 0.45 the PV = 4900 mL x 0.55, or 2695 mL.
1 PV = 65% removal 1.5 PV = 75% • 2 PV = 87% • 3 PV = 95% • IgM—80% intravascular (efficiently depleted due to limited reequilibration) • IgG—both intravascular (40%) and in tissues (removal less efficient, redistribution into plasma postapheresis over 24–48 hour period) •
Note: The volume processed during TPE procedures is often “capped” at 1.5 PV because of the minimal additional effect of increasing the procedure time above this level, i.e., there is only 12% additional removal/ replacement going from 1.5 to 2.0 PV.
A one-compartment model best describes the kinetics of removal in TPE. The rate of removal is not linear but curvilinear, that is very steep during the more efficient early stages of the exchange, then leveling off during the latter stages of the procedure as more of the replacement fluid and less of the original patient’s plasma is exchanged. During a TPE procedure, removal of immunoglobulin M (IgM) and fibrinogen, which are located predominantly in the intravascular compartment (~80%), is more complete than removal of immunoglobulin G (IgG) because only ~40% of this protein is intravascular. From a practical standpoint, IgM-mediated disorders require fewer TPE treatments to achieve a similar level of removal than IgG-mediated disorders. Lower-molecular-weight compounds that are highly diffusible (i.e., have a large volume of distribution) or are regulated actively in the plasma (such as calcium or potassium) are removed much less efficiently by TPE. After being depleted by TPE, the return of a substance toward baseline levels is governed by a balance of synthesis, catabolism, and reequilibration between compartments. Variability in these factors, as well as the binding characteristics of the substance, relates to the overall efficacy of a course of treatment. Table 21.4 depicts the proportion of an idealized compound that is removed based on the kinetic model.
Apheresis devices Two general types of instrumentation may be used to perform TPE: centrifugalbased and membrane-based filtration.
Centrifugal cell separators Centrifugal separation relies on the application of gravitational force to separate blood elements according to density. In order from lightest to heaviest, whole blood components may be separated into plasma (S.G. 1.025 to 1.029), platelets 1.040, lymphocytes (S.G. 1.070), granulocytes (S.G. 1.087 to 1.092), and red blood cells (S.G. 1.093 to 1.096). Centrifugal cell separators operate either
Therapeutic plasma exchange
•
CHAPTER 21
• Efficiency:
169
Table 21.4 Removal of a substance by TPE
Therapeutic plasma exchange CHAPTER 21
by discontinuous (alternates blood collection and reinfusion sequentially) or continuous flow. Continuous flow devices achieve greater efficiency by simultaneously collecting and reinfusing processed blood components. In a typical TPE channel configuration, the whole blood is withdrawn from the patient by means of an inlet pump. To prevent clotting, it is immediately mixed with an anticoagulant solution at a preset ratio, typically 10 to 14 parts of whole blood to 1 part of ACD-A (a citrate dextrose solution). The blood then enters the separation chamber, where an interface is established to separate the blood into component layers. The heavier cellular elements settle to the outside of the channel, while the lighter plasma remains at the inner aspect. The plasma is siphoned off through the plasma-out tube, while the cellular components are removed through the RBC return tube. Typical flow rates for therapeutic plasma exchange range from 60 to 95 mL/min, depending upon patient size, patient tolerance of side effects, and type of replacement solution being used.
170
Anticoagulation Most centrifugal cell separators employ citrate anticoagulants; protocols are also available for using heparin alone or heparin and citrate in combination. Use of citrate avoids potential bleeding risks of systemic anticoagulation; however, the hypocalcemia induced by citrate has certain potentially serious toxicities, including seizures and depression of cardiac function. For this reason, manufacturers of apheresis instrumentation have designed controls that regulate the maximum amount of citrate that can be infused. The maximum AC infusion rate is based on the average patient’s ability to metabolize citrate under normal physiological conditions. However, many patients, such as those with liver failure, have a reduced clearance of citrate. Therefore, individual factors need to be considered.
Priming of the extracorporeal circuit A saline prime is used in the external tubing and channel of the apheresis instrument in order to avoid hypotension due to a sudden volume deficit. The extracorporeal volume (ECV) or “dead space volume” within the TPE circuit varies among different machines, ranging between 170 to 250 mL. Dilution of an adult’s RBC mass by this volume is negligible, however, it may be substantial for a child. Red blood cell prime methods have been developed to minimize the effects of hemodilution.
Membrane filtration cell separators Membrane filtration technology is an extension of the use of synthetic biocompatible membranes employed in hemodialysis, ultrafiltration, and hemofiltration. The membrane is permeable to large molecular weight proteins but excludes cellular elements, including platelets. Pore sizes ranging from 0.2 to 0.6 microns allow passage of proteins with molecular weight ranges of more than 500,000 daltons. Membrane filters that are currently used have sieving coefficients of
Adverse effects of TPE Serious complications such as infection, thrombosis, pneumothorax, and hematoma formation are often related to the need for central venous access. Overall 3%–8% of TPE procedures may be associated with adverse reactions (Table 21.5). Most of these are easily recognized and treated. Severe reactions such as cardiac or respiratory arrest, and mortality (1–2/10,000 procedures) are rare. The more serious consequences are seldom due to the TPE procedure itself.
Citrate toxicity One part of acid citrate dextrose (ACD) solution is added to fourteen parts of whole blood immediately after withdrawal from patient. This prevents clotting in the apheresis machine. The citrate ions bind ionized calcium, resulting in transient hypocalcemia. Plasma products add to this side effect because of high citrate concentration. • Symptoms • Perioral tingling • Vibration sensation • Numbness and tingling in extremities • Nausea and emesis • May progress to muscle spasms, tetany, and seizure activity
Therapeutic plasma exchange CHAPTER 21
171
0.9–1.0. This implies that the protein composition of the filtrate and the plasma are nearly identical, even for very large molecules such as IgM. Cellulose diacetate, polyethylene, polypropylene, polyvinylchloride, and other synthetic materials are used to make membrane filters. After the addition of anticoagulant, the patient’s blood is pumped through either a parallel plate or hollow fiber filter at a continuous flow rate between 50 and 200 mL/min. The efficiency of filtration is determined by several parameters including the blood flow rate, composition and physical characteristics of the membrane, transmembrane pressure, geometry of the blood flow path, as well as the physical and chemical nature of the plasma proteins. A typical device features an anticoagulant syringe pump (usually employing heparin as the anticoagulant of choice), a blood pump, replacement fluid pump, and effluent pump. Blood is directed to the plasma filter by means of the blood pump. The hemoconcentrated blood leaves the plasma filter through the return line, where it is combined with replacement fluid and returned to the patient. The effluent side of the plasma filter leads to a waste bag. Studies comparing centrifugal and membrane filtration have found them to be similar with respect to safety and efficiency. TPE is not as rapid with membrane separators. Although use of systemic heparin anticoagulation may avoid some side effects of citrate, systemic heparinization is disadvantageous in some patients, such as those with coagulopathy.
Therapeutic plasma exchange CHAPTER 21
Table 21.5 Adverse events and frequency Event b
Overall rate Specific reaction rates Transfusion reactions (primarily due to plasma replacement) Citrate related nausea and/or vomiting, paresthesias Hypotensionc Vasovagal nausea and/or vomiting Pallor and/or diaphoresis Tachycardia Respiratory distress Tetany or seizure
Frequencya (%) 3–8 1.6 1.2 1.0 0.5 0.5 0.4 0.3 0.2
Notes: a Approximate rate based on published literature; b Higher rate associated with TPE in which plasma is used; c Autonomic dysfunction with hypotension is seen especially in patients treated for neurological conditions, including Guillain-Barre syndrome and chronic idiopathic demyelinating polyneuropathy (CIDP).
• Management
Decrease inlet flow (blood withdrawal) rate (or pause machine) Calcium gluconate infusion—in adults 10 mL 10% (1 gm) in 250 mL 0.9% saline solution may be added to albumin replacement fluid (not plasma). • Calcium chloride infusion—in adults, this is 3x more potent and acts faster than calcium gluconate because the ions dissociate immediately. Monitor patient q 15–30 min with [Ca 2+] levels. Vasovagal reactions: Generally manifested by sudden hypotension and bradycardia, diaphoresis, lightheadedness, and occasionally nausea and emesis. TPE is temporarily halted and legs are elevated to increase venous return. Reaction is usually self-limited but may progress to loss of consciousness. Bolus NSS, 200–400 mL may be given. Hypotension: Acute volume loss is prevented by priming the apheresis circuit with replacement fluid. Despite simultaneous replacement, patients such as those with autonomic neuropathy are sensitive and become hypotensive. These kind of patients generally respond to bolus saline, 200–400 mL. Allergic reactions: Mainly due to plasma proteins; rarely albumin or residual ethylene oxide sterilization of disposable plastic. Hemolysis: Very rare. Suspect use of hypotonic crystalloid solution or mechanical cause (kinked tubing) or patient red blood cell abnormality. Depletion of clotting factors: Prolonged prothrombin time and international normalized ratio (PT/INR), and/or activated partial thromboplastin time (APTT) that occurs with daily serial TPE using non-plasma replacement or cryodepleted plasma (see Table 21.6). TPE especially depletes fibrinogen—longer
172
• •
•
•
• • •
Advantages
Disadvantages
Viral inactivation Ease of use Reactions rare All proteins replaced
High cost Most proteins not replaced
Low cost Viral Safety Ease of use Slow catabolism
No proteins replaced Hypotensive reactions Dosage limit
Single-donor plasmaa
6% Hetastarch
High cost Inconvenientb Citrate reactions Urticaria Viral infection risk
Therapeutic plasma exchange
Fluid 5% Albumin
CHAPTER 21
Table 21.6 Colloid replacement fluids used in TPE
half-life (90 hours), slower recovery rate than other coagulation factors (3–4 days to return to normal). • Usually not manifest with every-other-day plasma exchanges • Treatment: Decrease frequency of procedures or use plasma or cryoprecipitate (donor exposure risk) • Transfusion-transmitted diseases (when plasma is used)—rare • Ace inhibitors • Symptoms: Flushing (vasodilation), hypotension, dyspnea, watery diarrhea. • Prekallikrein activator (an activator of bradykinin) is present in albumincontaining replacement solutions • Ace is identical to kininase ii—bradykinin degradation inhibited • Prevention: Withhold ace inhibitors at least 24 hours before procedure.
173
Note: TPE, therapeutic plasma exchange; a Fresh-frozen plasma or cryoprecipitate-poor plasma; b Must be thawed prior to use; must match patient ABO type.
This page intentionally left blank
Chapter 22
MARS: molecular adsorbent recirculating system Nigel Fealy and Rinaldo Bellomo
Molecular adsorbent recirculating system (MARS) is an artificial liver support system aimed at the removal of toxins in patients suffering from acute liver failure (ALF) or acute on chronic liver failure (AoCLF). MARS is performed through an additional circuit attached to a standard extracorporeal circuit (continuous renal replacement circuit), which uses albumin as a dialysis medium. Using albumin as carrier molecule, toxins are adsorbed onto specific sorbents. Most potential liver toxins such as bilirubin, ammonia, fatty acids, hydrophobic bile acids, and nitric oxide use albumin as their transport protein and, as a result, appear to be more effectively removed by an albumin-enriched dialysate. This albumin dialysate is regenerated online by passage through a second hemodialyser and two sorbent columns (charcoal and anion exchanger).
Definitions Acute liver failure (ALF)—is a syndrome in which rapid loss of metabolic and synthetic liver function leads to the hepatic encephalopathy and multiorgan failure in patients with no previous history of liver disease. Acute on chronic liver failure (AoCLF)—is a syndrome that occurs in patients with long-standing liver failure and cirrhosis of the liver where there is an acute decompensation of their disease process. Albumin dialysis—is a form of artificial liver support where normal serum albumin is used as a component of the dialysate as a basis for more effective protein-bound toxin removal. Artificial liver support—is any device designed to specifically purify blood form liver-related toxins. The role of these devices is to remove toxins, which may be responsible for hepatic encephalopathy and multiorgan failure secondary to liver failure.
175
Introduction
Molecular adsorbent recirculating system CHAPTER 22
176
Bioartificial liver support—is any form of liver support that uses filters impregnated with human or porcine liver cells (hepatocytes) to perform the three main functions of the liver: detoxification, biosynthesis, and regulation. Dialysis—is the separation of substances across a semipermeable membrane on the basis of particle size and/or concentration gradients. Extracorporeal circuit—is the path for blood flow outside the body. It includes the plastic tubing carrying the blood to the dialyzer from the access catheter and from the dialyzer back to the body via the access catheter. Liver support devices—are any man-made devices that are used to purify blood in the setting of liver failure. This term encompasses both artificial and bioartificial liver support systems.
Method The MARS treatment kit consists of an albumin hemodialyser, a standard hemodialyser, an activated carbon adsorber, and an anion exchanger. The circuit is filled with 500 mL of 20% human albumin solution. Albumin acts as dialysate and is pumped through a hollow fiber membrane (MARS flux dialyzer) countercurrent to blood [Figure 22.1 (A)]. Water-soluble substances diffuse into the albumin solution whilst albumin-bound toxins move by physicochemical interactions between plasma, albumin molecules bound to the dialysis side of the membrane, and the circulating albumin solution. Toxin-carrying albumin is then passed through another hemodialyzer countercurrent to a standard buffered dialysis solution where diffusive clearance of water-soluble substances occurs [Figure 22.1 (B)]. A concentration gradient is maintained by the circulation of the albumin solution and disposal of the albumin-bound toxins by passage through activated charcoal [Figure 22.1 (C)] and anion exchange columns [Figure 22.1 (D)] (see Figures 22.1 and 22.2).
Practical considerations The MARS treatment is achieved by the combined use of a stand-alone continuous renal replacement therapy (CRRT) machine or hemodialysis machine and the MARS albumin pump and monitor unit. The MARS albumin pump and monitor unit [Figure 22.3 (A)] is placed in series with a standard continuous veno-venous hemodialysis (CV VHD) circuit [Figure 22.3 (B)]. Depending on the external CRRT or dialysis machine used, the CRRT machine may act as a blood pump and dialysate controller or is more integrated for MARS use as with the Prisma and Prismaflex platforms. As with other renal replacement therapies, suitable vascular access is a key factor in achieving the prescribed treatment dose. The use of anticoagulation should be considered carefully. Often patients with ALF have some degree of autoanticoagulation and do not require anticoagulants to maintain MARS or CRRT circuits. Often the difficulty in treating patients with ALF is in determining
B
Figure 22.1 Extracorporeal and albumin dialysis circuit [molecular adsorbent recirculating system (MARS) monitor]. A = MARS flux dialyzer; B = standard high flux hemodialyzer; C = activated charcoal; D = anion exchange column
A MARS Monitor
Dialyser 1
Dialyser 2
Albumin intermediate circuit
V
QB = 150 –200 mL/min QA = 200 mL/min QD = 33 mL/min (2L/h)
CRRT machine
Ion exchange Activated charcoal resin cartiridge cartidge Dialysate
Figure 22.2 Schematic representation of a molecular adsorbent recirculating system (MARS) circuit. A = outflow lumen of dialysis catheter; V = inflow lumen of dialysis catheter; QB = blood flow; QA = albumin flow; QD = dialysate flow
Molecular adsorbent recirculating system
A
CHAPTER 22
C
177
D
A
178
CHAPTER 22
Molecular adsorbent recirculating system
B
Figure 22.3 Molecular adsorbent recirculating system (MARS) with Prisma continuous renal replacement therapy (CRRT) machine. A = MARS unit; B = Prisma CRRT machine
when to institute the MARS therapy, duration of therapy (intermittent vs. continuous), and when to cease the therapy. Table 22.1 outlines one set of recommendations for the use of MARS in ALF. After three days of consecutive intermittent or continuous treatments there is an expectation that the patient with ALF or AoCLF will have significant improvement both clinically and biochemically. At present there is insufficient data to demonstrate a survival benefit when MARS is instituted in patients with ALF or AoCLF. However, there is evidence to suggest that MARS’ impacts favorably on the complications of liver failure. MARS appears to improve several clinical parameters such as hemodynamic status, bilirubin levels, bile acid levels, encephalopathy, pruritus, and renal function. The effect of improving these parameters in patients with liver failure is to provide time for either liver regeneration or to bridge the patient safely to liver transplantation. A consideration when applying the therapy is modification of antibiotics and drug therapy. Theoretically, removal of both water-soluble and albumin-bound drugs is achieved during the MARS therapy and, therefore, adjustment of drug therapy and therapeutic drug level monitoring should be undertaken. The exposure of blood to an extracorporeal circuit initiates the coagulation cascade and may deplete clotting factors and lower the platelet count. In
Source: Adapted from Phua J, Hoe Lee K. Liver support devices. Curr Opin Crit Care. 2008;14:208-215.
patients with an already impaired coagulation state, observation of bleeding and investigation of platelet count should be undertaken during treatments and prior to recommencement of MARS therapy.
Summary The MARS treatment is a technically feasible therapeutic option for liver support in the intensive care environment. However, the setup is labor intensive compared to CRRT. The treatment option at present is currently limited to intensive care units (ICU) in specialist referral centers where highly skilled nurses are available as required to institute and maintain the therapy. MARS represents the most frequently used liver support therapy at present. It appears to allow for the safe removal of albumin-bound as well as water-bound toxic substances in patients with AoCLF and ALF. At present many physicians believe that the therapy is a useful adjunct to bridge patients to transplantation and/or potentially support patients to spontaneous recovery. As reports of clinical and biochemical improvements in patients continue to emerge, there will be an ongoing interest in these types of therapies.
Molecular adsorbent recirculating system CHAPTER 22
Start criteria Rising total bilirubin > 300 µmol/L and one of the following: 1. Hepatic encephalopathy of grade II or greater 2. Hepatorenal syndrome Intermittent MARS treatment 6–8 h of treatment with intermittent hemodialysis Use when hemodynamically stable and no evidence of cerebral edema Anticoagulation—none, heparin, or citrate (risk of citrate accumulation) Blood flow rate (QB) at 250 mL/min Albumin flow rate (QA) at 250 mL/min Continuous MARS treatment 24 h of treatment with continuous veno-venous hemodialysis Use when hemodynamically unstable or evidence of cerebral edema Anticoagulation—none, heparin, or citrate (risk of citrate accumulation) Blood flow rate (QB) at 180–200 mL/min Albumin flow rate (QA) at 180–200 mL/min Stop criteria Plan for at least 3 days of MARS treatment Stop when 1. total bilirubin is less than 200 µmol/L; 2. resolution of hepatic encephalopathy.
179
Table 22.1 Guidelines for the use of MARS in liver failure
Molecular adsorbent recirculating system CHAPTER 22
180
Key references Boyle M, Kurtovic J, Bihari D, Riordan S, Steiner C. Equipment review: the molecular adsorbent recirculating system (MARS). Crit Care. 2004;8(4):280-286. Cruz D, Bellomo R, Kellum J, de Cal M, Ronco C. The future of extracorporeal support. Crit Care Med. 2008;36(4):S243-S252. Evenpoel P, Laleman W, Wilmer A, et al. Prometheus versus molecular adsorbent recirculating system: comparison of efficiency in two different liver detoxification devices. Arch Ortop. 2006;30(4):276-284. Fealy N, Baldwin I, Boyle M. The molecular adsorbent recirculating system (MARS). Aust Crit Care. 2005;18(3):96-102. Mitzner S. Albumin dialysis: an update. Curr Opin Nephrol Hypertens. 2007;16:589–595. Phua J, Hoe Lee K. Liver support devices. Curr Opin Crit Care. 2008;14:208-215. Stadlbauer V, Jalan R. Acute liver failure: liver support therapies. Curr Opin Crit Care. 2007;13:215-221.
Chapter 23
Sorbents
Over the years, the possibility of removing solutes from blood to obtain blood purification has mainly focused on classic hemodialysis. However, the characteristics of some solutes that make their removal difficult and the limited efficiency of some dialysis membranes have spurred a significant interest in the use of further mechanisms of solute removal such as adsorption. Materials with high capacity of adsorption (sorbents) have been utilized for about 50 years in extracorporeal blood treatments of acute poisoning or uremia. With the recognition of the role of cytokines in systemic inflammatory response syndrome (SIRS) and sepsis, and the fact that most cytokines are poorly removable by conventional diffusive or convective blood purification modalities, treatment of sepsis based on sorbent technique has recently been explored.
Removal of target substances by sorbent in sepsis Endotoxin: Endotoxin is a lipopolysaccharide (LPS) and an outer membrane molecule essential for virtually all gram-negative bacteria. It is generally considered a major causative agent in shock states related to gram-negative bacteria infection. LPS will bind to LPS-binding protein (LBP) and be transferred to bind to surface molecule cluster of differentiation (CD) 14 when it enters into blood, presented in aggregate form or monomeric form. The signal of LPS combination with CD14 will be relayed by Toll-like receptor (TLR) to activate the nuclear factor NB(NF-NB) and produce multiple cytokines. Superantigen: Superantigen (SAg), which is a secreted production of gram-positive bacteria, plays an important role in activating and regulating the innate immune system, SAg is also known to be associated with toxic-shock like state in grampositive bacterial infection. Unlike conventional antigen, SAg bypasses normal antigen processing steps, binds directly as an intact protein to major histocompatibility complex (MHC) class II molecules on the surface of antigen-presenting cells and T cell receptor, and activates many more T cells than conventional
181
Dehua Gong and Claudio Ronco
Sorbents CHAPTER 23
antigen. SAg is the most powerful T cell mitogen ever discovered. Activated T cells then producte and release massive proinflammatory cytokines. Cytokines: Activation of immune system is almost present in all critically ill patients, particularly in patients with infection. In the early stage of immune activation, there is a production and release of many proinflammatory mediators, especially tumor necrosis factor-D (TNF-D), interleukin -6 (IL-6), IL-1, and IL-8. These cytokines augment the body response to the pathogen and result in systemic adaptation. At the same time antiinflammatory mechanism is also initiated, including production of IL-10, transforming growth factor-E and IL-13. If the over-responsiveness of immune system is still uncontrolled and persists for a period, the tissue damage and organ failure will occur, and the antiinflammatory effect will overweigh the proinflammatory effect, leading to immunoparalysis.
182
Selectivity of sorbent used for the removal of target substance According to the selectivity of target substance removal, sorbents can be divided into the following three groups: • Unselective porous particles: These kind of sorbents consist of paramount porous polymers, such as resin or activated charcoal (AC). Sorbents exist in granules, spheres, cylindrical pellets, flakes, and powder. They are solid particles with single particle diameter between 0.05 cm and 1.2 cm. Surface area to volume ratio is extremely high in sorbent particles, which varies from 300 to 1200 m2/g. They can also be defined as the following:(1) macroporous = pore size > 500 Å (50 nm); (2) mesoporous = pore size 20–500 Å; and (3) microporous = pore size < 20 Å. Usually they adsorb molecules onto their surface unspecifically by Van der Waals forces, electrostatic attraction, or hydrophobic affinity. Because molecules adsorbed onto the porous surface of sorbent must first pass through the pores, manipulating the pore size can to some extent control the molecules for removal. • Relative selective adsorption: The recent advancement of technique makes it possible to develop many new sorbents by immobilizing a ligand specific to a certain group of substances onto matrix fibers or particles. This kind of sorbents include Lixelle, CTR adsorber (Kaneka Corporation, Osaka, Japan), and CYT-860 (Toray Industries Inc., Tokyo, Japan). They employ hydrogen bond or hydrophobic interaction between ligand moiety and protein chemical groups to enhance protein adsorption capacity, and employ designed pore size distribution to specify the molecular weight of protein that can be adsorbed. Superantigenadsorbing device, which is prepared from a polystyrene-based composite fiber reinforced with polypropylene, is recently undergoing investigation. • Selective adsorption: Sorbents made by immobilization of more specific ligands onto matrix can target the adsorption on one certain substance or limit the adsorption within a very narrow range. Adsorber composed of polymyxin
Sorbents CHAPTER 23
B-immobilized fibers (PMX) has been used for adsorption of endotoxins in sepsis. Adsorbers based on macroporous beads immobilized with human serum albumin such as MATISSE also aim at endotoxins adsorption. The microspheres-based detoxification system provides a platform in which anti-TNF D antibody is immobilized onto microparticles with diameter range of 1–10 um. This system is designed to adsorb serum TNF D in early stage of sepsis.
When a liquid mixture is brought into contact with a microporous solid, adsorption of certain components in the mixture takes place on the internal surface of the solid. The maximum extent of adsorption occurs when equilibrium is reached. No theory for predicting adsorption curves is universally embraced. Instead, laboratory experiments must be performed at fixed temperature (separation processes are energy intensive and affecting entropy) for each liquid mixture and adsorbent to provide data for plotting curves called adsorption isotherms (Figure 23.1). Adsorption isotherms can be used to determine the amount of adsorbent required to remove a given amount of solute from the solvent. Another measure of the efficiency of the unit is obtained by using marker molecules to determine the so-called mass transfer zone. The mass transfer zone is the portion of the cartridge length that goes from a fully saturated sorbent to a completely unsaturated condition. Mass transfer zone determination also helps to define the design of the unit and the expected time of efficiency before saturation. However, both adsorption isotherms and mass transfer zone are not a clinical practical parameter to evaluate a sorbent’s adsorptive capacity. Extraction ratio
Amount adsorbed
Adsorption isotherm
Equilibrium concentration Figure 23.1 Typical example of an adsorption isotherm.
183
Efficiency of adsorption
Sorbents CHAPTER 23
is often used to reflect the removal ability of a sorbent, which is defined as the reduction ratio of solute concentration in blood or plasma after a single pass through the sorbent. The factors other than the sorbent per se also have impacts on extraction ratio, including blood or plasma flow rate, target solute burden in blood, and so on. In one treatment session, dynamic monitor of extraction ratio may reflect the saturation status of the sorbent. Another clinical useful parameter for demonstration of the removal effect of sorbent is reduction ratio of solute by a single session of treatment. However, the fact that both of these parameters cannot accurately reflect the removal ability of a sorbent makes the comparison between different sorbent difficult.
184
Biocompatibility of sorbents The concept of sorbent biocompatibility may have three meanings: first, the sorbent must be resistant and must not release any harmful substances into the body. Second, the contact of sorbent with plasma or blood will not induce activation of complement, immune system, and hemostasis system, nor result in hematological abnormality such as hemolysis, leucopenia, and thrombocytopenia. Third, the adsorption will not result in unwanted loss, such as albumin loss. However, so far no one sorbent fully reaches all these requirements. Commercial sorbent column usually contains a sieving device that allows free passage of blood but retains particles or their fragments, in order to prevent dissemination of small particles in the body. Some systems also have a built-in monitor device to detect the possible detached microparticles in blood. Blood-surface reaction depends on sorbent surface flatness and materials. Sometimes, surface-coating technique is used to improve sorbent biocompatibility, while in expense of adsorption efficiency. Another way to improve biocompatibility is plasma adsorption, in which only plasma pass through sorbent, blood cells are separated from plasma and bypass the sorbent, and finally blood is reconstituted after an extracorporeal single pass treatment. However, addition of plasma separator will make the procedure more complex. Researches on materials with high molecular weight and polymers provide the hope for emergence of new type of sorbent with good biocompatibility, especially, the new sorbent with high selectivity of adsorption and least unwanted loss.
Typical modalities of utilization of sorbents Typical modalities for the utilization of sorbents in extracorporeal therapies are represented in Figure 23.2. • Hemoperfusion (HP): HP is a technique in which the sorbent is placed in direct contact with blood in an extracorporeal circulation. It has a very simple circuit, but requires an extremely biocompatible sorbent and adequate anticoagulation of extracorporeal circuit (EC). For materials such as charcoal that
Blood in
CHAPTER 23
Blood out
Sorbents
Sorbent
A
B Sorbent
Hemodiafilter
Blood in
Blood out
Dialysate out
Dialysate in
C Hemofilter
Hemodiafilter Blood out
185
Blood in
Sorbent Dialysate out
D
Plasmafilter
Dialysate in
Hemodiafilter
Blood in
Blood out
Sorbent Dialysate out
Dialysate in
Figure 23.2 Possible modes of application of sorbents: (A) hemoperfusion (HP). (B) The sorbent unit is placed in series before the hemodialyzer (hemoperfusion-hemodialysis = HPHD). (C) The sorbent unit is placed online in the ultrafiltrate produced from a hemofilter. The hemofilter is placed in series with the hemodialyzer. The system is used for online hemodiafiltration in chronic patients and it is defined as paired filtration dialysis with sorbent (HFR). (D) The sorbent unit is placed online in the plasmafiltrate produced from a plasmafilter. The plasmafilter is placed in series with the hemodiafilter. The system is used for critically ill patients with septic shock and it is defined as coupled plasmafiltration adsorption (CPFA).
has poor biocompatibility, it has to be coated before its use in HP. More recently, synthetic polymers have been introduced with remarkable capacity for adsorption and better biocompatib